EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 91

Results Generated From:
Embase <1980 to 2022 Week 45>
Embase Weekly Updates (updates since 2022-11-04)

<1>
Accession Number
2017578566
Title
Meta-Analysis Comparing Percutaneous Closure Versus Medical Therapy for
Patent Foramen Ovale.
Source
American Journal of Cardiology. 172 (pp 174-177), 2022. Date of
Publication: 01 Jun 2022.
Author
Krittanawong C.; Virk H.U.H.; Kumar A.; Wang Z.; Mahtta D.; Khalid U.;
Denktas A.E.; Volpi J.J.; Jneid H.
Institution
(Krittanawong, Mahtta, Khalid, Denktas, Jneid) Michael E. DeBakey VA
Medical Center, Houston, Texas, United States
(Krittanawong, Mahtta, Khalid, Denktas, Jneid) Section of Cardiology,
Baylor School of Medicine, Houston, Texas, United States
(Virk) Department of Internal Medicine, Icahn School of Medicine at Mount
Sinai, New York, New York, United States
(Kumar) Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio,
United States
(Wang) Robert D. and Patricia E. Kern Center for the Science of Health
Care Delivery
(Wang) Division of Health Care Policy and Research, Department of Health
Sciences Research, Mayo Clinic, Rochester, Minnesota, United States
(Volpi) Department of Neurology, Houston Methodist Neurological Institute,
Houston, Texas, United States
Publisher
Elsevier Inc.

<2>
Accession Number
2016132836
Title
Systematic review of electrophysiology procedures in patients with
obstruction of the inferior vena cava.
Source
Journal of Cardiovascular Electrophysiology. 33(6) (pp 1300-1311), 2022.
Date of Publication: June 2022.
Author
Al-Sinan A.; Chan K.H.; Young G.D.; Martin A.; Sepahpour A.; Sy R.W.
Institution
(Al-Sinan, Chan, Sy) Department of Cardiology, Royal Prince Alfred
Hospital, Sydney, Australia
(Al-Sinan) Department of Cardiology, Waikato Hospital, Hamilton, New
Zealand
(Chan, Sy) Faculty of Medicine and Health, The University of Sydney,
Sydney, Australia
(Young) Department of Cardiology, Royal Adelaide Hospital, Adelaide,
Australia
(Martin) Green Lane Cardiovascular Service, Auckland City Hospital,
Auckland, New Zealand
(Sepahpour) Department of Cardiology, St. George Hospital, Sydney,
Australia
Publisher
John Wiley and Sons Inc
Abstract
Aims: The objective of the study was to conduct a systematic review to
describe and compare the different approaches for performing cardiac
electrophysiology (EP) procedures in patients with interrupted inferior
vena cava (IVC) or equivalent entities causing IVC obstruction.
<br/>Method(s): We conducted a structured search to identify manuscripts
reporting EP procedures with interrupted IVC or IVC obstruction of any
aetiology published up until August 2020. No restrictions were applied in
the search strategy. We also included seven local cases that met inclusion
criteria. <br/>Result(s): The analysis included 142 patients (mean age
48.9 years; 48% female) undergoing 143 procedures. Obstruction of the IVC
was not known before the index procedure in 54% of patients. Congenital
interruption of IVC was the most frequent cause (80%); and, associated
congenital heart disease (CHD) was observed in 43% of patients in this
setting. The superior approach for ablation was the most frequently used
strategy (52%), followed by inferior approach via the azygos or hemiazygos
vein (24%), transhepatic approach (14%), and retroaortic approach (10%).
Electroanatomical mapping (58%), use of long sheaths (41%), intracardiac
echocardiography (19%), transesophageal echocardiography (15%) and remote
controlled magnetic navigation (13%) were used as adjuncts to aid
performance. Ablation was successful in 135 of 140 procedures in which
outcomes were reported. Major complications were only reported in patients
undergoing AF ablation, including two patients with pericardial effusion,
one of whom required surgical repair, and another patient who died after
inadvertent entry into an undiagnosed atrioesophageal fistula from a
previous procedure. <br/>Conclusion(s): The superior approach is most
frequent approach for performing EP procedures in the setting of
obstructed IVC. Transhepatic approach is a feasible alternative, and may
provide a "familiar approach" for transseptal access when it is required.
Adjunctive use of long sheaths, intravascular echocardiography,
electro-anatomical mapping and remote magnetic navigation may be helpful,
especially if there is associated complex CHD. With careful planning, EP
procedures can usually be successfully performed with a low risk of
complications.<br/>Copyright &#xa9; 2022 The Authors. Journal of
Cardiovascular Electrophysiology published by Wiley Periodicals LLC.

<3>
Accession Number
2007403619
Title
Mechanical or biological heart valve for dialysis-dependent patients? A
meta-analysis.
Source
Journal of Thoracic and Cardiovascular Surgery. 163(6) (pp 2057-2071.e12),
2022. Date of Publication: June 2022.
Author
Chi K.-Y.; Chiang M.-H.; Kang Y.-N.; Li S.-J.; Chan Y.-T.; Chen Y.-C.;
Wang S.-T.
Institution
(Chi) Department of Education, Center for Evidence-Based Medicine, Taipei
Medical University Hospital, Taipei, Taiwan (Republic of China)
(Chiang) School of Medicine, College of Medicine, Taipei Medical
University, Taipei, Taiwan (Republic of China)
(Kang) Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical
University, Taipei, Taiwan (Republic of China)
(Kang) Institute of Health Policy & Management, College of Public Health,
National Taiwan University, Taipei, Taiwan (Republic of China)
(Li) Cardiovascular Research Center, Wan Fang Hospital, Taipei Medical
University, Taipei, Taiwan (Republic of China)
(Li) Taipei Heart Institute, Taipei Medical University, Taipei, Taiwan
(Republic of China)
(Li) Division of Cardiovascular Surgery, Department of Surgery, Wan Fang
Hospital, Taipei Medical University, Taipei, Taiwan (Republic of China)
(Chan) Department of General Medicine, Shuang Ho Hospital, Taipei Medical
University, Taipei, Taiwan (Republic of China)
(Chen, Wang) Department of Family Medicine, Taipei Medical University
Hospital, Taipei, Taiwan (Republic of China)
(Chen, Wang) Department of Family Medicine, School of Medicine, College of
Medicine, Taipei Medical University, Taipei, Taiwan (Republic of China)
(Chen) School of Nutrition and Health Sciences, College of Nutrition,
Taipei Medical University, Taipei, Taiwan (Republic of China)
(Chen) Graduate Institute of Metabolism and Obesity Sciences, Taipei
Medical University, Taipei, Taiwan (Republic of China)
(Wang) Health Management Center, Taipei Medical University Hospital,
Taipei, Taiwan (Republic of China)
Publisher
Elsevier Inc.
Abstract
Objective: The optimal selection of prosthetic heart valve for
dialysis-dependent patients remains controversial. We investigated the
comparative effectiveness and safety of mechanical prosthesis (MP) and
bioprosthesis (BP) for these patients. <br/>Method(s): After the
systematic review, we included studies that involved patients on dialysis
undergoing aortic valve replacement or mitral valve replacement (MVR) and
reported comparative outcomes of MP and BP. Meta-analysis was performed
using random-effects model. We conducted a subgroup analysis based on the
valve position and postoperative international normalized ratio (INR),
which was extracted from either tables or methods of each study. A
meta-regression was used to examine the effects of study-level covariates.
<br/>Result(s): We included 24 retrospective studies without
randomized-controlled trials, involving 10,164 participants (MP = 6934, BP
= 3230). Patients undergoing aortic valve replacement with MP exhibited a
better long-term survival effectiveness (hazard ratio, 0.64; 95%
confidence interval [CI], 0.47-0.86). Conversely, studies including MVR
demonstrated little difference in survival (hazard ratio, 0.90; 95% CI,
0.73-1.12). A meta-regression revealed that age had little effect on
long-term survival difference between MP and BP (beta = -0.0135, P =
.433). MP had a significantly greater bleeding risk than did BP when INR
was above 2.5 (incidence rate ratio, 10.58; 95% CI, 2.02-55.41). However,
when INR was below 2.5, bleeding events were comparable (incidence rate
ratio, 1.73; 95% CI, 0.78-3.82). The structural valve deterioration rate
was significantly lower in MP (risk ratio, 0.24; 95% CI, 0.14-0.44).
<br/>Conclusion(s): MP is a reasonable choice for dialysis-dependent
patients without additional thromboembolic risk requiring aortic valve
replacement, for its better long-term survival, durability, and
noninferior bleeding risk compared with BP. Conversely, BP might be an
appropriate selection for patients with MVR, given its similar survival
rate and lower bleeding risk. Although our meta-regression demonstrates
little influence of age on long-term survival difference between MP and
BP, further studies stratifying patients based on age cut-off are
mandatory.<br/>Copyright &#xa9; 2020 The American Association for Thoracic
Surgery. Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

<4>
Accession Number
638024362
Title
Atheroma or ischemia: which is more important for managing patients with
stable chest pain?.
Source
Future Cardiology. 18(5) (pp 417-429), 2022. Date of Publication: May
2022.
Author
Bashar H.; Hinton J.; Curzen N.
Institution
(Bashar, Hinton, Curzen) Coronary Research Group, University Hospital
Southampton NHS Foundation Trust, Southampton SO16 6YD, United Kingdom
(Hinton, Curzen) Faculty of Medicine, University of Southampton,
Southampton SO17 1BJ, United Kingdom
Publisher
Newlands Press Ltd
Abstract
In the evaluation and management of patients with stable chest
pain/chronic coronary syndrome, cardiologists need to be able to weigh up
the relative merits of managing these patients using either optimal
therapy alone or optimal therapy plus revascularization. These decisions
rely on an understanding of both the presence and the degree of coronary
atheroma and myocardial ischemia, and the impact that these have on
patients' symptoms and their prognosis. In this review the authors examine
the relative impact of the anatomical and physiological assessment of
patients with chronic coronary syndrome and how it can be used to achieve
optimal and tailored therapy.<br/>Copyright &#xa9; 2022 Future Medicine
Ltd.

<5>
Accession Number
2018374468
Title
Efficacy of Primary Closure Technique in Treatment of Post-Sternotomy
Mediastinitis in Paediatric Group: A Randomized Controlled Trial.
Source
International Journal of General Medicine. 15 (pp 7929-7939), 2022. Date
of Publication: 2022.
Author
Fadaly A.S.; Abdellatif G.M.; Saeed S.E.; Brik A.; Elsharawy M.; Deebis
A.; Elfwakhry R.M.; Shemais D.S.
Institution
(Fadaly, Saeed, Brik, Elsharawy, Deebis, Shemais) Department of
Cardiothoracic Surgery, Faculty of Human Medicine, Zagazig University,
Zagazig, Egypt
(Abdellatif) Department of Pediatric medicine, Faculty of Human Medicine,
Zagazig University, Zagazig, Egypt
(Elfwakhry) Department of Radiodiagnosis, Faculty of Human Medicine,
Zagazig University, Zagazig, Egypt
Publisher
Dove Medical Press Ltd
Abstract
Purpose: To assess the efficacy of primary sternal closure technique
compared to vacuum-assisted closure technique in treatment of post-cardiac
surgery mediastinitis in paediatric age group. Additionally, assessed
postoperative need for IV drug use, hospital stay length, wound and
sternal healing and survival. Hypotheses: primary sternal closure is a
reliable technique for treatment of poststernotomy mediastinitis following
cardiac surgery in paediatric age group. <br/>Material(s) and Method(s): A
prospective randomized controlled trial included 217 pediatric patients
developed post-cardiac surgery mediastinitis from 2016 to 2022. They were
randomly divided into primary sternal closure group (A) and
vacuum-assisted closure group (B) and operated by two cardiothoracic
surgeons. Follow-up of the patients was done for 6-months duration
following treatment of mediastinitis to assess postoperative need for
hospitalization, IV drug use, wound complications, sternal stability and
survival. <br/>Result(s): The final analysis included 101 patients in each
group. The chance of survival over 6 months after surgery was more for
primary sternal closure group (175.2) days versus (157.6) days for the
vacuum-assisted closure group, with significant difference Log Rank test
p-value (0.005). Duration for IV antibiotics use in the primary closure
group was 8.55+/-3.57 and it was 32.61+/-8.39 showing high statistically
significant difference (p<0.001). Patients in the primary closure group
had earlier discharge from hospital 15.77+/-4.18 than vacuum assisted
group 42.61+/-8.39, with high statistically significant difference
(p<0.001). Primary closure group showed better sternal stability and
sternotomy wound healing on clinical follow-up. <br/>Conclusion(s):
Primary sternal closure technique is a favorable technique over
vacuum-assisted closure technique for treatment of paediatric
mediastinitis following cardiac surgery. The reinforced sternal closure
technique is a reliable technique with promising results regarding IV
drugs need, hospitalization duration, survival and sternotomy wound
healing.<br/>Copyright &#xa9; 2022 Fadaly et al.

<6>
Accession Number
2018320234
Title
Prospective clinical intervention study of aripiprazole and risperidone in
the management of postoperative delirium in elderly patients after
cardiovascular surgery.
Source
Psychiatry and Clinical Neurosciences. 76(10) (pp 531-533), 2022. Date of
Publication: October 2022.
Author
Sugawara H.; Koyama A.; Maruyama T.; Koda Y.; Fukunaga H.; Ishikawa T.;
Takebayashi M.; Okamoto K.; Fukui T.; Hashimoto M.
Institution
(Sugawara) Department of Psychiatry, Kansai Rosai Hospital, Hyogo,
Amagasaki, Japan
(Sugawara) Department of Psychiatry, Osaka University Graduate School of
Medicine, Osaka, Suita, Japan
(Koyama, Koda, Ishikawa, Takebayashi) Department of Neuropsychiatry,
Kumamoto University Hospital, Kumamoto, Kumamoto, Japan
(Maruyama) Department of Social Work, Faculty of Human and Social Studies,
Nagasaki International University, Nagasaki, Sasebo, Japan
(Fukunaga) Department of Nursing, Kumamoto School of Nursing, Kumamoto,
Kumamoto, Japan
(Okamoto, Fukui) Department of Cardiovascular Surgery, Kumamoto University
Hospital, Kumamoto, Kumamoto, Japan
(Hashimoto) Department of Neuropsychiatry, Kindai University Faculty of
Medicine, Osaka, Sayama, Japan
Publisher
John Wiley and Sons Inc

<7>
Accession Number
2018179217
Title
Transcatheter aortic valve replacement for structural degeneration of
previously implanted transcatheter valves (TAVR-in-TAVR): a systematic
review.
Source
European Journal of Cardio-thoracic Surgery. 61(5) (pp 967-976), 2022.
Date of Publication: 01 May 2022.
Author
Gallo M.; Fovino L.N.; Blitzer D.; Doulamis I.P.; Guariento A.; Salvador
L.; Tagliari A.P.; Ferrari E.
Institution
(Gallo, Ferrari) Department of Cardiac Surgery, Cardiocentro Ticino
Institute, Via Tesserete 48, Lugano 6900, Switzerland
(Gallo, Salvador) Department of Cardiac Surgery, San Bortolo Hospital,
Vicenza, Italy
(Fovino) Department of Cardiology, University of Padova, Padova, Italy
(Blitzer) Department of Surgery, New York Presbyterian Hospital, Columbia
University, New York, NY, United States
(Doulamis) Department of Cardiac Surgery, Boston Children's Hospital,
Harvard Medical School, Boston, MA, United States
(Guariento) Department of Cardiovascular Surgery, Labatt Family Heart
Centre, The Hospital for Sick Children, University of Toronto, Toronto,
ON, Canada
(Tagliari) Postgraduate Program in Health Sciences: Cardiology and
Cardiovascular Sciences, Universidade Federal Do Rio Grande Dosul, Porto
Alegre, Brazil
(Ferrari) University of Zurich, Zurich, Switzerland
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: Transcatheter aortic valve replacement (TAVR) represents a
valid treatment for patients with aortic valve stenosis and high or
intermediate surgical risk. However, biological transcatheter valves can
also experience a structural degeneration after years, and a redo-TAVR
procedure (TAVR-in-TAVR) can be a valid option. We revised the current
available literature for indications, procedural and technical details and
outcome on TAVR-in-TAVR procedures for degenerated TAVR valves.
<br/>METHOD(S): A systematic search was conducted in the public medical
database for scientific articles on TAVR-in-TAVR procedures for
degenerated transcatheter valves. Data on demographics, indications, first
and second transcatheter valve type and size, mortality, complications and
follow-up were extracted and analysed. <br/>RESULT(S): A total of 13
studies (1 multicentre, 3 case series, 9 case reports) were included in
this review, with a total amount of 160 patients treated with TAVR-in-TAVR
procedures for transcatheter valve failure. The mean age was 74.8 +/- 7.8
with 84 males (52.8%). The mean elapsed time from the first TAVR procedure
was 58.1 +/- 23.4 months. Main indication for TAVR-in-TAVR was pure
stenosis (38.4%, with mean gradient of 44.5 +/- 18.5 mmHg), regurgitation
(31.4%), mixed stenosis and regurgitation (29.5%) and leaflet thrombosis
(8.8%). Procedural success rate was 86.8%, with second TAVR valve
malposition occurred in 4 cases (2.5%). The hospital mortality rate was
1.25% (2/160). Post-procedural echocardiographic control showed moderate
regurgitation in 5.6% of patients (9/160) and residual transvalvular mean
gradient >=20 mmHg in 5% of cases. Postoperative complications included
major vascular complications (8.7%), new pacemaker implantation (8.7%),
acute kidney failure (3.7%), stroke (0.6%) and coronary obstruction
(0.6%). The mean follow-up time was 6 +/- 5.6 months with 1
non-cardiovascular death reported. <br/>CONCLUSION(S): TAVR-in-TAVR
represents a valid alternative to standard surgery for the treatment of
degenerated transcatheter valves in high-risk patients. Despite these
promising results, further studies are required to assess durability and
haemodynamic performances of the second TAVR valve.<br/>Copyright &#xa9;
2021 The Author(s) 2021. Published by Oxford University Press on behalf of
the European Association for Cardio-Thoracic Surgery. All rights reserved.

<8>
Accession Number
2019705327
Title
Clinical impact of cardiac magnetic resonance in patients with suspected
coronary artery disease associated with chronic kidney disease
(AQUAMARINE-CKD study): study protocol for a randomized controlled trial.
Source
Trials. 23(1) (no pagination), 2022. Article Number: 904. Date of
Publication: December 2022.
Author
Noguchi T.; Ota H.; Matsumoto N.; Morita Y.; Oshita A.; Kawasaki E.;
Kawasaki T.; Moriwaki K.; Kato S.; Fukui K.; Hoshi T.; Watabe H.; Kanaya
T.; Asaumi Y.; Kataoka Y.; Otsuka F.; Takagi K.; Yoneda S.; Sawada K.;
Iwai T.; Matama H.; Honda S.; Fujino M.; Miura H.; Nishimura K.; Takase K.
Institution
(Noguchi, Asaumi, Kataoka, Otsuka, Takagi, Yoneda, Sawada, Iwai, Matama,
Honda, Fujino, Miura) Department of Cardiovascular Medicine, National
Cerebral and Cardiovascular Center, 6-1 Kishibe-shimmachi, Suita 564-8565,
Japan
(Ota) Department of Diagnostic Radiology, Tohoku University Hospital, 1-1
Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
(Matsumoto) Division of Cardiology, Department of Medicine, Nihon
University School of Medicine, Nihon University Hospital, 1-6
Kanda-surugadai, Chiyoda-ku, Tokyo 101-8309, Japan
(Morita) Department of Radiology, National Cerebral and Cardiovascular
Center, 6-1 Kishibe-Shimmachi, Suita 564-8565, Japan
(Oshita) Department of Cardiology, Ehime Prefectural Imabari Hospital,
4-5-5 Ishiicho, Imabari 794-0006, Japan
(Kawasaki) Department of Diabetes and Endocrinology, Shin-Koga Hospital,
120 Tenjin-cho, Kurume 830-8577, Japan
(Kawasaki) Cardiovascular and Heart Rhythm Center, Shin-Koga Hospital, 120
Tenjin-cho, Kurume 830-8577, Japan
(Moriwaki) Comprehensive Unit for Health Economic Evidence Review and
Decision Support, Research Organization of Science and Technology,
Ritsumeikan University, Kyoto 604-8520, Japan
(Kato, Fukui) Department of Cardiovascular Medicine, Kanagawa
Cardiovascular and Respiratory Center, Yokohama 236-0051, Japan
(Hoshi, Watabe) Cardiovascular Division, Faculty of Medicine, University
of Tsukuba, Ibaraki 305-8576, Japan
(Kanaya) Department of Cardiovascular Medicine, Dokkyo Medical University
Hospital, 880 kitakobayashi, Mibu, Tochigi 321-0293, Japan
(Nishimura) Department of Preventive Medicine and Epidemiology, National
Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita 564-8565,
Japan
(Takase) Department of Diagnostic Radiology, Tohoku University Graduate
School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan
Publisher
BioMed Central Ltd
Abstract
Background: Although screening for coronary artery disease (CAD) using
computed tomography coronary angiography in patients with stable chest
pain has been reported to be beneficial, patients with chronic kidney
disease (CKD) might have limited benefit due to complications of contrast
agent nephropathy and decreased diagnostic accuracy as a result of
coronary artery calcifications. Cardiac magnetic resonance (CMR) has
emerged as a novel imaging modality for detecting coronary stenosis and
high-risk coronary plaques without contrast media that is not affected by
coronary artery calcification. However, the clinical use of this
technology has not been robustly evaluated. <br/>Method(s): AQUAMARINE-CKD
is an open parallel-group prospective multicenter randomized controlled
trial of 524 patients with CKD at high risk for CAD estimated based on
risk factor categories for a Japanese urban population (Suita score)
recruited from 6 institutions. Participants will be randomized 1:1 to
receive a CMR examination that includes non-contrast T1-weighted imaging
and coronary magnetic angiography (CMR group) or standard examinations
that include stress myocardial scintigraphy (control group). Randomization
will be conducted using a web-based system. The primary outcome is a
composite of cardiovascular events at 1 year after study examinations:
all-cause death, death from CAD, nonfatal myocardial infarction, nonfatal
ischemic stroke, and ischemia-driven unplanned coronary intervention
(percutaneous coronary intervention or coronary bypass surgery).
<br/>Discussion(s): If the combination of T1-weighted imaging and coronary
magnetic angiography contributes to the risk assessment of CAD in patients
with CKD, this study will have major clinical implications for the
management of patients with CKD at high risk for CAD. Trial registration:
Japan Registry of Clinical Trials (jRCT) 1,052,210,075. Registered on
September 10, 2021.<br/>Copyright &#xa9; 2022, The Author(s).

<9>
Accession Number
2019411152
Title
Dose optimization of beta-lactams antibiotics in pediatrics and adults: A
systematic review.
Source
Frontiers in Pharmacology. 13 (no pagination), 2022. Article Number:
964005. Date of Publication: 21 Sep 2022.
Author
Haseeb A.; Faidah H.S.; Alghamdi S.; Alotaibi A.F.; Elrggal M.E.; Mahrous
A.J.; Abuhussain S.S.A.; Obaid N.A.; Algethamy M.; AlQarni A.; Khogeer
A.A.; Saleem Z.; Iqbal M.S.; Ashgar S.S.; Radwan R.M.; Mutlaq A.; Fatani
N.; Sheikh A.
Institution
(Haseeb, Alotaibi, Elrggal, Mahrous, Abuhussain) Department of Clinical
Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi
Arabia
(Faidah, Ashgar) Department of Microbiology, Faculty of Medicine, Umm
Al-Qura University, Makkah, Saudi Arabia
(Alghamdi) Department of Clinical Pharmacy, Faculty of Clinical Pharmacy,
Al Baha University, Al Baha, Saudi Arabia
(Obaid) Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura
University, Makkah, Saudi Arabia
(Algethamy) Department of Infection Prevention and Control Program, Alnoor
Specialist Hospital, Makkah, Saudi Arabia
(AlQarni) Infectious Diseases Department, Alnoor Specialist Hospital,
Makkah, Saudi Arabia
(Khogeer) Plan and Research Department, General Directorate of Health
Affairs of Makkah Region, Ministry of Health, Makkah, Saudi Arabia
(Khogeer) Medical Genetics Unit, Maternity and Children Hospital, Makkah
Healthcare Cluster, Ministry of Health, Makkah, Saudi Arabia
(Saleem) Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin
Zakariya Univrsity, Multan, Pakistan
(Iqbal) Department of Clinical Pharmacy, College of Pharmacy, Prince
Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
(Radwan) Pharmaceutical Care Department, Alnoor Specialist Hospital,
Ministry of Health, Makkah, Saudi Arabia
(Mutlaq) General Department of Pharmaceutical Care, Ministry of Health,
Riyadh, Saudi Arabia
(Fatani) King Abdulaziz University, Jeddah, Saudi Arabia
(Sheikh) Usher Institute, The University of Edinburgh, Edinburgh, United
Kingdom
Publisher
Frontiers Media S.A.
Abstract
Background: beta-lactams remain the cornerstone of the empirical therapy
to treat various bacterial infections. This systematic review aimed to
analyze the data describing the dosing regimen of beta-lactams.
<br/>Method(s): Systematic scientific and grey literature was performed in
accordance with Preferred Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines. The studies were retrieved and screened on the basis
of pre-defined exclusion and inclusion criteria. The cohort studies,
randomized controlled trials (RCT) and case reports that reported the
dosing schedule of beta-lactams are included in this study.
<br/>Result(s): A total of 52 studies met the inclusion criteria, of which
40 were cohort studies, 2 were case reports and 10 were RCTs. The majority
of the studies (34/52) studied the pharmacokinetic (PK) parameters of a
drug. A total of 20 studies proposed dosing schedule in pediatrics while
32 studies proposed dosing regimen among adults. Piperacillin (12/52) and
Meropenem (11/52) were the most commonly used beta-lactams used in
hospitalized patients. As per available evidence, continuous infusion is
considered as the most appropriate mode of administration to optimize the
safety and efficacy of the treatment and improve the clinical outcomes.
<br/>Conclusion(s): Appropriate antibiotic therapy is challenging due to
pathophysiological changes among different age groups. The optimization of
pharmacokinetic/pharmacodynamic parameters is useful to support
alternative dosing regimens such as an increase in dosing interval,
continuous infusion, and increased bolus doses.<br/>Copyright &#xa9; 2022
Haseeb, Faidah, Alghamdi, Alotaibi, Elrggal, Mahrous, Abuhussain, Obaid,
Algethamy, AlQarni, Khogeer, Saleem, Iqbal, Ashgar, Radwan, Mutlaq, Fatani
and Sheikh.

<10>
Accession Number
2021048430
Title
Sex differences among patients receiving ticagrelor monotherapy or aspirin
after coronary bypass surgery: A prespecified subgroup analysis of the
TiCAB trial.
Source
International Journal of Cardiology. (no pagination), 2022. Date of
Publication: 2022.
Author
Sandner S.; Kastrati A.; Niessner A.; Boning A.; Zeymer U.; Conradi L.;
Danner B.; Zimpfer D.; Farber G.; Manville E.; Schunkert H.; von Scheidt
M.; Grothusen C.; Cremer J.; Attmann T.; Friedrich I.; Oberhoffer M.;
Knosalla C.; Walther T.; Wimmer-Greinecker G.; Siepe M.; Grubitzsch H.;
Joost A.; Schaefer A.; Misfeld M.; Laufer G.; Wiedemann D.; Englberger L.;
Hambrecht R.
Institution
(Sandner, Manville) Department of Cardiac Surgery, Medical University of
Vienna, Austria
(Kastrati, Schunkert, von Scheidt) Deutsches Herzzentrum Munchen,
Technische Universitat Munchen, Germany
(Kastrati, Schunkert, von Scheidt) German Center for Cardiovascular
Research, Heart Alliance, Munich, Germany
(Niessner) Department of Internal Medicine II, Division of Cardiology,
Medical University of Vienna, Austria
(Boning) Department of Cardiovascular Surgery, University Hospital
Giessen, Germany
(Zeymer) Department of Cardiology, Klinikum Ludwigshafen and Institut fur
Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany
(Conradi, Schaefer) Department of Cardiovascular Surgery, University Heart
and Vascular Center Hamburg, Hamburg, Germany
(Danner) Department of Cardiac, Thoracic and Vascular Surgery, University
Medical Center, Gottingen, Germany
(Zimpfer) Department of Cardiac Surgery, Medical University Graz, Graz,
Austria
(Farber) Department of Cardiothoracic Surgery, Universitatsklinikum Jena,
Jena, Germany
(Grothusen, Cremer, Attmann) Department of Cardiac Surgery,
Universitatsklinikum Schleswig-Holstein, Kiel, Germany
(Friedrich) Department of Cardiothoracic Sugery, Krankenhaus der
Barmherzigen Bruder Trier, Germany
(Oberhoffer) Department of Cardiac Surgery, Klinik und Poliklinik fur
Herz- und Gefaschirurgie, Johannes Gutenberg Universitat Mainz, Mainz,
Germany
(Knosalla) Department of Cardiothoracic and Vascular Surgery, German Heart
Institute Berlin, Berlin, Germany
(Knosalla) Germany and German Center for Cardiovascular Research, Partner
Site Berlin, Berlin, Germany
(Walther) Department of Cardiac Surgery, Universitatsklinikum Frankfurt,
Frankfurt am Main, Germany
(Wimmer-Greinecker) Department for Cardiothoracic Surgery, Heart and
Vessel Center Bad Bevensen, Bad Bevensen, Germany
(Siepe) Department of Cardiac Surgery, University Hospital Bern,
Switzerland
(Grubitzsch) Department of Cardiovascular Surgery, Charite
Universitatsmedizin Berlin, Berlin, Germany
(Joost) Department of Cardiology, Angiology and Intensive Care Medicine,
Medical Clinic II, University Hospital Schleswig-Holstein, Lubeck, Germany
(Misfeld) Department of Cardiac Surgery, Leipzig Heart Center, Leipzig,
Germany
(Laufer, Wiedemann) Department of Cardiac Surgery, Medical University of
Vienna, Vienna, Austria
(Englberger) Department of Cardiac Surgery, University Hospital Bern,
Bern, Switzerland
(Hambrecht) Department of Cardiology and Angiology, Klinikum Links der
Weser, Bremen, Germany
Publisher
Elsevier Ireland Ltd
Abstract
Background: There is limited evidence on the association of sex with
outcomes among patients undergoing coronary bypass surgery (CABG) and
treated with ticagrelor monotherapy or aspirin. <br/>Method(s): This was a
pre-specified sub-analysis of TiCAB, an investigator-initiated
placebo-controlled randomized trial. Primary efficacy endpoint was the
composite of cardiovascular death, myocardial infarction, stroke, or
repeat revascularization 1 year after CABG. Safety endpoint was BARC type
2, 3 or 5 bleeding. <br/>Result(s): A total of 280 (15.0%) women and 1579
(85.0%) men were included. Compared with men, women were older (66.1 +/-
10.2 vs. 70.1 +/- 9.3 years) with more acute presentation (17.0% vs
21.1%). The incidence of the primary endpoint was similar between women
and men (9.2% vs. 8.9%, HR 1.08, 95%CI 0.71-1.66, P = 0.71).
Cardiovascular death occurred more often in women (2.9% vs 1.0%, adjusted
HR 2.87, 95%CI 1.23-6.70, P = 0.02). The incidence of bleeding was similar
between the sexes (2.2% vs. 2.5%, HR 0.91, 95% CI 0.51-1.65, P = 0.77).
Ticagrelor vs aspirin was associated with a similar risk of the primary
endpoint in women (10.6% vs. 7.9%, HR 1.39, 95%CI 0.63-3.05, P = 0.42) and
men (9.5% vs. 8.2%, HR 1.15, 95%CI 0.82-1.62, P =
0.41;p<inf>interaction</inf> = 0.69), and a similar risk of bleeding in
women (2.9% vs. 1.4%, HR 2.09, 95%CI 0.38-11.41, P = 0.40) and men (2.2%
vs. 2.8%, HR 0.80, 95%CI 0.42-1.52, P = 0.49;p<inf>interaction</inf> =
0.35). <br/>Conclusion(s): Among women and men undergoing CABG, ticagrelor
monotherapy was associated with a similar risk of the primary efficacy
endpoint and bleeding compared with aspirin. The risk of cardiovascular
death was increased in women irrespective of antiplatelet
therapy.<br/>Copyright &#xa9; 2022 The Author(s)

<11>
Accession Number
2020994377
Title
Meta-Analysis on the Association Between Nutritional Status and Outcomes
After Transcatheter Aortic Valve Implantation.
Source
American Journal of Cardiology. (no pagination), 2022. Date of
Publication: 2022.
Author
Kazemian S.; Tavolinejad H.; Rashedi S.; Yarahmadi P.; Farrokhpour H.;
Kolte D.
Institution
(Kazemian, Tavolinejad, Rashedi, Yarahmadi, Farrokhpour) Tehran Heart
Center, Cardiovascular Diseases Research Institute, Tehran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Kazemian, Tavolinejad, Rashedi, Yarahmadi, Farrokhpour) Cardiac Primary
Prevention Research Center, Cardiovascular Diseases Research Institute,
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Tavolinejad) Non-Communicable Diseases Research Center, Endocrinology and
Metabolism Population Sciences Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Kolte) Cardiology Division, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, United States
Publisher
Elsevier Inc.
Abstract
Malnutrition is a common co-morbidity among candidates for transcatheter
aortic valve implantation (TAVI). This study aimed to investigate the
association between nutritional status determined by objective nutritional
indices and outcomes of patients who underwent TAVI. We systematically
searched PubMed, Embase, Web of Science, Scopus, and Cochrane Library from
inception until April 18, 2022 to identify studies examining the
association of preprocedural nutritional status with post-TAVI outcomes.
Malnutrition was defined by objective nutritional indices-controlling
nutritional index, nutritional risk index, geriatric nutritional risk
index (GNRI), and prognostic nutritional index (PNI). The primary end
point was 1-year all-cause mortality. The review included 13 observational
studies and 6,785 patients who underwent TAVI. Malnutrition was associated
with a higher risk of 1-year all-cause mortality, as defined by either the
controlling nutritional index (hazard ratio [HR] 2.70, 95% confidence
interval [CI] 1.21 to 6.03, p = 0.015), GNRI (HR 1.79, 95% CI 1.09 to
2.93, p = 0.021), or PNI (HR 1.17, 95% CI 1.11 to 1.23, p <0.001). In the
meta-analysis of adjusted results, lower GNRI was independently associated
with higher 1-year mortality (HR 1.70, 95% CI 1.16 to 2.50, p = 0.006).
Lower GNRI was associated with increased risk of acute kidney injury
(relative risk [RR] 2.21, 95% CI 1.63 to 2.99, p <0.001) and 1-year
cardiovascular mortality (RR 2.50, 95% CI 1.66 to 3.78, p <0.001). Lower
PNI was associated with a higher risk of major vascular complications (RR
2.99, 95% CI 1.38 to 6.51, p = 0.006). In conclusion, baseline
malnutrition, as assessed by objective indices, is associated with worse
outcomes after TAVI. Future studies should focus on the value of
nutritional assessment and interventions to improve nutritional status in
patients who underwent TAVI.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<12>
Accession Number
2017014146
Title
Evaluation of indigenously developed closed-loop automated blood pressure
control system (claps): a preliminary study.
Source
Journal of Clinical Monitoring and Computing. 36(6) (pp 1657-1665), 2022.
Date of Publication: December 2022.
Author
Kumar S.; Puri G.D.; Mathew P.J.; Mandal B.
Institution
(Kumar, Puri, Mathew, Mandal) Department of Anaesthesia & Critical Care,
Postgraduate Institute of Medical Education & Research, Chandigarh, India
(Kumar) Nehru Hospital, Postgraduate Institute of Medical Education &
Research, , Anaesthesia Office 4th Floor, Chandigarh 160012, India
Publisher
Springer Science and Business Media B.V.
Abstract
Closed-loop systems have been designed to assist anesthetists in
controlling anesthetic drugs and also maintaining the stability of various
physiological variables in the normal range. In the present study, we
describe and clinically evaluated a novel closed-loop automated blood
pressure control system (CLAPS) in patients undergoing cardiac surgery
under cardiopulmonary bypass. Forty ASA II-IV adult patients undergoing
elective cardiac surgery were randomly allocated to receive adrenaline,
noradrenaline, phenylephrine and nitroglycerine (NTG) adjusted either
through CLAPS (CLAPS group) or manually (Manual group). The desired target
mean arterial blood pressure (MAP) for each patient in both groups was set
by the attending anesthesiologist. The hemodynamic performance was
assessed based on the percentage duration of time the MAP remained within
20% of the set target. Automated controller performances were compared
using performance error criteria of Varvel (MDPE, MDAPE, Wobble) and
Global Score. MAP was maintained a significantly longer proportion of time
within 20% of the target in the CLAPS group (79.4% vs. 65.5% p < 0.001,
't' test) as compared to the manual group. Median absolute performance
error, wobble, and Global score was significantly lower in the CLAPS
group. Hemodynamic stability was achieved with a significantly lower dose
of Phenyepherine in the CLAPS group (1870 mug vs. 5400 mug, p < 0.05, 't'
test). The dose of NTG was significantly higher in the CLAPS group (3070
mug vs. 1600 mug, p-value < 0.05, 't' test). The cardiac index and left
ventricular end-diastolic area were comparable between the groups.
Automated infusion of vasoactive drugs using CLAPS is feasible and also
better than manual control for controlling hemodynamics during cardiac
surgery. Trial registration number and date This trial was registered in
the Clinical Trial Registry of India under Registration Number
CTRI/2018/01/011487 (Retrospective; registration date; January 23,
2018).<br/>Copyright &#xa9; 2022, The Author(s), under exclusive licence
to Springer Nature B.V.

<13>
Accession Number
2015389119
Title
Prospective validation of gas man simulations of sevoflurane in
O<inf>2</inf>/air over a wide fresh gas flow range.
Source
Journal of Clinical Monitoring and Computing. 36(6) (pp 1881-1890), 2022.
Date of Publication: December 2022.
Author
Candries E.; De Wolf A.M.; Hendrickx J.F.A.
Institution
(Candries) Faculty of Medicine and Health Sciences, UZ Gent, Ghent
University, Corneel Heymanslaan 10, Ghent 9000, Belgium
(De Wolf) Department of Anesthesiology, Feinberg School of Medicine,
Northwestern University, Chicago, IL, United States
(Hendrickx) Department of Anesthesiology, OLV Hospital, Aalst, Belgium
(Hendrickx) Department of Basic and Applied Medical Sciences, Ghent
University, Ghent, Belgium
(Hendrickx) Department of Anesthesiology, UZ Leuven, Leuven, Belgium
(Hendrickx) Department of Cardiovascular Sciences, KU Leuven, Leuven,
Belgium
Publisher
Springer Science and Business Media B.V.
Abstract
The use of inhaled anesthetics has come under increased scrutiny because
of their environmental effects. This has led to a shift where sevoflurane
in O<inf>2</inf>/air has become the predominant gas mixture to maintain
anesthesia. To further reduce environmental impact, lower fresh gas flows
(FGF) should be used. An accurate model of sevoflurane consumption allows
us to assess and quantify the impact of the effects of lowering FGFs. This
study therefore tested the accuracy of the Gas Man model by determining
its ability to predict end-expired sevoflurane concentrations
(F<inf>ET</inf>sevo) in patients using a protocol spanning a wide range of
FGF and vaporizer settings. After IRB approval, 28 ASA I-II patients
undergoing a gynecologic or urologic procedure under general endotracheal
anesthesia were enrolled. Anesthesia was maintained with sevoflurane in
O<inf>2</inf>/air, delivered via a Zeus or FLOW-i workstation (14 patients
each). Every fifteen min, FGF was changed to randomly selected values
ranging from 0.2 to 6 L/min while the sevoflurane vaporizer setting was
left at the discretion of the anesthesiologist. The F<inf>ET</inf>sevo was
collected every min for 1 h. For each patient, a Gas Man simulation was
run using patient weight and the same FGF, vaporizer and minute
ventilation settings used during the procedure. For cardiac output, the
Gas Man default setting was used (= Brody formula). Gas Man's performance
was assessed by comparing measured with Gas Man predicted
F<inf>ET</inf>sevo using linear regression and Varvel's criteria [median
performance error (MDPE), median absolute performance error (MDAPE), and
divergence]. Additional analysis included separating performance for the
wash-in (0-15 min) and maintenance phase (15-60 min). For the FLOW-i,
MDPE, MDAPE and divergence were 1% [- 6, 8], 7% [3, 15] and - 0.96%/h [-
1.14, - 0.88], respectively. During the first 15 min, MDPE and MDAPE were
18% [1, 51] and 21% [8, 51], respectively, and during the last 45 min 0%
[- 7, 5] and 6% [2, 10], respectively. For the Zeus, MDPE, MDAPE and
divergence were 0% [- 5, 8], 6% [3, 12] and - 0.57%/h [- 0.85, - 0.16],
respectively. During the first 15 min, MDPE and MDAPE were 7% [- 6, 28]
and 13% [6, 32], respectively, and during the last 45 min - 1% [- 5, 5]
and 5% [2, 9], respectively. In conclusion, Gas Man predicts
F<inf>ET</inf>sevo in O<inf>2</inf>/air in adults over a wide range of FGF
and vaporizer settings using different workstations with both MDPE and
MDAPE < 10% during the first hour of anesthesia, with better relative
performance for simulating maintenance than wash-in. In the authors'
opinion, this degree of performance suffices for Gas Man to be used to
quantify the environmental impact of FGF reduction in real life practice
of the wash-in and maintenance period combined.<br/>Copyright &#xa9; 2022,
The Author(s), under exclusive licence to Springer Nature B.V.

<14>
Accession Number
2015177334
Title
Effects of changes in position, positive end-expiratory pressure and mean
arterial pressure on renal, portal and hepatic Doppler ultrasound
perfusion indices: a randomized crossover study in cardiac surgery
patients.
Source
Journal of Clinical Monitoring and Computing. 36(6) (pp 1841-1850), 2022.
Date of Publication: December 2022.
Author
Hermansen J.L.; Norskov J.; Juhl-Olsen P.
Institution
(Hermansen, Norskov, Juhl-Olsen) Department of Cardiothoracic- and
Vascular Surgery, Anaesthesia Section, Aarhus University Hospital, Palle
Juul-Jensens, Boulevard 99, Aarhus 8200, Denmark
(Hermansen, Juhl-Olsen) Department of Clinical Medicine, Aarhus
University, Palle Juul-Jensens Boulevard 82, Aarhus 8200, Denmark
Publisher
Springer Science and Business Media B.V.
Abstract
Point-of-care ultrasound perfusion indices can be used for detection of
AKI and venous congestion. Patients in the postoperative- and intensive
care units are frequently exposed to alternating treatment and loading
conditions. We aimed to study the effects of changes in preload (patient
positioning), positive end-expiratory pressure (PEEP) and afterload
(phenylephrine) on renal, portal and hepatic ultrasound indices. We
hypothesized that renal resistive index was not influenced by changes in
PEEP and patient positioning. This was a single-site, randomized,
crossover study. Patients above 18 years scheduled for elective open-heart
surgery at Aarhus University Hospital, Denmark, were available for
inclusion. Patients were randomized to a sequence of six combinations of
PEEP and position in addition to an increase in mean arterial pressure by
phenylephrine. Thirty-one patients participated in the study. Resistive
index was influenced by positional change (P = 0.007), but not by change
in PEEP (P = 0.50) (Table 1). Renal venous stasis index and portal
pulsatility fraction increased in the raised legs position (P <= 0.019),
but not with increases in PEEP. Renal venous flow pattern and hepatic
venous flow pattern were affected by position (P <= 0.019), but not by
PEEP. None of the ultrasound indices were significantly changed by
infusion of phenylephrine. Doppler perfusion indices were significantly
affected by changes in preload, but not by changes in PEEP or afterload.
Although the changes in the Doppler ultrasound indices were significant,
they were small in absolute numbers. Therefore, from a clinical
perspective, the ultrasound indices were robust. Trial registration
Registered at clinicaltrials.com, first posted online June 5th 2020,
identifier: NCT04419662.<br/>Copyright &#xa9; 2022, The Author(s), under
exclusive licence to Springer Nature B.V.

<15>
Accession Number
638805303
Title
Prophylactic Use of Antifibrinolytics During Pediatric Cardiac Surgery
With Cardiopulmonary Bypass on Postoperative Bleeding and Transfusion: A
Systematic Review and Meta-Analysis.
Source
Pediatric critical care medicine : a journal of the Society of Critical
Care Medicine and the World Federation of Pediatric Intensive and Critical
Care Societies. 23(11) (pp e517-e529), 2022. Date of Publication: 01 Nov
2022.
Author
Schertz K.; Karam O.; Demetres M.; Mayadunna S.; Faraoni D.; Nellis M.E.
Institution
(Schertz) Department of Pediatrics, New York-Presbyterian/Weill Cornell
Medicine, New York, NY
(Karam) Pediatric Critical Care Medicine, Yale School of Medicine, New
Haven, CT, United States
(Demetres) Samuel J. Wood Library & C.V. Starr Biomedical Information
Center, Weill Cornell Medicine, New York, NY
(Mayadunna, Faraoni, Nellis) Wagner College, New York, NY
Publisher
NLM (Medline)
Abstract
OBJECTIVES: To determine the effect of intraoperative antifibrinolytics,
including tranexamic acid (TXA), aminocaproic acid (EACA), or aprotinin,
on bleeding in children undergoing cardiac surgery with cardiopulmonary
bypass (CPB). DATA SOURCES: Relevant articles were systematically searched
from Ovid MEDLINE, Ovid EMBASE, CINAHL, Cochrane Library, and Web of
Science to November 15, 2021. STUDY SELECTION: Abstracts were screened,
and full texts were reviewed using predetermined inclusion and exclusion
criteria using the Preferred Reporting Items for Systematic Reviews and
Meta-analyses reporting guideline. DATA EXTRACTION: A standardized data
extraction tool was used. DATA SYNTHESIS: Sixty-eight studies including
28,735 patients were analyzed. TXA compared with placebo resulted in a
mean decrease in chest tube output of 9.1 mL/kg (95% CI, 6.0-12.3 mL/kg),
I2 equals to 65.2%, p value of less than 0.001, platelet requirement of
2.9 mL/kg (95% CI, 0.1-5.8 mL/kg), I2 =72.5%, p value less than 0.001 and
plasma requirement of 4.0 mL/kg (95% CI, 0.6-7.2 mL/kg), I2 equals to
94.5%, p value less than0.001. Aprotinin compared with placebo resulted in
a mean decrease in chest tube output of 4.3 mL/kg (2.4-6.2 mL/kg), I2
equals to 66.3%, p value of less than 0.001, platelet transfusion of 4.6
mL/kg (95% CI, 0.6-8.6 mL/kg), I2 equals to 93.6%, p value of less than
0.001, and plasma transfusion of 7.7 mL/kg (95% CI, 2.1-13.2 mL/kg), I2
equals to 95.3%, p value of less than 0.001. EACA compared with placebo
resulted in a mean decrease in chest tube output of 9.2 mL/kg (2.3-21.0
mL/kg), I2 equals to 96.4%, p value of less than 0.001, RBC transfusion of
7.2 mL/kg (95% CI, 2.4-12.1 mL/kg), I2 equals to 94.5%, p value equals to
0.002, and platelet transfusion of 10.7 mL/kg (95% CI, 2.9-18.5 mL/kg), I2
equals to 0%, p value of less than 0.001. No statistical difference was
observed in chest tube output when TXA was compared with aprotinin.
Subgroup analysis of cyanotic patients showed a significant decrease in
chest tube output, platelet requirement, and plasma requirement for
patients receiving aprotinin. Overall, the quality of evidence was
moderate. <br/>CONCLUSION(S): Antifibrinolytics are effective at
decreasing blood loss and blood product requirement in children undergoing
cardiac surgery with CPB although the quality of evidence is only
moderate.<br/>Copyright &#xa9; 2022 by the Society of Critical Care
Medicine and the World Federation of Pediatric Intensive and Critical Care
Societies.

<16>
Accession Number
2020813263
Title
Coronary Artery Bypass Surgery Without Saphenous Vein Grafting: JACC
Review Topic of the Week.
Source
Journal of the American College of Cardiology. 80(19) (pp 1833-1843),
2022. Date of Publication: 08 Nov 2022.
Author
Royse A.; Ren J.; Royse C.; Tian D.H.; Fremes S.; Gaudino M.; Benedetto
U.; Woo Y.J.; Goldstone A.B.; Davierwala P.; Borger M.; Vallely M.; Reid
C.M.; Rocha R.; Glineur D.; Grau J.; Shaw R.; Paterson H.; El-Ansary D.;
Boggett S.; Srivastav N.; Pawanis Z.; Canty D.; Bellomo R.
Institution
(Royse, Ren, Royse, El-Ansary, Boggett, Srivastav, Canty) Department of
Surgery, University of Melbourne, Melbourne, VIC, Australia
(Royse, Royse) Royal Melbourne Hospital, Melbourne, VIC, Australia
(Royse) Outcomes Research Consortium, Cleveland Clinic, Cleveland, OH,
United States
(Tian) Department of Anesthesia, Westmead Hospital, Sydney, NSW, Australia
(Fremes, Davierwala, Rocha) Department of Surgery, University of Toronto,
Toronto, ON, Canada
(Gaudino) Department of Surgery, Weill Cornell Medicine, New York, NY,
United States
(Benedetto) Universita degli Studi G. d'Annunzio, Chieti-Pescara, Italy
(Woo) Surgery, Stanford University, San Francisco, CA, United States
(Goldstone) Department of Surgery, New York Presbyterian Morgan Stanley
Children's Hospital, New York, NY, United States
(Davierwala, Borger) Department of Surgery, University Clinic of Cardiac
Surgery, Leipzig Heart Center, Leipzig, Germany
(Vallely) Department of Surgery, Ohio State University, Columbus, OH,
United States
(Reid) Department of Epidemiology, Curtin University, Perth, WA, Australia
(Glineur, Grau) Department of Surgery, Ottawa Heart Institute, Ottawa, ON,
Canada
(Glineur) Department of Surgery, Clinique St Luc Bouge, Bouge, Belgium
(Shaw) Department of Surgery, Valley Health, Ridgewood, NJ, United States
(Paterson) Department of Surgery, University of Sydney, Sydney, NSW,
Australia
(El-Ansary) Swinburn University, Melbourne, VIC, Australia
(Pawanis) Department of Surgery, Universitas Airlangga, Surabaya,
Indonesia
(Bellomo) Department of Critical Care, University of Melbourne, Melbourne,
VIC, Australia
Publisher
Elsevier Inc.
Abstract
Approximately 95% of patients of any age undergoing contemporary, coronary
bypass surgery will receive at least 1 saphenous vein graft (SVG). It is
recognized that SVG will develop progressive and accelerated
atherosclerosis, resulting in a stenosis, and in occlusion that occurs in
50% by 10 years postoperatively. For arterial conduits, there is little
evidence of progressive failure as for SVG. Could avoidance of SVG (total
arterial revascularization [TAR]) lead to a different late (>5 year)
survival? A literature review of 23 studies (N = 100,314 matched patients)
at a mean 8.8 years postoperative found reduced all-cause mortality for
TAR (HR: 0.77; 95% CI: 0.71-0.84; P < 0.001). An expanded analysis with a
new unpublished data set (N = 63,288 matched patients) was combined with
the literature review (N = 127,565). It found reduced all-cause mortality
for TAR (HR: 0.78; 95% CI: 0.72-0.85; P < 0.001). Additional Bayesian
analysis found a very high probability of a TAR-associated reduction
all-cause mortality.<br/>Copyright &#xa9; 2022

<17>
Accession Number
639448621
Title
NEPHROLOGY INTERVENTION IN PATIENTS WAITING FOR CARDIAC SURGERY: A
RANDOMIZED CLINICAL TRIAL.
Source
Nephrology. Conference: 57th Annual Scientific Meeting of the Australian
and New Zealand Society of Nephrology, ANZSN 2022. Sydney, NSW Australia.
27(Supplement 1) (pp 30), 2022. Date of Publication: October 2022.
Author
Oliveras L.; Codina S.; Coloma A.; Perez-Garzon R.M.; Sbraga F.; Boza E.;
Sabater J.; Luis Perez-Fernandez J.; Cruzado J.M.; Montero N.
Institution
(Oliveras, Codina, Coloma, Perez-Garzon, Sbraga, Boza, Sabater, Luis
Perez-Fernandez, Cruzado, Montero) Hospital Universitari De Bellvitge,
L'Hospitalet de Llobregat, Spain
Publisher
Blackwell Publishing
Abstract
Aim and Background: Acute kidney injury (AKI) is a frequent complication
after cardiac surgery. The objective is to evaluate whether a
nephrological intervention before scheduled cardiac surgery can reduce the
postoperative incidence of AKI. <br/>Method(s): Single-center randomized
controlled clinical trial of 371 participants undergoing elective cardiac
surgery. Exclusion criteria were prior renal replacement therapy and
emergent surgery. Nephrological intervention was performed at least 1
month before surgery and included preoperative study (analysis and
bioimpedance), optimization of hydration status, elimination or dose
minimization of nephrotoxic drugs, and correction of metabolic disorders.
We have done a perprotocol analysis using the R-program. Primary outcome
was AKI (KDIGO definition). <br/>Result(s): 176 patients were included in
the Nephrology Intervention group and 195 in the control group, without
differences in baseline characteristics (mean age 67.3 +/- 10.2 vs. 66.3
+/- 11.4 years old; 66.4% vs. 62.5% males; 25.6% vs. 25.6 type 2 diabetes
respectively). The most common surgery was heart-valve replacement (68.8
and 64.9%). An average of two nephrological interventions per patient were
performed, with a 75.5% success rate before surgery. The number of
patients with AKI was 96 (26.7% intervention group and 25.26% control
group [p = 0.843]): AKI stage 1: 33/176 vs. 34/194, AKI stage 2: 7/176 vs.
3/194, AKI stage 3: 7/176 vs. 3/194. Mortality at 1 year was 14 patients
(7 per group). Nephrological intervention was not associated with an
increased risk of AKI. In multivariate analysis, age, baseline creatinine
and time on extracorporeal-circulation were associated with AKI. There
were no differences in renal function at 12 months (89.3 +/- 29.1 vs. 87.4
+/- 8 mumol/mL). <br/>Conclusion(s): No differences have been detected in
incidence of AKI or mortality when a nephrological intervention is
performed prior to elective cardiac surgery.

<18>
Accession Number
2021046192
Title
Danish-German cardiogenic shock trial-DanGer shock: Trial design update.
Source
American Heart Journal. 255 (pp 90-93), 2023. Date of Publication: January
2023.
Author
Moller J.E.; Gerke O.
Institution
(Moller) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Moller, Gerke) Department of Clinical Research, University of Southern
Denmark, Odense, Denmark
(Moller) Department of Cardiology, the Heart Center, Copenhagen University
Hospital Rigshospitalet, Copenhagen, Denmark
(Gerke) Department of Nuclear Medicine, Odense University Hospital,
Odense, Denmark
Publisher
Elsevier Inc.
Abstract
Background: The main objective of the Danish German Cardiogenic Shock
trial (DanGer Shock ClinicalTrials.gov Identifier: NCT01633502) is to
assess the efficacy of the trans valvular axial flow device Impella CP in
treating patients with AMICS shock due to STEMI undergoing emergency
percutaneous coronary intervention. <br/>Method(s): This statistical
analysis plan represents an overview of the statistical methods which will
be used for analyzing the DanGer Shock trial. <br/>Result(s): The primary
study endpoint is death from all causes through 180 days in the intention
to treat population (all randomized consented patients). The secondary
endpoints comprise; composite event of the need for additional mechanical
support, need for cardiac transplantation, and death of all causes
whichever comes first; and days alive and out of hospital. As exploratory
analyses an as treated analysis of primary endpoint will be performed.
Composite safety endpoint will comprise of major bleeding, vascular
complications, device malfunction, damage to the aortic valve, and
significant hemolysis. The primary endpoint death rate at 180 days will be
analyzed using Cox proportional hazards analysis. The result will be
reported as hazard ratio and corresponding 95% confidence interval (95%
CI). No imputation of missing values will be performed. Additional
statistical analyses for predefined hemodynamic, metabolic, renal,
hematological, and health economics substudies will be specified in
separate protocols. <br/>Conclusion(s): Main analyses of the primary and
secondary outcomes of the DanGer Shock trial will be conducted according
to this publication.<br/>Copyright &#xa9; 2022 The Authors

<19>
Accession Number
2021013237
Title
Yield of Dual Therapy with Statin and Ezetimibe in the Treat Stroke to
Target Trial.
Source
Stroke. 53(11) (pp 3260-3267), 2022. Date of Publication: 01 Nov 2022.
Author
Amarenco P.; Kim J.S.; Labreuche J.; Charles H.; Giroud M.; Lee B.-C.;
Lavallee P.C.; Mahagne M.-H.; Meseguer E.; Nighoghossian N.; Steg P.G.;
Vicaut E.; Bruckert E.
Institution
(Amarenco, Charles, Lavallee, Meseguer) APHP, Department of Neurology and
Stroke Center, Bichat Hospital, INSERM LVTS-U1148, DHU FIRE, University of
Paris, France
(Amarenco) Population Health Research Institute, McMaster University,
Hamilton, ON, Canada
(Kim) Asan Medical Center, Seoul, South Korea
(Labreuche) CHU Lille, Department of Biostatistics, France
(Giroud) Department of Neurology, University Hospital of Dijon, Dijon
Stroke Registry, EA 7460, University of Burgundy, UBFC, France
(Lee) Department of Neurology, Hallym University Sacred Heart Hospital,
Anyang, South Korea
(Mahagne) Stroke Unit, Pasteur Hospital, Nice, France
(Nighoghossian) Hospices Civils de Lyon, Department of Neurology and
Stroke Center, Lyon University, France
(Steg) Universite de Paris, INSERM LVTS-U1148, France
(Steg) AP-HP, Hopital Bichat, France
(Vicaut) APHP, Department of Biostatistics, Universite Paris-Diderot,
Sorbonne-Paris Cite, Fernand Widal Hospital, Paris, France
(Bruckert) APHP, Department of Endocrinology, Pitie-Salpetriere Hospital,
Sorbonne University, Paris, France
Publisher
Wolters Kluwer Health
Abstract
Background: In atherosclerotic stroke, lipid-lowering treatment with a
target LDL (low-density lipoprotein) cholesterol of <70 compared with
100+/-10 mg/dL reduced the risk of subsequent cardiovascular events. This
post hoc analysis explored the relative effects of the combination of
statin and ezetimibe (dual therapy) and statin monotherapy in achieving
the lower LDL cholesterol target and in reducing the risk of major
vascular events, as compared with the higher target group. <br/>Method(s):
Patients with ischemic stroke in the previous 3 months or transient
ischemic attack within the previous 15 days and evidence of
cerebrovascular or coronary artery atherosclerosis were randomly assigned
to a target LDL cholesterol of <70 or 100+/-10 mg/dL, using statin and/or
ezetimibe as needed. The primary outcome was the composite of ischemic
stroke, myocardial infarction, new symptoms requiring urgent coronary or
carotid revascularization, and vascular death. Cox regression model
including lipid-lowering therapy as a time varying variable, after
adjustment for randomization strategy, age, sex, index event (stroke or
transient ischemic attack), and time since the index event.
<br/>Result(s): Among 2860 patients enrolled, patients who were on dual
therapy during the trial in the lower target group had a higher baseline
LDL cholesterol as compared to patients on statin monotherapy (141+/-38
versus 131+/-36, respectively, P<0.001). In patients on dual therapy and
on statin monotherapy, the achieved LDL cholesterol was 66.2 and 64.1
mg/dL respectively, and the primary outcome was reduced during dual
therapy as compared with the higher target group (HR, 0.60 [95% CI,
0.39-0.91]; P=0.016) but not during statin monotherapy (HR, 0.92 [95% CI,
0.70-1.20]; P=0.52), with no significant increase in intracranial
bleeding. <br/>Conclusion(s): In the TST trial (Treat Stroke to Target),
targeting an LDL cholesterol of < 70 mg/dL with a combination of statin
and ezetimibe compared with 100+/-10 mg/dL consistently reduced the risk
of subsequent stroke. Registration: URL: https://www.clinicaltrials.gov;
Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique
identifier: EUDRACT2009-A01280-57.<br/>Copyright &#xa9; 2022 Lippincott
Williams and Wilkins. All rights reserved.

<20>
Accession Number
2021013132
Title
Long-Term Mortality Follow-Up of Radial Artery Versus Saphenous Vein in
Coronary Artery Bypass Grafting: A Multicenter, Randomized Trial.
Source
Circulation. 146(17) (pp 1323-1325), 2022. Date of Publication: 25 Oct
2022.
Author
Goldman S.; McCarren M.; Sethi G.K.; Holman W.; Bakaeen F.G.; Wagner T.H.;
Wang Y.; Shih M.-C.; Edson R.
Institution
(Goldman) Sarver Heart Center, United States
(Sethi) University of Arizona, Tucson, United States
(McCarren) Hines Va Pharmacy Benefits Management, IL, United States
(Holman) University of Alabama, Birmingham Va Medical Center, United
States
(Bakaeen) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, OH, United States
(Wagner) Va Health Economics Resource Center, Palo Alto, CA, United States
(Wagner) Department of Surgery, Stanford University, Palo Alto, CA, United
States
(Wang, Shih, Edson) Cooperative Studies Program Coordinating Center, Palo
Alto Coordinating Center, Mountain View, CA, United States
Publisher
Lippincott Williams and Wilkins

<21>
Accession Number
2021013127
Title
Effect of Patient-Reported Preprocedural Physical and Mental Health on
10-Year Mortality After Percutaneous or Surgical Coronary
Revascularization.
Source
Circulation. 146(17) (pp 1268-1280), 2022. Date of Publication: 25 Oct
2022.
Author
Ono M.; Serruys P.W.; Garg S.; Kawashima H.; Gao C.; Hara H.; Lunardi M.;
Wang R.; O'Leary N.; Wykrzykowska J.J.; Piek J.J.; Mack M.J.; Holmes D.R.;
Morice M.-C.; Kappetein A.P.; Thuijs D.J.F.M.; Noack T.; Mohr F.W.;
Davierwala P.M.; Spertus J.A.; Cohen D.J.; Onuma Y.
Institution
(Ono, Kawashima, Hara, Wykrzykowska, Piek) Amsterdam Universitair Medische
Centra, University of Amsterdam, Heart Center, Department of Clinical and
Experimental Cardiology, Amsterdam Cardiovascular Sciences, Netherlands
(Ono, Serruys, Kawashima, Gao, Lunardi, Wang, O'Leary, Onuma) Department
of Cardiology, National University of Ireland, Galway, Ireland
(Ono, Serruys, Kawashima, Gao, Hara, Lunardi, Wang, Onuma) CURAM-Science
Foundation Ireland Centre for Research in Medical Devices, Galway, Ireland
(Serruys) National Heart and Lung Institute, Imperial College London,
United Kingdom
(Garg) Department of Cardiology, Royal Blackburn Hospital, United Kingdom
(Gao, Wang) Department of Cardiology, Radboud University, Nijmegen,
Netherlands
(Wykrzykowska) University Medical Center Groningen, Groningen, Netherlands
(Mack) Department of Cardiothoracic Surgery, Baylor University Medical
Center, Dallas, TX, United States
(Holmes) Department of Cardiovascular Diseases and Internal Medicine, Mayo
Clinic, Rochester, MN, United States
(Morice) Departement of Cardiologie, Hopital Prive Jacques Cartier,
Generale de Sante, Massy, France
(Kappetein, Thuijs) Department of Cardiothoracic Surgery, Erasmus
University Medical Centre, Rotterdam, Netherlands
(Noack, Mohr, Davierwala) University Department of Cardiac Surgery, Heart
Centre Leipzig, Germany
(Davierwala) Department of Surgery, University of Toronto, Canada
(Davierwala) Division of Cardiovascular Surgery, Peter Munk Cardiac
Centre, Toronto General Hospital, Canada
(Spertus) Department of Cardiology, Saint Luke's Mid America Heart
Institute, University of Missouri-Kansas City, United States
(Cohen) Cardiovascular Research Foundation, New York, NY, United States
(Cohen) St Francis Hospital, Roslyn, NY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Clinical and anatomical characteristics are often considered
key factors in deciding between percutaneous coronary intervention (PCI)
or coronary artery bypass grafting (CABG) in patients with complex
coronary artery disease (CAD) such as left-main CAD or 3-vessel disease.
However, little is known about the interaction between self-reported
preprocedural physical/mental health and clinical outcomes after
revascularization. <br/>Method(s): This subgroup analysis of the SYNTAXES
trial (SYNTAX Extended Survival), which is the extended follow-up of the
randomized SYNTAX trial (Synergy Between PCI With Taxus and Cardiac
Surgery) comparing PCI with CABG in patients with left-main CAD or
3-vessel disease, stratified patients by terciles of Physical (PCS) or
Mental Component Summary (MCS) scores derived from the preprocedural
36-Item Short Form Health Survey, with higher PCS and MCS scores
representing better physical and mental health, respectively. The primary
end point was all-cause death at 10 years. <br/>Result(s): A total of 1656
patients with preprocedural 36-Item Short Form Health Survey data were
included in the present study. Both higher PCS and MCS were independently
associated with lower 10-year mortality (10-point increase in PCS adjusted
hazard ratio, 0.84 [95% CI, 0.73-0.97]; P=0.021; in MCS adjusted hazard
ratio, 0.85 [95% CI, 0.76-0.95]; P=0.005). A significant survival benefit
with CABG over PCI was observed in the highest PCS (>45.5) and MCS (>52.3)
terciles with significant treatment-by-subgroup interactions (PCS
P^interaction=0.033, MCS P^interaction=0.015). In
patients with both high PCS (>45.5) and MCS (>52.3), 10-year mortality was
significantly higher with PCI compared with CABG (30.5% versus 12.2%;
hazard ratio, 2.87 [95% CI, 1.55-5.30]; P=0.001), whereas among those with
low PCS (<=45.5) or low MCS (<=52.3), there were no significant
differences in 10-year mortality between PCI and CABG, resulting in a
significant treatment-by-subgroup interaction
(P^interaction=0.002). <br/>Conclusion(s): Among patients with
left-main CAD or 3-vessel disease, patient-reported preprocedural physical
and mental health status was strongly associated with long-term mortality
and modified the relative treatment effects of PCI versus CABG. Patients
with the best physical and mental health had better 10-year survival with
CABG compared with PCI. Assessment of self-reported physical and mental
health is important when selecting the optimal revascularization strategy.
Registration: URL: https://www.clinicaltrials.gov; SYNTAXES Unique
identifier: NCT03417050. URL: https://www.clinicaltrials.gov; SYNTAX
Unique identifier: NCT00114972.<br/>Copyright &#xa9; 2022 Lippincott
Williams and Wilkins. All rights reserved.

<22>
Accession Number
2021013036
Title
Feasibility of selective coronary angiography and percutaneous coronary
intervention following self-expanding transcatheter aortic valve
replacement: a systematic review and meta-analysis.
Source
Coronary Artery Disease. 33(8) (pp 678-681), 2022. Date of Publication: 01
Dec 2022.
Author
Gin J.H.; Castles A.; Koshy A.N.; Yudi M.B.
Institution
(Gin, Castles, Koshy, Yudi) Department of Cardiology, Austin Health,
United States
(Castles, Koshy, Yudi) Department of Medicine, The University of
Melbourne, Melbourne, VIC, Australia
Publisher
Lippincott Williams and Wilkins

<23>
Accession Number
2021013031
Title
A systematic review and meta-analysis of coronary artery disease and
revascularization in lung transplant patients.
Source
Coronary Artery Disease. 33(8) (pp 661-669), 2022. Date of Publication: 01
Dec 2022.
Author
Fialka N.M.; Bozso S.J.; El-Andari R.; Kang J.J.H.; Laing B.; Meyer S.R.;
Nagendran J.
Institution
(Fialka, El-Andari) Faculty of Medicine and Dentistry, Canada
(Bozso, Kang, Meyer, Nagendran, Nagendran) Division of Cardiac Surgery,
Department of Surgery, Canada
(Laing) Department of Surgery, University of Alberta, Edmonton, AB, Canada
Publisher
Lippincott Williams and Wilkins
Abstract
Coronary artery disease (CAD) is common in candidates for lung
transplantation (LTx) and has historically been considered a relative
contraindication to transplantation. We look to review the outcomes of LTx
in patients with CAD and determine the optimum revascularization strategy
in LTx candidates. PubMed, Medline and Web of Science were systematically
searched by three authors for articles comparing the outcomes of LTx in
patients with CAD and receiving coronary revascularization. In total 1668
articles were screened and 12 were included in this review.Preexisting CAD
in LTx recipients was not associated with significantly increased
postoperative morbidity or mortality. The pooled estimates of mortality
rate at 1, 3 and 5 years indicated significantly inferior survival in LTx
recipients with a prior history of coronary artery bypass grafting (CABG)
[odds ratio (OR), 1.84; 95% confidence interval (CI), 1.53-2.22; P <
0.00001; I²= 0%; OR, 1.52; 95% CI, 1.21-1.91; P = 0.0003;
I²= 0%; OR, 1.62; 95% CI, 1.13-2.33; P = 0.008; I²=
71%, respectively). However, contemporary literature suggests that
survival rates in LTx recipients with CAD that received revascularization
either by percutaneous coronary intervention (PCI), previous or
concomitant CABG, are similar to patients who did not receive
revascularization. Trends in postoperative morbidity favored CABG in the
rates of myocardial infarction and repeat revascularization, whereas rates
of stroke favored PCI. The composite results of this study support the
consideration of patients with CAD or previous coronary revascularization
for LTx. Prospective, randomized controlled trials with consistent patient
populations and outcomes reporting are required to fully elucidate the
optimum revascularization strategy in LTx candidates.<br/>Copyright &#xa9;
2022 Lippincott Williams and Wilkins. All rights reserved.

<24>
Accession Number
2021013023
Title
Patient blood management and patient safety.
Source
Current Opinion in Anaesthesiology. 35(6) (pp 733-737), 2022. Date of
Publication: 01 Dec 2022.
Author
Zacharowski K.; Zoller H.; Steinbicker A.U.
Institution
(Zacharowski, Steinbicker) Department of Anaesthesiology, Intensive Care
Medicine and Pain Therapy, University Hospital Frankfurt, Goethe
University Frankfurt, Germany
(Zoller) Department of Medicine I, Christian Doppler Laboratory on Iron
and Phosphate Biology, Medical University of Innsbruck, Innsbruck, Austria
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of reviewThe particular fields within patient blood management
(PBM) and patient safety reviewed here include novel insights into
bleeding therapy, autologous cell salvage, and perioperative anemia
therapy.Recent findingWorld Health Organization has published that
implementation of PBM is important but has not yet been performed in all
hospitals. Two antibodies that mimic the function of FVIII, Emicizumab,
and Mim8 have been developed. Tranexamic acid (TXA) has been investigated
further in patients with hip surgery and shows reduction of bleeding.
Thrombocytopenia in patients undergoing cardiac surgery is a particular
concern that has been investigated in another trial. The use of autologous
cell salvage was updated in form of a review and meta-analysis. And last
but not least, intravenous iron in preoperative anemia therapy can reduce
the number of transfusions, but especially iron carboxymaltose can cause
hypophosphatemia.SummaryPBM should be further implemented in more
hospitals. Emicizumab and Mim8 are indicated in acquired hemophilia or
hemophilia A with inhibitors. TXA was confirmed to reduce bleeding.
Autologous cell salvage is state of the art to reduce transfusion
requirements in major cardiac and noncardiac surgery. Serum phosphate
concentrations should be monitored after administration of intravenous
iron compounds.<br/>Copyright &#xa9; 2022 Lippincott Williams and Wilkins.
All rights reserved.

<25>
Accession Number
2021029565
Title
Combined retropleural thoracotomy and posterior spinal approach for
thoracic dumbbell Schwannoma: Case series and review of the literature.
Source
Journal of Clinical Neuroscience. 106 (pp 173-179), 2022. Date of
Publication: December 2022.
Author
Kurland D.B.; Lau D.; Dalle Ore C.L.; Haddad A.; Deviren V.; Ames C.P.
Institution
(Kurland, Lau) Department of Neurological Surgery, New York University,
New York, NY, United States
(Lau, Dalle Ore, Haddad, Ames) Department of Neurological Surgery,
University of California, San Francisco, San Francisco, CA, United States
(Deviren) Department of Orthopedic Surgery, University of California, San
Francisco, San Francisco, CA, United States
Publisher
Churchill Livingstone
Abstract
Background: Dumbbell schwannomas of the thoracic spine are challenging to
cure surgically. Surgeons are familiar with posterolateral approaches to
the spine, however, these may provide inadequate exposure for large tumors
extending to ventral extraspinal compartments. Ventrolateral transpleural
approaches offer direct access to the ventral thoracic spine and
intrathoracic cavity, though are associated with increased morbidity and
pulmonary complications, and may necessitate a staged procedure in order
to address concomitant dorsal pathology. Herein we describe our experience
with single-stage, posterior approach to dumbbell schwannomas with large
ventral extraspinal components, and review the literature regarding
surgical approaches for these tumors. <br/>Method(s): Retrospective review
of patients who underwent a single-stage, posterior spinal surgery for
thoracic dumbbell schwannomas from 2008 to 2018. Inclusion criteria were
age > 18 years and ventral thoracic tumor component. <br/>Result(s): Three
patients underwent a simultaneous retropleural thoracotomy and posterior
spinal approach, through a single incision, for the resection of dumbbell
(intradural and extradural) schwannomas. Mean age was 49.7 years and 2
patients were female. All patients were neurologically intact at baseline.
Lesions were 4-8.2 cm in the largest dimension (mean 6.1 cm). GTR was
achieved in all patients. One pleural rent occurred intraoperatively;
there were no other intraoperative or perioperative complications. At a
mean follow-up of 14.1 months all patients remained motor and sensory
intact and there was no evidence of recurrence. <br/>Conclusion(s): The
combined retropleural thoracotomy-posterior spinal approach provides safe
and sufficient access for resection of large dumbbell schwannomas of the
thoracic spine.<br/>Copyright &#xa9; 2022

<26>
Accession Number
2020977792
Title
Outcomes of Coronary Artery Disease Patients with Severe Left Ventricular
Dysfunction Undergoing Surgical Management.
Source
Heart Surgery Forum. 25(2) (pp E204-E212), 2022. Date of Publication:
2022.
Author
Ponnuru S.; Radhakrishnan B.K.; Sudevan R.; Karunakaran J.
Institution
(Ponnuru, Radhakrishnan, Karunakaran) Department of CVTS, Sree Chitra
Tirunal Institute for Medical Sciences and Technology, Kerala,
Thiruvananthapuram, India
(Sudevan) Amrita Institute of Medical Sciences and Research Centre,
Kerala, Kochi, India
Publisher
Forum Multimedia Publishing LLC
Abstract
Background: Surgical revascularization by coronary artery bypass grafting
(CABG) is the gold standard treatment for coronary artery disease. But, in
patients with severe left ventricular dysfunction (ischemic
cardiomyopathy), the result of CABG is different from those with normal
left ventricular function. The coronary artery disease pattern in the
Indian subconti-nent is different from the western world, due to the
diffuse nature of coronary involvement, the smaller size of native
vessels, increased prevalence of diabetes mellitus and other risk factors,
and more prevalence of severe left ventricular dysfunction. Most of the
studies regarding the surgical outcomes in ischemic cardiomyopathy come
from western countries. This study attempts to assess the outcomes of
surgical management of ischemic cardiomyopathy in the Indian subcontinent.
<br/>Method(s): A single-center retrospective cohort study was conducted
at Sree Chitra Tirunal Institute for Medical Sciences and Technology,
Thiruvananthapuram. The data of CAD pa-tients, who underwent surgical
coronary revascularization for severe LV dysfunction from January 2010 to
December 2014, were collected from the hospital records and through
tele-phonic interviews in a structured study proforma. A total of 146
patients satisfied the criteria and were followed up for a period of 5
years. <br/>Result(s): The mean age of the study population was 55.6 (8.8)
years. Male preponderance was observed (94.52%; N = 138). CABG alone was
done in 62.3% (N = 91) of the study partici-pants. CABG with linear
plication was done in 23.3% (N = 34), CABG with MV repair in 7.5% (N =
11), and CABG with DORS in 6.8% (N = 10). The majority of patients (N =
54, 37%) received 4 grafts. Thirty-day mortality observed in the study
population was 11 (7.5%). The causes documented were cardiac causes in 9
(82%), cerebrovascular events in one (9%), and septicemia in one (9%). The
mean of 5-year survival of the study population was 94.2 (3.5) months with
95% CI 87.32, 101.13. There was a substantial improvement in the degree of
mitral regurgitation. Ejection fraction (EF) also showed improvement. The
mean preoperative EF was 29.51 (4.84%) and that of post-op was 39.92
(9.0%). <br/>Conclusion(s): Despite the challenges of diffusely diseased
coronary arteries, severe LV dysfunction, addressing associated
significant MR and ventricular aneurysms, the outcome of surgical
management of CAD with severe LV dysfunction, in the Indian population can
be done with acceptable results. Randomized control studies in this subset
can provide more solid evidence in this regard.<br/>Copyright &#xa9; 2022
Forum Multimedia Publishing LLC. All rights reserved.

<27>
Accession Number
2020958715
Title
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After
Transcatheter Aortic Valve Replacement in Japanese Patients - A
Subanalysis of the ENVISAGE-TAVI AF Trial -.
Source
Circulation Journal. 86(11) (pp 1756-1763), 2022. Date of Publication:
2022.
Author
Watanabe Y.; Hayashida K.; Yamamoto M.; Yamanaka F.; Yamasaki K.; Naganuma
T.; Ohno Y.; Yamawaki M.; Morioka N.; Mizutani K.; Tada N.; Ueno H.;
Nishina H.; Izumo M.; Nakajima Y.; Ando K.; Takagi K.; Kimura T.; Sugio
K.; Dangas G.; Van Mieghem N.M.; Hengstenberg C.; Chen C.; Jin J.;
Unverdorben M.; Saito S.
Institution
(Watanabe) Division of Cardiology, Teikyo University Hospital, Tokyo,
Japan
(Hayashida) Department of Cardiology, Keio University School of Medicine,
Tokyo, Japan
(Yamamoto) Department of Cardiology, Toyohashi Heart Center, Aichi, Japan
(Yamanaka) Shonan Kamakura General Hospital, Kamakura, Japan
(Yamasaki) Sapporo Higashi Tokushukai Hospital, Hokkaido, Japan
(Naganuma) New Tokyo Hospital, Chiba, Japan
(Ohno) Tokai University Hospital, Isehara, Japan
(Yamawaki) Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
(Morioka) Department of Cardiology, Kishiwada Tokushukai Hospital, Osaka,
Japan
(Mizutani) Department of Cardiovascular Medicine, Osaka City University
Hospital, Osaka, Japan
(Tada) Department of Cardiology, Sendai Kousei Hospital, Miyagi, Japan
(Ueno) Department of Cardiology, Toyama University Hospital, Toyama, Japan
(Nishina) Department of Cardiology, Tsukuba Medical Center Hospital,
Tsukuba, Japan
(Izumo) Division of Cardiology, St. Marianna University, School of
Medicine Hospital, Kawasaki, Japan
(Nakajima) Division of Cardiology, Iwate Medical University, Iwate, Japan
(Ando) Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu,
Japan
(Takagi) Department of Cardiology, Ogaki Municipal Hospital, Gifu, Japan
(Kimura, Sugio) Daiichi Sankyo Co., Ltd., Tokyo, Japan
(Dangas) Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai
Hospital, New York, NY, United States
(Van Mieghem) Department of Cardiology, Erasmus University Medical Center,
Thoraxcenter, Rotterdam, Netherlands
(Hengstenberg) Division of Cardiology, Vienna General Hospital, Medical
University, Vienna, Austria
(Chen, Jin, Unverdorben) Daiichi Sankyo, Inc., Basking Ridge, NJ, United
States
(Saito) Division of Cardiology & Catheterization Laboratories, Shonan
Kamakura General Hospital, Kamakura, Japan
Publisher
Japanese Circulation Society
Abstract
Background: Japanese patients undergoing transcatheter aortic valve
replacement (TAVR) are often female and have a small body size,
potentially impacting bleeding risk with antithrombotic therapy. Outcomes
of direct oral anticoagulant use in these patients with atrial
fibrillation (AF) need to be clarified. <br/>Methods and Results: This
prespecified analysis included Japanese patients from ENVISAGE-TAVI AF, a
prospective, randomized, open-label, adjudicator-masked trial that
compared treatment with edoxaban and vitamin K antagonists (VKAs) in
patients with AF after TAVR. The primary efficacy and safety outcomes were
net adverse clinical events (NACE; composite of all-cause death,
myocardial infarction, ischemic stroke, systemic embolic event, valve
thrombosis, and International Society on Thrombosis and Haemostasis
[ISTH]-defined major bleeding) and ISTH-defined major bleeding,
respectively. Intention-to-treat (ITT) and on-treatment analyses were
performed. Overall, 159 Japanese patients were enrolled (edoxaban group:
82, VKA group: 77) and followed for on average 483 days. Mean patient age
was 83.8 years; 52.2% were female. In the ITT analysis, NACE rates were
10.9%/year with edoxaban and 12.5%/year with VKA (hazard ratio [HR], 0.85;
95% confidence interval [CI], 0.38-1.90); major bleeding occurred in
8.9%/year and 7.3%/year, respectively (HR, 1.17; 95% CI, 0.45-3.05). In
edoxaban- and VKA-treated patients, rates of ischemic stroke were
1.8%/year and 1.0%/year, respectively; fatal bleeding rates were 0.9%/year
and 2.0 %/year. On-treatment results were similar to ITT.
<br/>Conclusion(s): In Japanese patients with AF after successful TAVR,
edoxaban and VKA treatment have similar safety and efficacy
profiles.<br/>Copyright &#xa9; 2022 Japanese Circulation Society. All
rights reserved.

<28>
Accession Number
2019977492
Title
Dynamic parameters for fluid responsiveness in mechanically ventilated
children: A systematic review.
Source
Frontiers in Pediatrics. 10 (no pagination), 2022. Article Number:
1010600. Date of Publication: 21 Oct 2022.
Author
Yenjabog P.; Kanchongkittiphon W.; Chutipongtanate S.; Lertbunrian R.;
Ungprasert P.
Institution
(Yenjabog, Lertbunrian) Division of Pediatric Critical Care, Department of
Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
(Kanchongkittiphon) Division of Allergy and Immunology, Department of
Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
(Chutipongtanate) Pediatric Translational Research Unit, Department of
Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
(Chutipongtanate) Department of Clinical Epidemiology and Biostatistics,
Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand
(Chutipongtanate) Chakri Naruebodindra Medical Institute, Faculty of
Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand
(Ungprasert) Department of Rheumatic and Immunologic Diseases, Cleveland
Clinic, Cleveland, OH, United States
Publisher
Frontiers Media S.A.
Abstract
Objective: Fluid administration is the initial step of treatment of
unstable pediatric patients. Evaluation of fluid responsiveness is crucial
in mechanically ventilated children to avoid fluid overload, which
increases mortality. We aim to review and compare the diagnostic
performance of dynamically hemodynamic parameters for predicting fluid
responsiveness in mechanically ventilated children. <br/>Design(s): A
systematic review was performed using four electronic databases, including
PubMed, EMBASE, Scopus, and Central, for published articles from 1 January
2010 to 31 December 2020. Studies were included if they described
diagnostic performance of dynamic parameters after fluid challenge was
performed in mechanically ventilated children. <br/>Setting(s): Pediatric
intensive and cardiac intensive care unit, and operative room.
<br/>Patient(s): Children aged 1 month to 18 years old who were under
mechanical ventilation and required an intravenous fluid challenge.
<br/>Measurements and Main Results: Twenty-seven studies were included in
the systematic review, which included 1,005 participants and 1,138 fluid
challenges. Respiratory variation in aortic peak velocity was reliable
among dynamic parameters for predicting fluid responsiveness in
mechanically ventilated children. All studies of respiratory variation in
aortic peak velocity showed that the area under the receiver operating
characteristic curve ranged from 0.71 to 1.00, and the cutoff value for
determining fluid responsiveness ranged from 7% to 20%. Dynamic parameters
based on arterial blood pressure (pulse pressure variation and stroke
volume variation) were also used in children undergoing congenital heart
surgery. The plethysmography variability index was used in children
undergoing neurological and general surgery, including the pediatric
intensive care patients. <br/>Conclusion(s): The respiratory variation in
aortic peak velocity exhibited a promising diagnostic performance across
all populations in predicting fluid responsiveness in mechanically
ventilated children. High sensitivity is advantageous in non-cardiac
surgical patients and the pediatric intensive care unit because early
fluid resuscitation improves survival in these patients. Furthermore, high
specificity is beneficial in congenital heart surgery because fluid
overload is particularly detrimental in this group of patients. Systematic
Review Registration:
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=206400<br/
>Copyright 2022 Yenjabog, Kanchongkittiphon, Chutipongtanate, Lertbunrian
and Ungprasert.

<29>
Accession Number
639446356
Title
Insulin signaling in the central nervous system, a possible
pathophysiological mechanism of anesthesia-induced delayed neurocognitive
recovery/postoperative neurocognitive disorder: a narrative review.
Source
Expert review of neurotherapeutics. (no pagination), 2022. Date of
Publication: 04 Nov 2022.
Author
Qeva E.; Sollazzo C.; Bilotta F.
Institution
(Qeva, Sollazzo, Bilotta) Department of Anesthesia and Intensive Care
Medicine, "Sapienza" University of Rome, 'Policlinico Umberto I' Hospital,
Rome 00161, Italy
(Qeva) Department of Anesthesia, Intensive Care and Emergency, University
of Turin, 'Citta Della Salute e Della Scienza' Hospital, Turin 10126,
Italy
Publisher
NLM (Medline)
Abstract
INTRODUCTION: Impairment in neurocognitive functions ranges between
delayed neurocognitive recovery (DNR) and postoperative neurocognitive
disorders (pNCD). Incidence varies from 11% after non-cardiac surgery to
60% after cardiac surgery. AREAS COVERED: Insulin receptors (IRs)
signaling pathway in the central nervous system (CNS) could be a possible
pathophysiological mechanism of anesthesia-induced DNR/pNCD and
perioperative intranasal insulin administration could be a preventive
approach. This hypothesis is supported by the following evidence: effects
of IRs-CNS signaling pathway on neuronal survival, neuroprotection and
neuromodulation; higher incidence of DNR/pNCD in patients who presented
insulin resistance; neurotoxicity induced to IRs signaling pathways after
exposure to general and local anesthetics; improvement of neurocognitive
impairment after insulin exposure. This narrative review was conducted
after a literature search of PubMed, EMBASE and SCOPUS online medical data
performed in May 2022. The following search terms were used: insulin
receptors in peripheral tissues, insulin receptors and brain,
postoperative neurocognitive impairment, insulin resistance and cognitive
impairment, insulin receptors and anesthesia exposure, intranasal insulin
and postoperative cognitive impairment. EXPERT OPINION: Perioperative
intranasal insulin is shown to be protective and future studies should
address: the role of insulin as a neuromodulator; its integration into
neuroprotection approaches; patient populations that might benefit from
this approach; a well-defined protocol of intranasal insulin
administration in a perioperative background and other disciplines; and
possible collateral effects.

<30>
Accession Number
639444429
Title
Early Transcatheter or Surgical Aortic Valve Replacement Versus
Conservative Management in Asymptomatic Patients with Severe Aortic
Stenosis: A Systematic Review and Meta-Analysis.
Source
Current problems in cardiology. (pp 101477), 2022. Date of Publication:
31 Oct 2022.
Author
Yasmin F.; Shaikh A.; Asghar M.S.; Najeeb H.; Moeed A.; Waqar E.; Ram
M.D.; Nankani A.; Ochani R.K.; Jawed R.; Aamir M.; Ullah W.; Waqar F.;
Johnson D.M.
Institution
(Yasmin, Najeeb, Moeed, Waqar, Ram, Nankani, Ochani) Department of
Internal Medicine, Dow University of Health Sciences, PK, Karachi 74200,
Pakistan
(Shaikh) Department of Medicine, Aga Khan University Hospital, 74800 PK,
Karachi, Pakistan
(Asghar) Division of Nephrology and Hypertension, Mayo Clinic, Rochester,
United States
(Jawed) Department of Internal Medicine, Liaquat National Hospital and
Medical College, PK, Karachi 74800, Pakistan
(Aamir) Lehigh Valley Heart Specialists, Lehigh Valley Health Network,
Allentown PA 18103, United States
(Ullah, Johnson) Division of Cardiology, Sidney Kimmel Medical College,
Thomas Jefferson University Hospitals, Philadelphia PA 19107, United
States
(Waqar) Division of Cardiovascular Health and Disease, University of
Cincinnati College of Medicine, Cincinnati, United States
Publisher
NLM (Medline)
Abstract
The merits of conservative management versus early intervention in
patients with asymptomatic severe aortic stenosis remain unknown. Digital
databases (MEDLINE, Google Scholar, and Embase) were searched for all
relevant studies from inception through September 2022. Studies comparing
conservative management with early intervention were compared using a
random-effects model to calculate risk ratios (RRs) with 95% confidence
interval (CI). A total of 11 studies comprising 5,030 patients (1,874
patients were in the early intervention i.e., surgical aortic valve
replacement (SAVR) and transcatheter aortic valve replacement (TAVR)
group, and 3,156 in the conservative group) were included in the analysis.
The average follow-up time was 4.49 years. Early intervention was
associated with a significantly reduced risk of heart failure
hospitalization (RR 0.27, 95% CI 0.11- 0.67; P=0.004), cardiac (RR 0.38,
95% CI 0.26 - 0.56; P < 0.00001), non-cardiac (RR 0.40, 95% CI 0.31-0.50;
P < 0.00001), and all-cause mortality (RR 0.35, 95% CI 0.27 - 0.44; P <
0.00001) compared with conservative management. There was no significant
difference in the 30-day mortality (RR 1.30, 95% CI 0.22 - 7.66; P=0.77),
90-day mortality (RR 0.49, 95% CI 0.12 - 2.02; P=0.32) or myocardial
infarction (RR 0.57, 95% CI 0.32 - 1.02; P=0.06) between the two groups.
This meta-analysis shows statistically significant reductions in the risk
for all-cause mortality, cardiac specific mortality, non-cardiac
mortality, sudden cardiac death, and heart failure hospitalizations in
patients with asymptomatic aortic stenosis who underwent early
intervention as opposed to conservative management.<br/>Copyright &#xa9;
2022. Published by Elsevier Inc.

<31>
Accession Number
2017277595
Title
Analgesic efficacy of ultrasound guided unilateral erector spinae plane
block for laparoscopic inguinal hernia repair: a randomized controlled
study.
Source
Turkish Journal of Medical Sciences. 52(3) (pp 631-640), 2022. Date of
Publication: 2022.
Author
Altinsoy S.; Ozkan D.; Akelma F.K.; Ergil J.
Institution
(Altinsoy, Ozkan, Akelma, Ergil) Department of Anaesthesiology and
Reanimation, Diskapi Yildirim Beyazit Training and Research Hospital,
University of Health Sciences, Ankara, Turkey
Publisher
Turkiye Klinikleri
Abstract
Background/aim: Although laparoscopic inguinal herniorrhaphy is associated
with faster return to daily activity, inadequate postoperative pain
control can cause prolonged hospital stays and patient discomfort. Erector
spinae plane block (ESP) can be administered for postoperative pain
management in abdominal and thoracic surgery. We investigated the effects
of unilateral ESP block application in laparoscopic hernia surgery.
<br/>Material(s) and Method(s): A total of 60 patients who were scheduled
for laparoscopic inguinal hernia surgery were included. ESP block was
performed in group E (n = 30) after induction of anesthesia. There was no
intervention in Group C (n = 30). Postoperative pain was assessed by the
patient using the numeric rating scale (NRS) at postanesthetic care unit
(PACU),1, 4, 6, 12, and 24 h after surgery. The quality of postoperative
functional recovery was evaluated using the quality of recovery-40
questionnaire. <br/>Result(s): NRS scores were lower in Group E (n = 30)
than in Group C (n = 30) at PACU, 1^th, 4^th,
6^th hours in both rest and movement. Total tramadol consumption
was reduced at postoperative 24 h by the ESP block [median(IQR), 60(40)
versus 85(30)]. Quality of recovery score of the patients after operation
was better in the ESP group than in the control group [mean(SD),
177.9(6.5) in group E and 173.2(7.09) in group C with mean differences:
4.633 and CI: 95% (1.11 to 8.15) respectively]. <br/>Conclusion(s):
Unilateral ESP blocks in laparoscopic inguinal hernia surgery reduce both
postoperative pain levels and analgesic consumption. In addition, the ESP
block could be used safely in pain management of this type of surgery and
improve the quality of recovery.<br/>Copyright &#xa9; 2022, TUBITAK

<32>
Accession Number
2020995106
Title
Routine revascularization with percutaneous coronary intervention in
patients with coronary artery disease undergoing transcatheter aortic
valve implantation - the third nordic aortic valve intervention trial -
NOTION-3.
Source
American Heart Journal. 255 (pp 39-51), 2023. Date of Publication: January
2023.
Author
Sabbah M.; Veien K.; Niemela M.; Freeman P.; Linder R.; Ioanes D.;
Terkelsen C.J.; Kajander O.A.; Koul S.; Savontaus M.; Karjalainen P.;
Erglis A.; Minkkinen M.; Jorgensen T.; Sondergaard L.; De Backer O.;
Engstrom T.; Lonborg J.
Institution
(Sabbah, Jorgensen, Sondergaard, De Backer, Engstrom, Lonborg) Department
of Cardiology, Copenhagen University Hospital - Rigshospitalet, Denmark
(Veien) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Niemela) Department of Cardiology, Oulu University Hospital, University
of Oulu, Finland
(Freeman) Department of Cardiology, Aalborg University Hospital, Denmark
(Linder) Department of Medicine, Karolinska Institutet, Stockholm, Sweden
(Linder) Division of Cardiovascular Medicine, Department of Clinical
Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm,
Sweden
(Ioanes) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Terkelsen) The Danish Heart Foundation
(Terkelsen) Department of Cardiology, Aarhus University Hospital, Aarhus,
Denmark
(Kajander, Karjalainen, Minkkinen) Heart and Lung Center, Helsinki
University Hospital and Helsinki University, Helsinki, Finland
(Koul) Department of Cardiology, Clinical Sciences, Lund University, Skane
University Hospital, Lund, Sweden
(Savontaus) Heart Center, Turku University Hospital, Finland
(Erglis) University of Latvia, Riga, Latvia
(Sondergaard, Engstrom) Department of Clinical Medicine, University of
Copenhagen, Denmark
Publisher
Elsevier Inc.
Abstract
Background: Coronary artery disease (CAD) frequently coexists with severe
aortic valve stenosis (AS) in patients planned for transcatheter aortic
valve implantation (TAVI). How to manage CAD in this patient population is
still an unresolved question. In particular, it is still not known whether
fractional flow reserve (FFR) guided revascularization with percutaneous
coronary intervention (PCI) is superior to medical treatment for CAD in
terms of clinical outcomes. Study design: The third Nordic Aortic Valve
Intervention (NOTION-3) Trial is an open-label investigator-initiated,
multicenter multinational trial planned to randomize 452 patients with
severe AS and significant CAD to either FFR-guided PCI or medical
treatment, in addition to TAVI. Patients are eligible for the study in the
presence of at least 1 significant PCI-eligible coronary stenosis. A
significant stenosis is defined as either FFR <=0.80 and/or diameter
stenosis >90%. The primary end point is a composite of first occurring
all-cause mortality, myocardial infarction, or urgent revascularization
(PCI or coronary artery bypass graft performed during unplanned hospital
admission) until the last included patient have been followed for 1 year
after the TAVI. NOTION-3 is a multicenter, multinational randomized trial
aiming at comparing FFR-guided revascularization vs medical treatment of
CAD in patients with severe AS planned for TAVI.<br/>Copyright &#xa9; 2022
The Author(s)

<33>
Accession Number
2018426787
Title
Newer P2Y<inf>12</inf> Inhibitors vs Clopidogrel in Acute Myocardial
Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review
and Meta-analysis.
Source
Mayo Clinic Proceedings. 97(6) (pp 1074-1085), 2022. Date of Publication:
June 2022.
Author
Patlolla S.H.; Kandlakunta H.; Kuchkuntla A.R.; West C.P.; Murad M.H.;
Wang Z.; Kochar A.; Rab S.T.; Gersh B.J.; Holmes D.R.; Zhao D.X.;
Vallabhajosyula S.
Institution
(Patlolla) Department of Cardiovascular Surgery, Mayo Clinic, Rochester,
MN
(West) Division of General Internal Medicine, Mayo Clinic, Rochester, MN
(Murad) Division of Preventive, Occupational, and Aerospace Medicine, Mayo
Clinic, Rochester, MN
(West) Department of Medicine, Division of Clinical Trials and
Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic,
Rochester, MN
(Murad, Wang) Robert D. and Patricia E. Kern Center for the Science of
Health Care Delivery, Mayo Clinic, Rochester, MN
(Wang, Gersh, Holmes) Department of Cardiovascular Medicine, Mayo Clinic,
Rochester, MN
(Patlolla, Murad) Center for Clinical and Translational Science, Mayo
Clinic Graduate School of Biomedical Sciences, Rochester, MN
(Kandlakunta) Department of Medicine, Staten Island University Hospital,
Staten Island, NY
(Kuchkuntla) Department of Medicine, Rosalind Franklin University
Hospital, Chicago, IL
(Kochar) Division of Cardiovascular Medicine, Department of Medicine,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA
(Rab) Section of Interventional Cardiology, Division of Cardiovascular
Medicine, Department of Medicine, Emory University School of Medicine,
Atlanta
(Zhao, Vallabhajosyula) Section of Cardiovascular Medicine, Department of
Medicine, Wake Forest University School of Medicine, Winston-Salem, NC,
United States
Publisher
Elsevier Ltd
Abstract
Objective: To evaluate the outcomes, safety, and efficacy of dual
antiplatelet therapy (DAPT) with newer P2Y<inf>12</inf> inhibitors
compared with clopidogrel in patients with acute myocardial infarction
(AMI) complicated by cardiac arrest (CA) or cardiogenic shock (CS).
<br/>Patients and Methods: MEDLINE, EMBASE, and the Cochrane Library were
queried systematically from inception to January 2021 for comparative
studies of adults (>=18 years) with AMI-CA/CS receiving DAPT with newer
P2Y<inf>12</inf> inhibitors as opposed to clopidogrel. We compared
outcomes (30-day or in-hospital and 1-year all-cause mortality, major
bleeding, and definite stent thrombosis) of newer P2Y<inf>12</inf>
inhibitors and clopidogrel in patients with AMI-CA/CS. <br/>Result(s):
Eight studies (1 randomized trial and 7 cohort studies) comprising 1100
patients (695 [63.2%] receiving clopidogrel and 405 [36.8%] receiving
ticagrelor or prasugrel) were included. The population was mostly male
(68.5%-86.7%). Risk of bias was low for these studies, with between-study
heterogeneity and subgroup differences not statistically significant.
Compared with the clopidogrel cohort, the newer P2Y<inf>12</inf> cohort
had lower rates of early mortality (odds ratio [OR], 0.60; 95% CI, 0.45 to
0.81; P=.001) (7 studies) and 1-year mortality (OR, 0.51; 95% CI, 0.36 to
0.71; P<.001) (3 studies). We did not find a significant difference in
major bleeding (OR, 1.21; 95% CI, 0.71 to 2.06; P=.48) (6 studies) or
definite stent thrombosis (OR, 2.01; 95% CI, 0.63 to 6.45; P=.24) (7
studies). <br/>Conclusion(s): In patients with AMI-CA/CS receiving DAPT,
compared with clopidogrel, newer P2Y<inf>12</inf> inhibitors were
associated with lower rates of early and 1-year mortality. Data on major
bleeding and stent thrombosis were inconclusive.<br/>Copyright &#xa9; 2022
Mayo Foundation for Medical Education and Research

<34>
Accession Number
2018008262
Title
Effect of preoperative renin-angiotensin system blockade on vasoplegia
after cardiac surgery: A systematic review with meta-analysis.
Source
World Journal of Cardiology. 14(4) (pp 250-259), 2022. Date of
Publication: 01 Apr 2022.
Author
Noubiap J.J.; Nouthe B.; Sia Y.T.; Spaziano M.
Institution
(Noubiap) The University of Adelaide, Adelaide, SA 5000, Australia
(Nouthe) Department of Medicine, University of British Columbia, Vancouver
V6T 1W5, Canada
(Sia) Department of Medicine, Regional Trois-Rivieres Hospital
(CIUSSS-MCQ), Trois-Rivieres 5000, Canada
(Spaziano) Department of Cardiology, McGill University Health Centre,
Montreal, QC H4A 3J1, Canada
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND Vasoplegia is a common complication of cardiac surgery but its
causal relationship with preoperative use of renin angiotensin system
(RAS) blockers [angiotensin converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARB)] is still debated. AIM To update and
summarize data on the effect of preoperative use of RAS blockers on
incident vasoplegia. METHODS All published studies from MEDLINE, EMBASE,
and Web of Science providing relevant data through January 13, 2021 were
identified. A random-effects meta-analysis method was used to pool
estimates, and post-cardiac surgery shock was differentiated from
vasoplegia. RESULTS Ten studies reporting on a pooled population of 15672
patients (none looking at ARBs exclusively) were included in the
meta-analysis. All were case-control studies. Use of ACEIs was associated
with an increased risk of vasoplegia [pooled adjusted odds ratio (Aor) of
2.06, 95%CI: 1.45-2.93] and increased inotropic/vasopressor support
requirement (pooled aOR 1.19, 95%CI: 1.10-1.29). Post-cardiac surgery
shock was increased in the presence of left ventricular dysfunction
(pooled aOR 2.32, 95%CI: 1.60-3.36; I² 49%) but not increased
by the use of beta blockers (pooled aOR 0.78, 95%CI: 0.36-1.69;
I² 77%). Two randomized control trials (RCTs), not eligible for
the meta-analysis, did not show an association between continuation of RAS
blockers and vasoplegia. CONCLUSION Preoperative continuation of ACEIs is
associated with an increased need for inotropic support postoperatively
and with an increased risk of vasoplegia in observational studies but not
in RCTs. The absence of a consensus definition of vasoplegia should lead
to the use of perioperative cardiovascular monitoring when designing RCTs
to better understand this discrepancy.<br/>Copyright &#xa9; The Author(s)
2022. Published by Baishideng Publishing Group Inc. All rights reserved.

<35>
Accession Number
2020998205
Title
Comparison between Cardiac CTA and Echocardiography for Assessment of
Ventricular Septal Rupture Diameter and Its Effect on Transcatheter
Closure.
Source
Cardiovascular Therapeutics. 2022 (no pagination), 2022. Article Number:
5011286. Date of Publication: 2022.
Author
Chen T.; Liu Y.; Zhang J.; Sun Z.; Cheng J.; Han Y.; Gao C.
Institution
(Chen, Liu, Zhang, Sun, Cheng, Han, Gao) People's Hospital of Zhengzhou
University, Heart Center of Henan Provincial People's Hospital, Central
China Fuwai Hospital, Henan Key Laboratory of Coronary Heart Disease
Control, Henan Research Center for Cardiovascular Epidemiology, Zhengzhou
450003, China
Publisher
Hindawi Limited
Abstract
Objective. This study is aimed at comparing cardiac computed tomographic
angiography (CTA) with echocardiography in the assessment of ventricular
septal perforation diameter. Methods. A total of 44 ventricular septal
rupture (VSR) patients undertaking transcatheter occlusion were included
and randomly divided into the CTA group and echocardiography group with a
1: 1 ratio. Clinical data, operation-related data, and 30 d follow-up data
were collected and analyzed. Results. Incidence of closure failure,
occluder displacement, poor occluder molding, and occluder waist diameter
shrinkage between the two groups were not statistically different. The
mean residual shunt volume in the echocardiography group (4.2 (3.1, 5.9)
mm) was significantly higher than that in the CTA group (2.1 (0, 4.0) mm)
with a p value of 0.005. However, no significant differences were found in
all-cause mortality and incidence of operative complications within 30
days after surgery. Within the CTA group, the correlation was strongest
between postoperative occluder diameter and long diameter measured by CTA
with a correlation coefficient of 0.799 and p<0.001, followed by the
correlation between postoperative occluder diameter and mean diameter
measured by CTA with a correlation coefficient of 0.740 and p<0.001. The
diameter measured by echocardiography was not correlated to postoperative
occlude diameter. Conclusion. Assessment of VSR diameter by cardiac CTA is
more accurate than by echocardiography.<br/>Copyright &#xa9; 2022 Tongfeng
Chen et al.

<36>
Accession Number
2012120610
Title
Prevalence of Return to Work in Cardiovascular Patients After Cardiac
Rehabilitation: A Systematic Review and Meta-analysis.
Source
Current Problems in Cardiology. 47(7) (no pagination), 2022. Article
Number: 100876. Date of Publication: July 2022.
Author
Sadeghi M.; Rahiminam H.; Amerizadeh A.; Masoumi G.; Heidari R.; Shahabi
J.; Mansouri M.; Roohafza H.
Institution
(Sadeghi) Cardiac Rehabilitation Research Center, Isfahan Cardiovascular
Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran,
Islamic Republic of
(Rahiminam, Amerizadeh) Heart Failure Research Center, Cardiovascular
Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran,
Islamic Republic of
(Masoumi) Anesthesiology Department, Chamran Cardiovascular Medical and
Research Hospital, Isfahan University of Medical Sciences, Isfahan, Iran,
Islamic Republic of
(Heidari, Mansouri, Roohafza) Isfahan Cardiovascular Research Center,
Cardiovascular Research Institute, Isfahan University of Medical Sciences,
Isfahan, Iran, Islamic Republic of
(Shahabi) Interventional Cardiology Research Center, Cardiovascular
Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran,
Islamic Republic of
Publisher
Elsevier Inc.
Abstract
The present systematic review and meta-analysis aimed to clarify the
effects of cardiac rehabilitation (CR) on the prevalence of return to work
(RTW) in cardiovascular diseases (CVDs) patients. CR plays a very
important role in the management of CVDs and improves the patients'
physical activity, quality of life, and a decrease in the cost of
healthcare. RTW is the most important goal in the rehabilitation of CVD
patients. PubMed, Web of Science, Scopus, and Google scholar were searched
systematically from inception up to January 2021 for English published
clinical trials and observational studies. In total, 16 studies were
analyzed, of them, 8 were controlled studies. Pooled results showed that
the mean age of patients was 52.30 (50.04, 54.57). The prevalence of RTW
in the CR attending group was 66% (60%, 71%) and in the control group was
58% (47%, 68%). Subgroup analysis showed that the proportion of RTW was
higher in white-collars 76% (73%-79%) compared to. blue-collars 63%
(56%-70%). Out-patient CR with 72% (61%-81%) RTW was more effective
compared to in-patient CR with 62% (44%- 78%) and usual care (control). It
can be concluded that CR especially out-patient CR increases the
prevalence of RTW but not much. Improved and appropriate CR programs
related to each individual's disease and patient condition which follow
the valid guidelines might help to increase the effectiveness of CR in
terms of RTW.<br/>Copyright &#xa9; 2021 Elsevier Inc.

<37>
Accession Number
2011542431
Title
Spontaneous versus mechanical ventilation during video-assisted
thoracoscopic surgery for spontaneous pneumothorax: A randomized trial.
Source
Journal of Thoracic and Cardiovascular Surgery. 163(5) (pp 1702-1714.e7),
2022. Date of Publication: May 2022.
Author
Liu J.; Liang H.; Cui F.; Liu H.; Zhu C.; Liang W.; He J.; Wang W.; Jiang
S.; Dong Q.; Liang L.; Yang H.; Jin J.; Shen J.; Dai T.; He K.; Cai K.;
Feng S.; Wang H.; Zhang Z.; Huang H.; Cheng C.; Liu Z.; Qiao K.; Xia Z.;
Liu X.; Wang G.; Huang T.; Xu S.; Shen Q.; Tan W.; Ding J.; Liu Y.; Ye J.;
Yu J.; Zhang H.; Feng X.; Ma M.; Duan Z.; Li Y.; Ma H.; Ng C.S.H.;
Gonzalez-Rivas D.; Pompeo E.; Daley E.; Flores R.M.; Shargall Y.; Ismail
M.; Ang K.-L.; Ambrogi V.; Elkhouly A.
Institution
(Liu, Liang, Cui, Liang, He) National Clinical Research Center for
Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical
University, Guangzhou, China
(Liu, Liang, Cui, Liang, He) Department of Thoracic Surgery, the First
Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
(Liu) Department of Anesthesia, the First Affiliated Hospital of Guangzhou
Medical University, Guangzhou, China
(Zhu) Department of Thoracic Surgery, Taizhou Hospital, Taizhou, China
(He) Southern Medical University, Guangzhou, China
Publisher
Elsevier Inc.
Abstract
Objective: Spontaneous ventilation video-assisted thoracic surgery
(SV-VATS) is reported to have superior or equal efficacy on postoperative
recovery to mechanical ventilation VATS (MV-VATS). However, perioperative
safety of the SV-VATS blebectomy is not entirely demonstrated.
<br/>Method(s): We performed a noninferiority, randomized controlled trial
(No. NCT03016858) for primary spontaneous pneumothorax patients aged 16 to
50 years undergoing a SV-VATS and the MV-VATS procedure. The trial was
conducted at 10 centers in China from April 2017 to January 2019. The
primary outcome was the comparison of intra- and postoperative
complications between SV-VATS and MV-VATS procedures. Secondary outcomes
included total analgesia dose, change of vital sign during surgery,
procedural duration, recovery time, postoperative visual analog pain
scores, and hospitalization length. <br/>Result(s): In this study, 335
patients were included. There was no significant difference between the
SV-VATS group and the MV-VATS group in the intra- and postoperative
complication rates (17.90% vs 22.09%; relative risk, 0.81; 95% confidence
interval, 0.52-1.26; P =.346). The SV-VATS group was associated with
significantly decreased total dose of intraoperative opioid agents; that
is, sufentanil (11.37 mug vs 20.92 mug; P <.001) and remifentanil (269.78
mug vs 404.96 mug; P <.001). The SV-VATS procedure was also associated
with shorter extubation time (12.28 minutes vs 17.30 minutes; P <.001),
postanesthesia care unit recovery time (25.43 minutes vs 30.67 minutes; P
=.02) and food intake time (346.07 minute vs 404.02 minutes; P =.002).
Moreover, the SV-VATS procedure deceased the anesthesia cost compared with
the MV-VATS ($297.81 vs $399.81; P <.001). <br/>Conclusion(s): SV-VATS was
shown to be noninferior to MV-VATS in term of complication rate and in
selected patients undergoing blebectomy for primary spontaneous
pneumothorax.<br/>Copyright &#xa9; 2021

<38>
Accession Number
2020641644
Title
Eosinophilic Myocarditis Presenting as Cardiac Tamponade: A Diagnostic
Challenge.
Source
European Journal of Case Reports in Internal Medicine. 9(9) (no
pagination), 2022. Date of Publication: 2022.
Author
Vo K.; Nishimura Y.; Yokoyama J.; Wasko A.; Miyake T.; Vu K.; Zhang J.;
Moreno J.P.; Banerjee D.; Kim L.; Chong C.
Institution
(Vo, Nishimura, Yokoyama, Wasko, Miyake, Chong) Department of Medicine,
John A. Burns School of Medicine, University of Hawaii, Honolulu, HI,
United States
(Vu, Zhang, Moreno, Banerjee) Queen's Heart Institute, Queen's Medical
Center, Honolulu, HI, United States
(Kim) Hawaii Pathologists' Laboratory, Queen's Medical Center, Honolulu,
HI, United States
Publisher
SMC Media Srl
Abstract
Eosinophilic myocarditis (EM) is a rare cause of acute heart failure. It
can occur secondary to drug hypersensitivity, autoimmune diseases such as
vasculitis, idiopathic hypereosinophilic syndrome (HES) or malignancy, but
is often under-recognized and underdiagnosed, being confused with other
causes of heart failure. While EM is associated with various clinical
symptoms, it is rarely associated with cardiac tamponade that requires
urgent pericardiocentesis. Here we describe a patient with EM who
presented with cardiac tamponade and decompensated heart failure likely
secondary to autoimmune disease.<br/>Copyright European Journal of Case
Reports in Internal Medicine - &#xa9; EFIM 2022.

<39>
Accession Number
639404331
Title
The Fried Frailty Phenotype in Patients Undergoing Cardiac Surgery: A
Systematic Review and Meta-Analysis.
Source
The heart surgery forum. 25(5) (pp E652-E659), 2022. Date of Publication:
12 Sep 2022.
Author
Nguyenhuy M.; Chang J.; Xu R.; Virk S.; Saxena A.
Institution
(Nguyenhuy) Western Hospital, Footscray, Melbourne, VIC, Australia.
michaelnh1@gmail.com
(Chang) The Royal Melbourne Hospital, Parkville, Melbourne, VIC, Australia
(Xu) The University of Melbourne, Parkville, Melbourne, VIC, Australia
(Virk) Department of Cardiology, Concord Repatriation General Hospital,
Concord West, NSW, Australia
(Saxena) Department of Cardiothoracic Surgery and Transplantation, Fiona
Stanley Hospital, Murdoch, WA, Australia
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Frailty is an increasingly recognized marker of poor surgical
outcomes in cardiac surgery. Frailty first was described in the seminal
"Fried" paper, which constitutes the longest-standing and most
well-recognized definition. This study aimed to assess the impact of the
Fried and modified Fried frailty classifications on patient outcomes
following cardiac surgery. <br/>METHOD(S): The PUBMED, MEDLINE, and EMBASE
databases were searched from January 2000 until August 2021 for studies
evaluating postoperative outcomes using the Fried or modified Fried
frailty indexes in open cardiac surgical procedures. Primary outcomes were
one-year survival and postoperative quality of life. Secondary outcomes
included postoperative complications, intensive care unit (ICU) length of
stay (LOS), total hospital LOS, and institutional discharge.
<br/>RESULT(S): Eight eligible studies were identified. Meta-analysis
identified that frailty was associated with an increased risk of one-year
mortality (Risk Ratio [RR]:2.23;95% confidence interval [CI]1.17 -4.23),
postoperative complications (RR 1.78;95% CI 1.27 - 2.50), ICU LOS (Mean
difference [MD] 21.2 hours;95% CI 8.42 - 33.94), hospital LOS (MD 3.29
days; 95% CI 2.19 - 4.94), and institutional discharge (RR 3.29;95% CI
2.19 - 4.94). A narrative review of quality of life suggested an
improvement following surgery, with frail patients demonstrating a greater
improvement from baseline over non-frail patients. <br/>CONCLUSION(S):
Frailty is associated with a higher degree of surgical morbidity, and
frail patients are twice as likely to experience mortality within one-year
post-operatively. Despite this, quality of life also improves dramatically
in frail patients. Frailty, in itself, does not constitute a
contraindication to cardiac surgery.

<40>
Accession Number
2019386964
Title
A structured narrative review of clinical and experimental studies of the
use of different positive end-expiratory pressure levels during thoracic
surgery.
Source
Clinical Respiratory Journal. 16(11) (pp 717-731), 2022. Date of
Publication: November 2022.
Author
Yueyi J.; Jing T.; Lianbing G.
Institution
(Yueyi, Lianbing) The Affiliated Cancer Hospital of Nanjing Medical
University, Nanjing, China
(Jing, Lianbing) Department of Anesthesiology, Jiangsu Cancer Hospital,
Nanjing, China
Publisher
John Wiley and Sons Inc
Abstract
Objectives: This study aimed to present a review on the general effects of
different positive end-expiratory pressure (PEEP) levels during thoracic
surgery by qualitatively categorizing the effects into detrimental,
beneficial, and inconclusive. Data source: Literature search of Pubmed,
CNKI, and Wanfang was made to find relative articles about PEEP levels
during thoracic surgery. We used the following keywords as one-lung
ventilation, PEEP, and thoracic surgery. <br/>Result(s): We divide the
non-individualized PEEP value into five grades, that is, less than 5, 5,
5-10, 10, and more than 10 cmH<inf>2</inf>O, among which 5
cmH<inf>2</inf>O is the most commonly used in clinic at present to
maintain alveolar dilatation and reduce the shunt fraction and the
occurrence of atelectasis, whereas individualized PEEP, adjusted by test
titration or imaging method to adapt to patients' personal
characteristics, can effectively ameliorate intraoperative oxygenation and
obtain optimal pulmonary compliance and better indexes relating to
respiratory mechanics. <br/>Conclusion(s): Available data suggest that
PEEP might play an important role in one-lung ventilation, the
understanding of which will help in exploring a simple and economical
method to set the appropriate PEEP level.<br/>Copyright &#xa9; 2022 The
Authors. The Clinical Respiratory Journal published by John Wiley & Sons
Ltd.

<41>
Accession Number
2019075225
Title
Feasibility and oncological outcomes of video-assisted thoracic surgery
versus thoracotomy for pathologic N2 disease in non-small cell lung
cancer: A comprehensive systematic review and meta-analysis.
Source
Thoracic Cancer. 13(21) (pp 2917-2928), 2022. Date of Publication:
November 2022.
Author
Li X.; Huang K.; Deng H.; Zheng Q.; Xiao T.; Yu J.; Zhou Q.
Institution
(Li, Huang, Deng, Zheng, Xiao, Yu, Zhou) Lung Cancer Center, West China
Hospital of Sichuan University, Chengdu, China
(Yu) Department of Radiation Oncology and Shandong Provincial Key
Laboratory of Radiation Oncology, Shandong First Medical University and
Shandong Academy of Medical Sciences, Jinan, China
(Yu) Research Unit of Radiation Oncology, Chinese Academy of Medical
Sciences, Jinan, China
Publisher
John Wiley and Sons Inc
Abstract
This meta-analysis aimed to evaluate the feasibility and oncological
outcomes between video-assisted thoracic surgery (VATS) and thoracotomy
for non-small cell lung cancer (NSCLC) patients with pathologic N2 (pN2)
disease. Data for analysis included short-term outcomes and long-term
outcomes. We calculated the weighted mean differences (WMDs) for
continuous data and the results of overall survival (OS) and disease free
survival (DFS) were pooled using the hazard ratios (HRs) with 95%
confidence intervals (CIs). Heterogeneity was assessed using the Q-test
and I²-test. Sensitivity analysis was performed to further
examine the stability of pooled HRs and WMDs. In the pooled analyses of 10
eligible studies, results showed that VATS for NSCLC patients with pN2
disease yielded significantly less blood loss (WMD = -61.43; 95%
confidence intervals [CI], [-87.69, -35.18]; p < 0.001), less
post-operation hospital stay (WMD, -1.62; 95% CI, [-2.96, -0.28]; p =
0.02), and comparable operation time (WMD, -8.32; 95% CI, [-23.88, 7.23];
p = 0.29), post-operation complication rate (risk ratio [RR], 0.95; 95%
CI, [0.78, 1.15]; p = 0.59), chest tube duration to thoracotomy (WMD,
-0.64; 95% CI, [-1.45, 0.17]; p = 0.12), extent of lymph node dissection
(WMD, -1.46; 95% CI, [-3.87, 0.95]; p = 0.23) and 1-year OS (HR, 1.30; 95%
CI, [0.96, 1.76]; p = 0.09) than thoracotomy. However, VATS may improve
3-year OS (HR, 1.26; 95% CI, [1.12, 1.42]; p = 0.0002) and yield
comparable 1-year DFS (HR, 1.14; 95% CI, [0.89, 1.46]; p = 0.32) and
3-year DFS (HR, 1.03; 95% CI, [0.88, 1.22]; p = 0.70) for NSCLC patients
with pN2 disease than thoracotomy. VATS could yield less surgical trauma
and improve post-operative recovery than thoracotomy. Moreover, VATS may
improve the oncological outcomes of those patients.<br/>Copyright &#xa9;
2022 The Authors. Thoracic Cancer published by China Lung Oncology Group
and John Wiley & Sons Australia, Ltd.

<42>
Accession Number
2020895277
Title
Randomized comparison of the clinical Outcome of single versus Multiple
Arterial grafts: Quality of Life (ROMA:QOL)-Rationale and Study Protocol.
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 8(5) (pp
510-517), 2022. Date of Publication: 01 Sep 2022.
Author
Masterson Creber R.; Safford M.; Ballman K.; Myers A.; Fremes S.; Gaudino
M.
Institution
(Masterson Creber, Ballman, Myers) Division of Health Informatics,
Department of Population Health Sciences, Weill Cornell Medicine, 425 East
61st Street, Suite 301, New York, NY 10065, United States
(Safford) Division of General Internal Medicine, Department of Medicine,
Weill Cornell Medicine, 1300 York Ave F-2007, New York, NY 10065, United
States
(Fremes) Department of Surgery (Cardiac), Schulich Heart Centre,
Sunnybrook Health Science, University of Toronto, 2075 Bayview Avenue,
H-Wing Room H410, Toronto, ON M4N 3M5, Canada
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
525 E 68th St M-404, New York, NY 10065, United States
Publisher
Oxford University Press
Abstract
Aims: The objective of the Randomized comparison of the Outcome of single
vs. Multiple Arterial grafts: Quality of Life (ROMA:QOL) trial is to
evaluate the impact of coronary artery bypass graft surgery (CABG) on
quality of life (QOL). The primary hypothesis of ROMA:QOL is that
participants in the multiple arterial graft (MAG) will report time-varying
changes in QOL that will be lower in the post-operative recovery period
and higher after 12 months compared to patients in the single arterial
graft (SAG). The secondary hypotheses are that both groups will have
improvements in symptoms at 12 months, and that compared to the SAG group,
participants in the MAG group will experience better physical functioning
and physical and mental health symptoms. <br/>Methods and Results: An
estimated 2111 participants will be enrolled from the parent ROMA trial
from 13 countries. Outcome assessments include the Seattle Angina
Questionnaire (SAQ) (primary outcome), Short Form-12v2, EuroQol-5D
(EQ-5D)-5L, PROMIS-29, and PROMIS Neuropathic Pain measured at baseline,
first post-operative visit, 6, 12, 24, 36, 48, and 60 months. The analysis
for the primary outcome, the change in the SAQ from baseline to 12 months,
will be compared across all time-points between the two treatment arms.
<br/>Conclusion(s): The ROMA:QOL trial will answer whether there are
differences in QOL, physical and mental health symptoms overall for CABG,
by MAG and SAG intervention arms, by sex, and between patients with and
without diabetes. <br/>Copyright &#xa9; 2021 Published on behalf of the
European Society of Cardiology. All rights reserved.

<43>
Accession Number
2021012969
Title
Preventive Effect of Berberine on Postoperative Atrial Fibrillation.
Source
Circulation: Arrhythmia and Electrophysiology. 15(10) (pp 648-654), 2022.
Date of Publication: 01 Oct 2022.
Author
Zhang J.; Wang Y.; Jiang H.; Tao D.; Zhao K.; Yin Z.; Han J.; Xin F.; Jin
Y.; Wang H.
Institution
(Zhang, Wang, Jiang, Tao, Zhao, Yin, Han, Xin, Jin, Wang) Department of
Cardiovascular Surgery, General Hospital of Northern Theater Command,
Liaoning, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Postoperative atrial fibrillation (POAF) is one of the most
common complications of cardiac surgery, but the underlying factors
governing POAF are not well understood. The aim of this study was to
investigate the efficacy of berberine administration on POAF.
<br/>Method(s): We conducted a randomized, double-blind,
placebo-controlled trial with patients who underwent isolated coronary
artery bypass grafting in China to study the impact of oral berberine on
the incidence of POAF. A total of 200 patients who underwent coronary
artery bypass grafting were randomized into the berberine group (n=100)
and the placebo group (n=100). All patients underwent 7-day continuous
telemetry and Holter monitoring. <br/>Result(s): The primary outcome was
the incidence of POAF at 7 days. Secondary outcomes included clinical
outcomes, POAF burden, intestinal endotoxin, and serum inflammatory
biomarker levels. The POAF incidence was reduced from 35% to 20% under
berberine treatment (hazard ratio, 0.5 [95% CI, 0.29-0.78]; P=0.0143).
Perioperative mortality and morbidity did not differ between the 2 groups.
POAF burden and the dose of amiodarone were significantly reduced in the
berberine group. Oral berberine significantly decreased
lipopolysaccharide, CRP (C-reactive protein), and IL (interleukin)-6
levels. Elevated lipopolysaccharide after surgery has been associated with
POAF. <br/>Conclusion(s): Our results showed that administration of
berberine may be effective for reducing the occurrence of POAF after
coronary artery bypass grafting. Registration: URL:
https://www.chictr.org.cn; Unique identifier:
ChiCTR2000028839.<br/>Copyright &#xa9; 2022 Lippincott Williams and
Wilkins. All rights reserved.

<44>
Accession Number
2020994555
Title
Revascularization strategies versus optimal medical therapy in chronic
coronary syndrome: A network meta-analysis.
Source
International Journal of Cardiology. (no pagination), 2022. Date of
Publication: 2022.
Author
Galli M.; Benenati S.; Zito A.; Capodanno D.; Zoccai G.B.; Ortega-Paz L.;
Iaconelli A.; D'Amario D.; Porto I.; Burzotta F.; Trani C.; De Caterina
R.; Gaudino M.; Escaned J.; Angiolillo D.J.; Crea F.
Institution
(Galli, Burzotta, Trani, Crea) Catholic University of the Sacred Heart,
Rome, Italy
(Galli) Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
(Benenati, Porto) Cardiovascular Disease Unit, IRCCS Ospedale Policlinico
San Martino, IRCCS Italian Cardiology Network, Genova, Italy
(Zito, Iaconelli, D'Amario, Burzotta, Trani, Crea) Department of
Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario
Agostino Gemelli IRCCS, Rome, Italy
(Capodanno) Division of Cardiology, Azienda Ospedaliero Universitaria
Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy
(Zoccai) Department of Medical-Surgical Sciences and Biotechnologies,
Sapienza University, Latina, Rome, Italy
(Zoccai) Mediterranea Cardiocentro, Napoli, Italy
(Ortega-Paz, Angiolillo) Division of Cardiology, University of Florida
College of Medicine, Jacksonville, FL, United States
(Porto) Cardiovascular Disease Chair, Department of Internal Medicine
(Di.M.I.), University of Genoa, Genoa, Italy
(De Caterina) University of Pisa and University Cardiology Division, Pisa
University Hospital, Pisa, Italy
(Gaudino) Department of Cardiothoracic Surgery, Weill Cornell Medicine,
New York City, NY, United States
(Escaned) Hospital Clinico San Carlos IDISSC, Complutense University,
Madrid, Spain
(De Caterina) Fondazione VillaSerena per la Ricerca, Citta Sant'Angelo,
Pescara, Italy
Publisher
Elsevier Ireland Ltd
Abstract
Background: The impact of myocardial revascularization on outcomes and
prognosis in patients with chronic coronary syndrome (CCS) without left
main (LM) disease or reduced left ventricle ejection fraction (LVEF) may
be influenced by the revascularization strategy adopted. <br/>Method(s):
We performed a network meta-analysis including 18 randomized controlled
trials comparing different revascularization strategies, including
angiography-guided percutaneous coronary intervention (PCI),
physiology-guided PCI and coronary artery bypass graft (CABG), in patients
with CCS without LM disease or reduced LVEF. <br/>Result(s): Compared with
medical therapy, all revascularization strategies were associated with a
reduction of the primary endpoint, as defined in each trial, the extent of
which was modest with angiography-guided PCI (IRR 0.86, 95% CI 0.75-0.99)
and greater with physiology-guided PCI (IRR 0.60, 95% CI 0.47-0.77) and
CABG (IRR 0.58, 95% CI 0.48-0.70). Moreover, angiography-guided PCI was
associated with an increase of the primary endpoint compared to
physiology-guided PCI (IRR 1.43, 95% CI 1.14-1.79) and CABG (IRR 1.49, 95%
CI 1.27-1.74). CABG was the only strategy associated with reduced
myocardial infarction (IRR 0.68, 95% CI 0.52-0.90), cardiovascular death
(IRR 0.76, 95% CI 0.64-0.89), and all-cause death (IRR 0.87, 95% CI
0.77-0.99), but increased stroke (IRR 1.69, 95% CI 1.04-2.76).
<br/>Conclusion(s): In CCS patients without LM disease or reduced LVEF,
physiology-guided PCI and CABG are associated with better outcomes than
angiography-guided PCI. Compared with medical therapy, CABG is the only
revascularization strategy associated with a reduction of myocardial
infarction and death rates, at the cost of higher risk of stroke. Study
registration: This study is registered in PROSPERO
(CRD42022313612).<br/>Copyright &#xa9; 2022 Elsevier B.V.

<45>
Accession Number
639434335
Title
Impact of prior coronary artery bypass grafting on periprocedural and
short-term outcomes of patients undergoing transcatheter aortic valve
replacement: a systematic review and meta-analysis.
Source
Coronary artery disease. (no pagination), 2022. Date of Publication: 04
Nov 2022.
Author
Machanahalli Balakrishna A.; Ismayl M.; Palicherla A.; Aboeata A.;
Goldsweig A.M.; Zhao D.X.; Vallabhajosyula S.
Institution
(Machanahalli Balakrishna, Ismayl, Palicherla) Department of Internal
Medicine, Creighton University School of Medicine, Omaha, NE, United
States
(Aboeata) Division of Cardiovascular Medicine, Department of Medicine,
Creighton University School of Medicine, Omaha, NE, United States
(Goldsweig) Department of Cardiovascular Medicine, University of Nebraska
Medical Center, Omaha, NE, United States
(Zhao, Vallabhajosyula) Section of Cardiovascular Medicine, Department of
Medicine, Wake Forest University School of Medicine, Winston-Salem, NC,
United States
Publisher
NLM (Medline)
Abstract
BACKGROUND: The effect of prior coronary artery bypass graft (CABG) on the
outcomes of transcatheter aortic valve replacement (TAVR) remains
incompletely characterized. In this meta-analysis, we investigated the
impact of prior CABG on TAVR outcomes. <br/>METHOD(S): A systematic search
was conducted in PubMed, Google Scholar, and Cochrane databases from
inception to 24 July 2022, using the search terms 'TAVR', 'CABG',
'peri-procedural complications', and 'mortality'. The major outcomes were
peri-procedural complications, intraprocedural mortality, 30-day
mortality, and 30-day cardiac mortality. We used random-effects models to
aggregate data and to calculate pooled incidence and risk ratios with 95%
confidence intervals (CIs). <br/>RESULT(S): Among 116 results from the
systematic search, a total of 8 studies (5952 patients) were included.
Compared to patients without previous CABG, patients with prior CABG
undergoing TAVR were younger, predominantly male sex, had more
comorbidities, higher rates of peri-procedural myocardial infarction (MI)
[relative risk (RR) 1.93; 95% CI, 1.09-3.43; P=0.03], but lower rates of
stroke (RR 0.71; 95% CI, 0.51-0.99; P=0.04), major vascular complications
(RR 0.70; 95% CI, 0.51-0.95; P=0.02), and major bleeding (RR 0.70; 95% CI,
0.56-0.88; P=0.002). There were no significant differences between the two
cohorts in rates of pacemaker implantation, cardiac tamponade, acute
kidney injury, intra-procedural mortality, 30-day mortality, and 30-day
cardiac mortality. <br/>CONCLUSION(S): Among patients undergoing TAVR, a
history of prior CABG was not associated with an increased risk of
periprocedural complications (except for acute MI) or short-term mortality
compared to those without CABG.<br/>Copyright &#xa9; 2022 Wolters Kluwer
Health, Inc. All rights reserved.

<46>
Accession Number
639431003
Title
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease:
A Report of the American Heart Association/American College of Cardiology
Joint Committee on Clinical Practice Guidelines.
Source
Circulation. (no pagination), 2022. Date of Publication: 02 Nov 2022.
Author
Isselbacher E.M.; Preventza O.; Hamilton Black J.; Augoustides J.G.; Beck
A.W.; Bolen M.A.; Braverman A.C.; Bray B.E.; Brown-Zimmerman M.M.; Chen
E.P.; Collins T.J.; DeAnda A.; Fanola C.L.; Girardi L.N.; Hicks C.W.; Hui
D.S.; Schuyler Jones W.; Kalahasti V.; Kim K.M.; Milewicz D.M.; Oderich
G.S.; Ogbechie L.; Promes S.B.; Gyang Ross E.; Schermerhorn M.L.;
Singleton Times S.; Tseng E.E.; Wang G.J.; Woo Y.J.
Institution
(Augoustides) SCA representative
(Bolen) ACR representative
(Bray) AHA/ACC Joint Committee on Clinical Data Standards liaison
(Brown-Zimmerman) Lay stakeholder representative
(Collins) SCAI representative
(Girardi) AATS representative
(Schuyler Jones, Woo) AHA/ACC Joint Committee on Clinical Practice
Guidelines liaison
(Kim) STS representative
(Schermerhorn) SVS representative
(Singleton Times) AHA/ACC staff representative
Publisher
NLM (Medline)
Abstract
AIM: The "2022 ACC/AHA Guideline for the Diagnosis and Management of
Aortic Disease" provides recommendations to guide clinicians in the
diagnosis, genetic evaluation and family screening, medical therapy,
endovascular and surgical treatment, and long-term surveillance of
patients with aortic disease across its multiple clinical presentation
subsets (ie, asymptomatic, stable symptomatic, and acute aortic
syndromes). <br/>METHOD(S): A comprehensive literature search was
conducted from January 2021 to April 2021, encompassing studies, reviews,
and other evidence conducted on human subjects that were published in
English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and
other selected databases relevant to this guideline. Additional relevant
studies, published through June 2022 during the guideline writing process,
were also considered by the writing committee, where appropriate.
Structure: Recommendations from previously published AHA/ACC guidelines on
thoracic aortic disease, peripheral artery disease, and bicuspid aortic
valve disease have been updated with new evidence to guide clinicians. In
addition, new recommendations addressing comprehensive care for patients
with aortic disease have been developed. There is added emphasis on the
role of shared decision making, especially in the management of patients
with aortic disease both before and during pregnancy. The is also an
increased emphasis on the importance of institutional interventional
volume and multidisciplinary aortic team expertise in the care of patients
with aortic disease.

<47>
Accession Number
2020898401
Title
Impella Versus Extracorporeal Membranous Oxygenation (ECMO) for
Cardiogenic Shock: A Systematic Review and Meta-analysis.
Source
Current Problems in Cardiology. 48(1) (no pagination), 2023. Article
Number: 101427. Date of Publication: January 2023.
Author
Ahmad S.; Ahsan M.J.; Ikram S.; Lateef N.; Khan B.A.; Tabassum S.; Naeem
A.; Qavi A.H.; Ardhanari S.; Goldsweig A.M.
Institution
(Ahmad) Department of Internal Medicine, East Carolina University,
Greenville, NC
(Ahsan) Division of Cardiovascular Medicine, Iowa Heart Center, Des
Moines, IA, United States
(Ikram) Department of Internal Medicine, SEGi University, MY, Petaling
Jaya, Malaysia
(Lateef, Goldsweig) Division of Cardiovascular Medicine, University of
Nebraska Medical Center, Omaha, NE, United States
(Khan) Department of Internal Medicine, The Jewish Hospital - Mercy
Health, Cincinnati, OH, United States
(Tabassum, Naeem) Department of Internal Medicine, King Edward Medical
University, Lahore, PK
(Qavi, Ardhanari) Division of Cardiovascular Medicine, East Carolina
University, Greenville, NC
Publisher
Elsevier Inc.
Abstract
The use of mechanical circulatory support (MCS) in cardiogenic shock (CS)
is increasing. We conducted a systematic review and meta-analysis to
compare the outcomes of Impella use with extracorporeal membranous
oxygenation (ECMO) support in patients with CS. We searched the Medline,
EMBASE, Cochrane, and Clinicaltrials.gov databases for observational
studies comparing Impella to ECMO in patients with CS. Risk ratios (RRs)
for categorical variables and standardized mean differences (SMDs) for
continuous variables were calculated with 95% confidence intervals (CIs)
using a random-effects model. Twelve retrospective studies and one
prospective study (Impella n=6652, ECMO n=1232) were identified. Impella
use was associated with lower incidence of in-hospital mortality (RR 0.88
[95% CI 0.80-0.94], P=0.0004), stroke (RR 0.30 [0.21-0.42], P<0.00001),
access-site bleeding (RR 0.50 [0.37-0.69], P<0.0001), major bleeding (RR
0.56 [0.39-0.80], P=0.002), and limb ischemia (RR 0.42 [0.27-0.65],
P=0.0001). Baseline lactate levels were significantly lower in the Impella
group (SMD -0.52 [-0.73- -0.31], P<0.00001). There was no significant
difference in mortality at 6-12 months, MCS duration, need for MCS
escalation, bridge-to-LVAD or heart transplant, and renal replacement
therapy use between Impella and ECMO groups. In patients with CS, Impella
device use was associated with lower in-hospital mortality, stroke, and
device-related complications than ECMO. However, patients in the ECMO
group had higher baseline lactate levels.<br/>Copyright &#xa9; 2022
Elsevier Inc.

<48>
Accession Number
639334111
Title
Effects of recombinant erythropoietin on hemoglobin levels and blood
transfusion needs in patients with preoperative anemia undergoing cardiac
surgery.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 466-471), 2022. Date of
Publication: October-December 2022.
Author
Totonchi Z.; Noohi F.; Futuhi F.; Azarfarin R.; Radbin P.
Institution
(Totonchi, Radbin) Department of Cardiac Anesthesia, Rajaie Cardiovascular
Medical and Research Center, Iran University of Medical Sciences, Tehran,
Iran, Islamic Republic of
(Noohi) Department of Cardiology, Cardiovascular Intervention Research
Center, Rajaie Cardiovascular Medical and Research Center, Iran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
(Futuhi) Department of Nephrology, Loghman Hakim Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Azarfarin) Department of Cardiology, Cardio-Oncology Research Center,
Rajaie Cardiovascular Medical and Research Center, Iran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Preoperative anemia is an important and relatively common
problem in patients undergoing cardiac surgery, and its treatment is
crucial in improving postoperative outcomes. The use of recombinant
erythropoietin is one of the suggested methods in this field. Therefore,
in the present study, we sought to evaluate the effects of recombinant
erythropoietin on hemoglobin (Hb) levels and blood transfusion needs in
cardiac surgery in patients with preoperative anemia. <br/>Method(s): This
randomized nonblind clinical trial was performed on patients with
mild-To-moderate anemia (Hb <12 g/dL in men and Hb <11 g/dL in women)
undergoing cardiac surgery at a referral heart hospital (Tehran, Iran).
The patients were randomly divided into two groups of 33 patients. In the
intervention group, recombinant erythropoietin was administered at a dose
of 500 IU/kg one to three days before surgery. Intra-and postoperative Hb
levels and the need for blood transfusion were recorded during surgery and
for 3 days afterward. <br/>Result(s): The use of packed red blood cells in
the operating room was similar in the intervention and control groups (P =
0.156), but it was significantly lower in the intensive care unit in the
intervention group (P = 0.030). The mean Hb, which was initially identical
in the two groups (P > 0.05), showed a significantly lower decrease in the
intervention group (P = 0.001). No significant differences were observed
concerning other variables. <br/>Conclusion(s): The use of recombinant
erythropoietin (500 IU/kg/day) one to three days before cardiac surgery in
our anemic patients blunted a reduction in Hb levels and decreased blood
transfusion needs.<br/>Copyright &#xa9; 2022 Wolters Kluwer Medknow
Publications. All rights reserved.

<49>
Accession Number
639334104
Title
A comparison of the success rate of radial artery cannulation between the
ultrasound-guided and conventional palpation techniques in elderly
patients undergoing cardiothoracic surgery.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 447-452), 2022. Date of
Publication: October-December 2022.
Author
Chanthawong S.; Tribuddharat S.; Sathitkarnmanee T.; Suwongkrua T.;
Silarat S.; Plengpanich P.
Institution
(Chanthawong, Tribuddharat, Sathitkarnmanee, Suwongkrua, Silarat,
Plengpanich) Department of Anesthesiology, Faculty of Medicine, Khon Kaen
University, Khon Kaen, Thailand
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Ultrasound-guided (USG) radial artery cannulation against the
standard palpation technique increases the first attempt rate in both
pediatric and adult patients. The objective of this study was to evaluate
the benefits of USG versus the palpation technique in improving the first
attempt rate in elderly patients. <br/>Method(s): The patients over 65
years of age were randomized to the USG or Palpation group. The radial
artery identification in the USG group was performed with the aid of the
Sonimage HS 1. In the Palpation group, the radial artery was identified by
manual palpation. The operators were cardiothoracic anesthesiologists.
Overall success was defined as cannulation completed within 10 min.
<br/>Result(s): Eighty patients (40 in each group) were recruited. The
respective first attempt and overall success rate for the USG group were
similar to the Palpation group (P > 0.999 and P = 0.732). The time to the
first attempt and overall success were also similar (P = 0.075 and P =
0.636). The number of attempts, number of catheters used, and failure
rates were similar between the groups (P = 0.935, P = 0.938, and P =
0.723). The number of successful cannulations within 10 min was similar
for both the groups as categorized by the radial artery diameter (P =
0.169). <br/>Conclusion(s): The USG did not increase the first attempt or
overall success rate of radial artery cannulation in the elderly patients
undergoing cardiothoracic surgery. The time to first attempt and overall
success were similar between both the groups. The number of attempts and
number of catheters used were similar between both groups.<br/>Copyright
&#xa9; 2022 Wolters Kluwer Medknow Publications. All rights reserved.

<50>
Accession Number
639334101
Title
Randomized control study of nebulized colistin as an adjunctive therapy in
ventilator-Associated pneumonia in pediatric postoperative cardiac
surgical population.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 435-440), 2022. Date of
Publication: October-December 2022.
Author
Bharathi K.; Bhat A.; Pruthi G.; Simha P.
Institution
(Bharathi) Department of Cardiac Anaesthesiology, Sri Jayadeva Institute
of Cardiovascular Sciences and Research, Mysore, Karnataka, India
(Bhat, Pruthi, Simha) Department of Cardiac Anaesthesiology, Sri Jayadeva
Institute of Cardiovascular Sciences and Research, Karnataka, Bangalore,
India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Ventilator-Associated pneumonia (VAP) with multidrug-resistant
(MDR) gram negative organisms is a common problem in intensive care unit
(ICU). Aerosolized antibiotics enhance the efficacy of systemic
antibiotics when added as adjuvants. <br/>Aim(s): The primary objective of
the study was to compare the clinical and bacteriological outcome of
patients with VAP who were administered intravenous (IV) antibiotics alone
with those patients who were treated with adjunctive nebulized colistin
(NC) along with IV antibiotics. The secondary objective was to study the
occurrence of any adverse events during colistin nebulization. Settings
and Design: The study was a prospective, randomized, double-blinded
controlled study conducted at a tertiary-care teaching institution.
<br/>Material(s) and Method(s): Ninety-eight children from surgical ICU
aged less than 12 years who were diagnosed with VAP due to gram negative
bacteria following cardiac surgery were chosen and divided randomly into
two groups. The experimental group (NC group) was treated with systemic
antibiotics along with NC, whereas the control group (NS group) was
administered systemic antibiotics with nebulized normal saline (NS).
Clinical and bacteriological outcomes were noted. Statistical analysis was
done using SPSS Version 20.0 software. The patient characteristics were
compared using independent Student's t test and Chi-square test.
<br/>Result(s): There was a statistically significant reduction in the
duration of mechanical ventilation, postoperative ICU and hospital stay (P
< 0.05) in the NC group compared with the NS group. <br/>Conclusion(s):
Aerosolized colistin may be considered as an adjunct to systemic IV
antibiotics in pediatric patients with VAP due to gram negative bacteria
susceptible to colistin.<br/>Copyright &#xa9; 2022 Wolters Kluwer Medknow
Publications. All rights reserved.

<51>
Accession Number
639334082
Title
The use of cerebral oximetry in cardiac surgery: A systematic review and
meta-Analysis of randomized controlled trials.
Source
Annals of Cardiac Anaesthesia. 25(4) (pp 384-398), 2022. Date of
Publication: October-December 2022.
Author
Chiong X.; Wong Z.; Lim S.; Ng T.; Ng K.
Institution
(Chiong) School of Medicine, University of Aberdeen, Netherlands
(Wong) School of Medicine, International Medical University, Kuala Lumpur,
Malaysia
(Lim, Ng, Ng) Department of Anesthesiology, Faculty of Medicine,
University of Malaya, Kuala Lumpur, Malaysia
Publisher
Wolters Kluwer Medknow Publications
Abstract
High prevalence of cerebral desaturation is associated with postoperative
neurological complications in cardiac surgery. However, the evidence use
of cerebral oximetry by correcting cerebral desaturation in the reduction
of postoperative complications remains uncertain in the literature. This
systematic review and meta-Analysis aimed to examine the effect of
cerebral oximetry on the incidence of postoperative cognitive dysfunction
in cardiac surgery. Databases of MEDLINE, EMBASE, and CENTRAL were
searched from their inception until April 2021. All randomized controlled
trials comparing cerebral oximetry and blinded/no cerebral oximetry in
adult patients undergoing cardiac surgery were included. Observational
studies, case series, and case reports were excluded. A total of 14 trials
(n = 2,033) were included in this review. Our pooled data demonstrated
that patients with cerebral oximetry were associated with a lower
incidence of postoperative cognitive dysfunction than the control group
(studies = 4, n = 609, odds ratio [OR]: 0.15, 95% confidence interval
[CI]: 0.04 to 0.54, P = 0.003, I 2 = 88%; certainty of evidence = very
low). In terms of postoperative delirium (OR: 0.75, 95%CI: 0.50-1.14, P =
0.18, I 2 = 0%; certainty of evidence = low) and postoperative stroke (OR:
0.81 95%CI: 0.37-1.80, P = 0.61, I 2 = 0%; certainty of evidence = high),
no significant differences (P > 0.05) were reported between the cerebral
oximetry and control groups. In this meta-Analysis, the use of cerebral
oximetry monitoring in cardiac surgery demonstrated a lower incidence of
postoperative cognitive dysfunction. However, this finding must be
interpreted with caution due to the low level of evidence, high degree of
heterogeneity, lack of standardized cognitive assessments, and cerebral
desaturation interventions.<br/>Copyright &#xa9; 2022 Wolters Kluwer
Medknow Publications. All rights reserved.

<52>
Accession Number
638024373
Title
Computed tomography coronary angiography as the noninvasive in stable
coronary artery disease? Long-term outcomes meta-analysis.
Source
Future Cardiology. 18(5) (pp 407-416), 2022. Date of Publication: May
2022.
Author
De Campos D.; Teixeira R.; Saleiro C.; Lopes J.; Botelho A.; Goncalves L.
Institution
(De Campos, Teixeira, Saleiro, Lopes, Botelho, Goncalves) Centro
Hospitalar e Universitario de Coimbra - Hospital Geral, Quinta dos Vales,
Sao Martinho do Bispo 108, Coimbra 3041-801, Portugal
(Teixeira, Goncalves) Faculdade de Medicina, Universidade de Coimbra, R.
Larga 2, Coimbra 3000-370, Portugal
Publisher
Newlands Press Ltd
Abstract
Aim: To compare outcomes of coronary computed tomography angiography
(CCTA) with that of functional testing (FT) in stable coronary artery
disease. <br/>Method(s): We searched PubMed, Embase, and Cochrane for
randomized controlled trials (RCTs). A random-effects meta-analysis
targeting all-cause death and nonfatal acute coronary syndromes was
performed. <br/>Result(s): Eight RCTs enrolling 29,579 patients were
included. Pooled relative risk (RR) for the primary end point was similar
between CCTA and FT (RR = 0.97; 95% CI: 0.76-1.22). CCTA outperformed FT
in nonfatal myocardial infarction (MI) (RR = 0.59; 95% CI: 0.41-0.83) and
in downstream testing (OR: 0.47; 95% CI: 0.21-1.01). <br/>Conclusion(s):
Updated data of stable coronary artery disease suggests that CCTA improved
nonfatal MI and downstream testing.<br/>Copyright &#xa9; 2022 Future
Medicine Ltd.

<53>
Accession Number
2020828810
Title
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Source
New England Journal of Medicine. 387(11) (pp 978-988), 2022. Date of
Publication: 15 Sep 2022.
Author
Connolly S.J.; Karthikeyan G.; Nt M.; Haileamlak A.; El Sayed A.; El
Ghamrawy A.; Damasceno A.; Avezum A.; Dans A.M.L.; Gitura B.; Hu D.;
Kamanzi E.R.; Maklady F.; Fana G.; Gonzalez-Hermosillo J.A.; Musuku J.;
Kazmi K.; Zuhlke L.; Gondwe L.; Ma C.; Paniagua M.; Ogah O.S.;
Molefe-Baikai O.J.; Lwabi P.; Chillo P.; Sharma S.K.; Cabral T.T.J.;
Tarhuni W.M.; Benz A.; van Eikels M.; Krol A.; Pattath D.; Balasubramanian
K.; Rangarajan S.; Ramasundarahettige C.; Mayosi B.; Yusuf S.
Institution
(Connolly, Benz, Krol, Pattath, Balasubramanian, Rangarajan,
Ramasundarahettige, Yusuf) Population Health Research Institute, McMaster
University, Hamilton, ON, Canada
(Karthikeyan) All India Institute of Medical Sciences, New Delhi, India
(Nt, Mayosi) Division of Cardiology, Faculty of Health Sciences,
University of Cape Town, Cape Town, South Africa
(Zuhlke) South African Medical Research Council, Cape Town, South Africa
(Haileamlak) Jimma University Medical Center, Jimma, Ethiopia
(El Sayed) University of Gazira, Wad Madani, Sudan
(El Ghamrawy) Mahalla Heart Center, El Mahalla El Kubra, Egypt
(Maklady) Suez Canal University Hospital, Ismailia, Egypt
(Damasceno) Faculty of Medicine, Eduardo Mondlane University, Maputo,
Mozambique
(Avezum) International Research Center, Hospital Alemao Oswaldo Cruz, Sao
Paulo, Brazil
(Dans) College of Medicine, University of the Philippines, Manila,
Philippines
(Gitura) Kenyatta National Hospital, Nairobi, Kenya
(Hu) The People's Hospital of Peking University, Beijing, China
(Ma) Beijing Anzhen Hospital, Beijing, China
(Kamanzi) The University Teaching Hospital of Kigali, Kigali, Rwanda
(Fana) The University of Zimbabwe, College of Health Sciences, Harare,
Zimbabwe
(Gonzalez-Hermosillo) Instituto Nacional de Cardiologia Ignacio Chavez,
Mexico City, Mexico
(Musuku) The University Teaching Hospital, Lusaka, Zambia
(Kazmi) The National Institute of Cardiovascular Diseases, Karachi,
Pakistan
(Gondwe) Kamuzu Central Hospital, Lilongwe, Malawi
(Paniagua) Barrio Obrero Hospital, Asuncion, Paraguay
(Ogah) The Department of Medicine, University of Ibadan-College Hospital,
Ibadan, Nigeria
(Molefe-Baikai) Princess Marina Hospital, University of Botswana,
Gaborone, Botswana
(Lwabi) Uganda Heart Institute, Kampala, Uganda
(Chillo) Muhimbili University of Health and Allied Sciences, Dar es
Salaam, Tanzania
(Sharma) The B.P. Koirala Institute of Health Sciences, Dharan, Nepal
(Cabral) St. Elizabeth Catholic General Hospital, Kumbo, Cameroon
(Tarhuni) Department of Medicine, University of Saskatchewan, Saskatoon,
Canada
(Tarhuni) The Department of Medicine, Western University, London, ON,
Canada
(Tarhuni) The Windsor Cardiac Centre, Windsor, ON, Canada
(Benz) The Department of Cardiology, Cardiology I, University Medical
Center Mainz, Johannes Gutenberg University, Mainz, Germany
(van Eikels) Bayer, Berlin, Germany
Publisher
Massachussetts Medical Society
Abstract
BACKGROUND Testing of factor Xa inhibitors for the prevention of
cardiovascular events in patients with rheumatic heart disease-associated
atrial fibrillation has been limited. METHODS We enrolled patients with
atrial fibrillation and echocardiographically documented rheumatic heart
disease who had any of the following: a CHA<inf>2</inf>DS<inf>2</inf>VASc
score of at least 2 (on a scale from 0 to 9, with higher scores indicating
a higher risk of stroke), a mitral-valve area of no more than 2
cm², left atrial spontaneous echo contrast, or left atrial
thrombus. Patients were randomly assigned to receive standard doses of
rivaroxaban or dose-adjusted vitamin K antagonist. The primary efficacy
outcome was a composite of stroke, systemic embolism, myocardial
infarction, or death from vascular (cardiac or noncardiac) or unknown
causes. We hypothesized that rivaroxaban therapy would be noninferior to
vitamin K antagonist therapy. The primary safety outcome was major
bleeding according to the International Society of Thrombosis and
Hemostasis. RESULTS Of 4565 enrolled patients, 4531 were included in the
final analysis. The mean age of the patients was 50.5 years, and 72.3%
were women. Permanent discontinuation of trial medication was more common
with rivaroxaban than with vitamin K antagonist therapy at all visits. In
the intention-to-treat analysis, 560 patients in the rivaroxaban group and
446 in the vitamin K antagonist group had a primary-outcome event.
Survival curves were nonproportional. The restricted mean survival time
was 1599 days in the rivaroxaban group and 1675 days in the vitamin K
antagonist group (difference, -76 days; 95% confidence interval [CI], -121
to -31; P<0.001). A higher incidence of death occurred in the rivaroxaban
group than in the vitamin K antagonist group (restricted mean survival
time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28).
No significant between-group difference in the rate of major bleeding was
noted. CONCLUSIONS Among patients with rheumatic heart disease-associated
atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a
composite of cardiovascular events or death than rivaroxaban therapy,
without a higher rate of bleeding.<br/>Copyright &#xa9; 2022 Massachusetts
Medical Society.

<54>
Accession Number
2018329252
Title
Joint Recommendations From The Latin American Association of Cardiac and
Endovascular Surgery (LACES) and The Cardiovascular Anesthesia Committee
of The Latin American Confederation of Anesthesia Societies (CLASA) on the
Timing for Cardiac Surgery After COVID-19 Infection.
Source
Brazilian Journal of Cardiovascular Surgery. 37(5) (pp 754-764), 2022.
Date of Publication: 2022.
Author
Dayan V.; Straneo P.; Arguello M.J.; Vaca M.; Enriquez L.E.; Krogh G.;
Humani C.A.C.; Iza M.P.C.; Fernandez E.L.; Roque R.R.; Pinto X.M.;
Figueroa R.A.; Heilbron O.F.; Schioppi M.; Alvarez B.B.C.; Marin-Cuartas
M.; Gomes W.J.; Riva J.
Institution
(Dayan, Straneo) Department of Cardiac Surgery, Centro Cardiovascular
Universitario, Universidad de la Republica del Uruguay, Montevideo,
Uruguay
(Arguello) Department of Cardiac Surgery, Sanatorio Britanico, Rosario,
Argentina
(Vaca) Department of Anesthesia, Hospital Calderon Guardia, San Jose,
Costa Rica
(Enriquez) Department of Anesthesia, Clinica Imbanaco Quironsalud, Cali,
Colombia
(Krogh) Department of Cardiac Surgery, Pontificia Universidad Catolica de
Chile, Santiago de Chile, Chile
(Humani) Department of Cardiac Surgery, Clinica San Felipe, Lima, Peru
(Iza) Department of Anesthesia, Hospital Vozandes, Quito, Ecuador
(Fernandez) Department of Cardiac Surgery, Instituto Cardiovascular de
Buenos Aires, Buenos Aires, Argentina
(Roque) Department of Anesthesia, Instituto Nacional Cardiovascular
(INCOR-EsSalud), Lima, Peru
(Pinto) Department of Anesthesia, Hospital Metropolitano, Pontificia
Universidad Catolica del Ecuador, Quito, Ecuador
(Figueroa) Department of Anesthesia, Hospital de Cardiologia, Monterrey,
Mexico
(Heilbron) Department of Cardiac Surgery, Clinica PortoAzul, Barranquilla,
Colombia
(Schioppi) Department of Cardiac Surgery, Instituto Cardiologico Infantil,
Montevideo, Uruguay
(Alvarez) Department of Cardiac Surgery, Centro Medico Nacional de
Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico
(Marin-Cuartas) Department of Cardiac Surgery, Leipzig Heart Center,
Leipzig, Germany
(Gomes) Cardiovascular Surgery Discipline and Hospital Sao Paulo, Escola
Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Sao
Paulo, Brazil
(Riva) Department of Anesthesia, Facultad de Medicina, Universidad de la
Republica, Montevideo, Uruguay
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Introduction: Since the coronavirus disease 2019 (COVID-19) pandemic,
cardiac surgeries in patients with previous infection by COVID-19 were
suspended or postponed, which led to surgeries performed in patients with
an advanced stage of their disease and an increase in the waiting list.
There is a heterogeneous attitude in Latin America on the optimal timing
to cardiac surgery in patients with previous COVID-19 infection due to
scarce data on its outcome. Two Latin American associations joined to
establish common suggestions on the optimal timing of surgery in patients
with previous COVID-19 infection. <br/>Method(s): Data collection was
performed using a pre-established form, which included year of
publication, objective, type of study (prospective/retrospective,
descriptive/analytical), number of patients, year of study, waiting time
between infection and surgery, type of surgery, morbidity, mortality, and
conclusions regarding the association between mortality and morbidity.
Final recommendations were approved by the board of directors of Latin
American Association of Cardiac and Endovascular Surgery (LACES) and Latin
American Confederation of Anesthesia Societies (CLASA). <br/>Result(s): Of
the initial 1,016 articles, 11 comprised the final selection. Only six of
them included patients who underwent cardiac surgery. According to the
analyzed literature, optimal timing for cardiac surgery needs to consider
the following aspects: deferable surgery, symptomatic COVID-19 infection,
completeness of COVID-19 vaccination. <br/>Conclusion(s): These
recommendations derive from the analysis of the scarce literature
published at present on outcomes after cardiac surgery in patients with
previous COVID-19 infection. These are to be taken as a dynamic
recommendation in which Latin American reality was taken into
consideration.<br/>Copyright &#xa9; 2022, Sociedade Brasileira de Cirurgia
Cardiovascular. All rights reserved.

<55>
Accession Number
2018182057
Title
Effects of Dexmedetomidine Pretreatment, Posttreatment, and Whole-Course
Pumping on Myocardial Damage during Cardiac Valve Replacement.
Source
International Heart Journal. 63(5) (pp 837-842), 2022. Date of
Publication: 2022.
Author
Gao S.; Ma G.; Zhou L.; Guan S.; Zhang J.
Institution
(Gao, Ma, Zhou, Guan) Department of Anesthesia, Tai'an City Central
Hospital, Tai'an, China
(Zhang) Taishan Sanatorium and Hospital of Shandong Province, Tai'an,
China
Publisher
International Heart Journal Association
Abstract
To compare the effects of dexmedetomidine (DEX) pretreatment,
posttreatment, and whole-course pumping on myocardial protection during
cardiac valve replacement. One hundred and twenty patients undergoing
cardiac valve replacement were randomly divided into the follow groups:
DEX pretreatment (D1 group), DEX posttreatment (D2 group), DEX
whole-course pumping (D3 group), and Control (C group). The concentrations
of cardiac troponin I (cTnI), malondialdehyde (MDA), tumor necrosis factor
alpha (TNF-alpha), rate of spontaneous heart rebound after aortic opening,
time to heart rebound, incidence of arrhythmia, and use of sufentanil and
vasoactive drugs were recorded. Compared with group C, the concentrations
of cTnI, MDA, and TNF-alpha in the D1, D2, and D3 groups were lower,
especially in the latter. The time to heart rebound was prolonged in all
three groups (P < 0.05). The rate of automatic rebound was increased (P <
0.05) while the incidence of arrhythmia was decreased (P < 0.05) in all
groups compared with group C. Group D3 had the highest rate of automatic
rebound and the lowest incidence of arrhythmia. Compared with groups C and
D2, the use of sufentanil and dopamine was lower in groups D1 and D3 (P <
0.05), especially in the latter. During cardiac valve replacement, DEX
pretreatment, posttreatment, and whole-course pumping could have
myocardial protective effects. The latter showed better
effects.<br/>Copyright &#xa9; 2022, International Heart Journal
Association. All rights reserved.

<56>
Accession Number
2018179218
Title
Five-year outcomes in trials comparing transcatheter aortic valve
implantation versus surgical aortic valve replacement: a pooled
meta-analysis of reconstructed time-to-event data.
Source
European Journal of Cardio-thoracic Surgery. 61(5) (pp 977-987), 2022.
Date of Publication: 01 May 2022.
Author
Barili F.; Freemantle N.; Musumeci F.; Martin B.; Anselmi A.; Rinaldi M.;
Kaul S.; Rodriguez-Roda J.; Di Mauro M.; Folliguet T.; Verhoye J.-P.;
Sousa-Uva M.; Parolari A.
Institution
(Barili) Department of Cardiac Surgery, S. Croce Hospital, Cuneo, Italy
(Barili) Department of Epidemiology, Harvard T.H. Chan School of Public
Health, 677 Huntington Ave, Boston, MA 02115, United States
(Freemantle) Institute of Clinical Trials and Methodology, University
College London, London, United Kingdom
(Musumeci) Department of Heart and Vessels, Cardiac Surgery Unit and Heart
Transplantation Center, S. Camillo-Forlanini Hospital, Rome, Italy
(Martin) Department of Research and Third Mission Area, University of
Turin, Turin, Italy
(Anselmi, Verhoye) Division of Thoracic and Cardiovascular Surgery,
Pontchaillou University Hospital, Rennes, France
(Rinaldi) Department of Cardiac Surgery, Aou "citta della Salute e della
Scienza di Torino", University of Turin, Turin, Italy
(Kaul) Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles,
CA, United States
(Rodriguez-Roda) Department of Cardiac Surgery, Ramon y Cajal University
Hospital, Madrid, Spain
(Di Mauro) Cardiothoracic and Vascular Department, Maastricht University
Medical Center, Maastricht, Netherlands
(Folliguet) Department of Cardiac Surgery, Hopital Henri Mondor, Paris,
France
(Sousa-Uva) Department of Cardiothoracic Surgery, Hospital de Santa Crux,
Carnaxide, Portugal
(Parolari) Universitary Cardiac Surgery Unit, Irccs Policlinico S. Donato,
Italy
(Parolari) Department of Biomedical Sciences for Health, University of
Milan, Milan, Italy
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES: The incidence of outcomes in trials comparing transcatheter
aortic valve implantation (TAVI) and surgical aortic valve replacement
(SAVR) is expected to be different in the short and long term. We planned
a meta-analysis of reconstructed time-to-event data from trials comparing
TAVI and SAVR to evaluate their time-varying effects on outcomes.
<br/>METHOD(S): We performed a systematic review of the literature from
January 2007 through September 2021 on Medline, Embase, the Cochrane
Central Register of Controlled Trials and specialistic websites, including
randomized trials with allocation to TAVI or SAVR that reported at least
1-year follow-up and that graphed Kaplan-Meier curves of end points. The
comparisons were done with grouped frailty Cox models in a landmark
framework and fully parametric models. <br/>RESULT(S): Seven trials were
included (7770 participants). TAVI showed a lower incidence of the
composite of death or stroke in the first 6 months [risk-stratified hazard
ratio (HR) 0.66, 95% confidence interval (CI) 0.56-0.77, P-value <0.001],
with an HR reversal after 24 months favouring SAVR (risk-stratified HR
1.25; 95% CI 1.08-1.46; P-value 0.003). These outcomes were confirmed for
all-cause death (risk-stratified HR after 24 months 1.18; 95% CI
1.03-1.35; P-value 0.01). TAVI was also associated with an increased
incidence of rehospitalization after 6 months (risk-stratified HR 1.42;
95% CI 1.06-1.91; P-value 0.018) that got worse after 24 months
(risk-stratified HR 1.67; 95% CI 1.24-2.24; P-value <0.001).
<br/>CONCLUSION(S): Although it could appear that there is no difference
between TAVI and SAVR in the 5-year cumulative results, TAVI shows a
strong protective effect in the short term that runs out after 1 year.
TAVI becomes a risk factor for all-cause mortality and the composite end
point after 24 months and for rehospitalization after 6
months.<br/>Copyright &#xa9; 2021 The Author(s) 2021. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<57>
Accession Number
2015174201
Title
Tranexamic acid for obstetric hemorrhage: Prophylaxis, treatment, both,
neither?.
Source
Anaesthesia Critical Care and Pain Medicine. 40(5) (no pagination), 2021.
Article Number: 100953. Date of Publication: October 2021.
Author
Smith C.T.; Arnolds D.E.; Lim G.
Institution
(Smith, Lim) Department of Anesthesiology & Perioperative Medicine, UPMC,
United States
(Arnolds) Department of Anesthesiology, University of Michigan, United
States
(Lim) Department of Obstetrics & Gynecology, University of Pittsburgh
School of Medicine, United States
Publisher
Elsevier Masson s.r.l.

<58>
Accession Number
2019919652
Title
One-stage hybrid coronary revascularization for the treatment of
multivessel coronary artery disease- Periprocedural and long-term results
from the "HYBRID-COR" feasibility study.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 1016255. Date of Publication: 19 Oct 2022.
Author
Sanetra K.; Buszman P.P.; Jankowska-Sanetra J.; Cisowski M.; Fil W.;
Gorycki B.; Bochenek A.; Slabon-Turska M.; Konopko M.; Kazmierczak P.;
Gerber W.; Milewski K.; Buszman P.E.
Institution
(Sanetra) Clinic of Cardiovascular Surgery, Andrzej Frycz Modrzewski
Krakow University, Krakow, Poland
(Sanetra, Bochenek, Gerber) Department of Cardiac Surgery, American Heart
of Poland, Bielsko-Biala, Poland
(Buszman, Fil, Konopko) Department of Cardiology, Andrzej Frycz Modrzewski
Krakow University, Krakow, Poland
(Buszman, Jankowska-Sanetra, Fil, Gorycki, Milewski) Department of
Cardiology, American Heart of Poland, Bielsko-Biala, Poland
(Buszman, Bochenek, Milewski) Center for Cardiovascular Research and
Development, American Heart of Poland, Katowice, Poland
(Cisowski) Department of Cardiac Surgery, University Hospital, Institute
of Medical Sciences, University of Opole, Opole, Poland
(Bochenek, Gerber, Milewski) Faculty of Medicine, University of
Technology, Katowice, Poland
(Slabon-Turska) Department of Obstetrics and Gynecology, Provincial
Specialist Hospital, Wroclaw, Poland
(Kazmierczak) American Heart of Poland, Katowice, Poland
(Buszman) Department of Epidemiology, Medical University of Silesia,
Katowice, Poland
Publisher
Frontiers Media S.A.
Abstract
Background: The constant growth of interest in hybrid coronary artery
revascularization (HCR) is apparent. Yet, few studies report outcomes of
the one-stage HCR. Consequently, the status of such procedures is not
adequately supported in clinical guidelines. The aim of this study was to
report the safety, feasibility, and long term-outcomes of the one-stage
HCR. <br/>Methods and Results: Patients were enrolled in the prospective
one-stage hybrid coronary revascularization program (HYBRID-COR). They
underwent a one-stage hybrid revascularization procedure while on double
antiplatelet therapy (DAPT) with Ticagrelor: endoscopic atraumatic
coronary artery bypass grafting (EACAB) for revascularization of the left
anterior descending (LAD) artery and percutaneous intervention in non-LAD
arteries with contemporary drug-eluting stents. The composite primary
endpoint included MACCE (major adverse cardiac and cerebrovascular events:
death, myocardial infarction, stroke, and repeated revascularization) in
long-term observation. The study cohort consisted of 30 patients (68%
male) with stable coronary artery disease (26.7%) and unstable angina
(73.3%). Procedural success was 100%. No death, myocardial infarction
(MI), or stroke were observed in the perioperative period. One patient
(3.3%) required chest revision and blood transfusion due to surgical
bleeding. Kidney injury was noted in two patients (6.6%). In a long-term
follow-up (median; IQR: 4.25; 2.62-4.69 years), two patients (6.6%)
underwent repeated revascularization and one patient (3.3%) died due to
MI. The overall primary endpoint rate was 9.9%. <br/>Conclusion(s):
One-stage hybrid revascularization, on DAPT, is a feasible, safe, and
efficient way of achieving complete revascularization in selected
patients. The complication rate is low and acceptable. Further randomized
trials are required.<br/>Copyright &#xa9; 2022 Sanetra, Buszman,
Jankowska-Sanetra, Cisowski, Fil, Gorycki, Bochenek, Slabon-Turska,
Konopko, Kazmierczak, Gerber, Milewski and Buszman.

<59>
Accession Number
2019925288
Title
Troponin as a predictor of outcomes in transcatheter aortic valve
implantation: systematic review and meta-analysis.
Source
General Thoracic and Cardiovascular Surgery. (no pagination), 2022. Date
of Publication: 2022.
Author
Khuong J.N.; Liu Z.; Campbell R.; Jackson S.M.; Borg Caruana C.; Ramson
D.M.; Penny-Dimri J.C.; Perry L.A.
Institution
(Khuong, Liu, Jackson, Perry) Department of Anaesthesia, Royal Melbourne
Hospital, Melbourne, VIC, Australia
(Khuong, Liu, Jackson) Melbourne Medical School, University of Melbourne,
Melbourne, VIC, Australia
(Campbell) Department of Medicine, University of New South Wales, Sydney,
NSW, Australia
(Borg Caruana) Department of Medicine, Deakin University, Geelong, VIC,
Australia
(Ramson, Penny-Dimri) Department of Medicine, Monash University,
Melbourne, VIC, Australia
Publisher
Springer
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is emerging as
a therapeutic gold standard in the management of aortic stenosis. However,
post-procedural complications of this procedure are being increasingly
recognised. We therefore performed this systematic review and
meta-analysis on the prognostic value of elevated troponin prior to TAVI
to predict risk of post-procedural complications. <br/>Method(s): We
searched Medline (Ovid), Embase (Ovid), and the Cochrane Library from
inception until May 2022, and included studies on the association between
elevated pre-procedural troponin with 30-day mortality, long-term
mortality, and post-procedural myocardial injury (PPMI). We generated
summary odds ratios (OR) and hazards ratios (HR) using random-effects
meta-analysis and performed subgroup analyses to evaluate differences in
troponin threshold selection. Inter-study heterogeneity was tested using
the I² test. <br/>Result(s): We included 10 studies involving
4200 patients. Serum troponin elevation prior to TAVI was significantly
associated with long-term mortality [HR = 2.09 (95% CI 1.30-3.36)], but
not with 30-day mortality [OR 1.76 (95% CI 0.96-3.22)]. Subgroup analysis
showed a trend towards increased effect size and statistical significance
for 30-day mortality as troponin elevation was more narrowly defined. Two
studies reported on PPMI and found no statistically significant mean
difference between groups. <br/>Conclusion(s): Raised serum troponin is
associated with increased long-term mortality following TAVI. Further
clarification on the optimal troponin threshold for risk identification is
required. High-quality studies that utilise ROC analysis for threshold
selection are warranted.<br/>Copyright &#xa9; 2022, The Author(s), under
exclusive licence to The Japanese Association for Thoracic Surgery.

<60>
Accession Number
639422091
Title
Coronary angiography of the ex-situ beating donor heart in a portable
organ care system.
Source
Catheterization and cardiovascular interventions : official journal of the
Society for Cardiac Angiography & Interventions. (no pagination), 2022.
Date of Publication: 02 Nov 2022.
Author
Meredith T.; Scheuer S.; Hoffman M.; Joshi Y.; Kathir K.; Gunalingam B.;
Roy D.; Wilson S.; Jansz P.; Macdonald P.; Muller D.
Institution
(Meredith, Hoffman, Kathir, Gunalingam, Roy, Wilson, Muller) Department of
Interventional Cardiology, St Vincent's Hospital, Sydney, NSW, Australia
(Meredith, Scheuer, Joshi, Jansz, Macdonald) Victor Chang Cardiac Research
Institute, Darlinghurst, NSW, Australia
(Meredith, Scheuer, Joshi, Jansz, Macdonald, Muller) Faculty of Medicine
and Health, University of New South Wales, Sydney, NSW, Australia
(Scheuer, Joshi, Jansz, Macdonald) Department of Heart and Lung
Transplantation, St Vincent's Hospital, Sydney, NSW, Australia
Publisher
NLM (Medline)
Abstract
OBJECTIVES: To determine safety and feasibility of ex-situ coronary
angiography. BACKGROUND: To cater for the perpetually growing demand for
heart donors, interest in donation following circulatory death (DCD) has
been rekindled. Further pursuit of donor pool expansion has led to
eligibility extension to "marginal" donors who are at higher risk of
coronary artery disease (CAD). Excluding CAD in potentially eligible DCD
donors, for whom ante-mortem angiography is commonly not permitted, is
therefore challenging. Ex-situ coronary angiography serves as an ethical
and feasible diagnostic tool to assess for preclusive CAD. <br/>METHOD(S):
We undertook a systematic review of the published literature and
institutional retrospective review of case experience with ex-situ
coronary angiography of donor hearts, supported by a portable organ care
system. <br/>RESULT(S): Combined literature and institutional case review
yielded nine total cases of ex-situ coronary angiography of donor human
hearts plus one experimental porcine model. Of the eight cases of ex-situ
coronary angiography performed at our institute, all were conducted
without complication or injury to the allograft. Two thirds of reported
human cases have proceeded to successful transplantation.
<br/>CONCLUSION(S): Diagnostic coronary angiography of the ex-situ beating
donor heart is safe, feasible, and demonstrates novel clinical utility in
mitigating subsequent transplantation of unsuitable allografts. In the
setting of suspected coronary atherosclerosis of the donor heart, which
may preclude favorable transplantation outcomes, ex-situ coronary
angiography should be considered at eligible transplant
centers.<br/>Copyright &#xa9; 2022 The Authors. Catheterization and
Cardiovascular Interventions published by Wiley Periodicals LLC.

<61>
Accession Number
639421692
Title
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major
Coronary Events in Patients With Acute Myocardial Infarction: Insights
From the PARADISE-MI Trial.
Source
Circulation. (no pagination), 2022. Date of Publication: 02 Nov 2022.
Author
Mehran R.; Steg P.G.; Pfeffer M.A.; Jering K.; Claggett B.; Lewis E.F.;
Granger C.; Kober L.; Maggioni A.; Mann D.L.; McMurray J.J.V.; Rouleau
J.-L.; Solomon S.D.; Ducrocq G.; Berwanger O.; De Pasquale C.G.;
Landmesser U.; Petrie M.; Leng D.S.K.; van der Meer P.; Lefkowitz M.; Zhou
Y.; Braunwald E.
Institution
(Mehran) Zena and Michael A. Wiener Cardiovascular Institute, Icahn School
of Medicine at Mount Sinai
(Steg) AP-HP (Assistance Publique-Hopitaux de Paris), FACT (French
Alliance for Cardiovascular Trials) and INSERM U-1148, France
(Pfeffer, Jering, Claggett, Solomon, Braunwald) Cardiovascular Division,
Brigham and Women's Hospital and Harvard Medical School, S.D.S., Boston,
B.C, United States
(Lewis) Division of Cardiovascular Medicine, Stanford University School of
Medicine, Stanford University, Palo Alto, Mexico
(Granger) Duke University Medical Center, Durham, United Kingdom
(Kober) Professor of Cardiology, Department of Clinical Medicine,
University of Copenhagen, Denmark
(Maggioni) ANMCO Research Center, Heart Care Foundation, Florence, United
States
(Mann) Washington University Medical Center, St Louis, United States
(McMurray, Petrie) British Heart Foundation Cardiovascular Research
Centre, University of Glasgow, United Kingdom
(Rouleau) Montreal Heart Institute, University of Montreal, QC, Canada
(Ducrocq) Departement de Cardiologie, Hopital Bichat Assistance Publique
Hopitaux de Paris. France (G.D.), France
(Berwanger) Academic Research Organization (ARO), Hospital Israelita
Albert Einstein, Brazil
(De Pasquale) Department of Cardiovascular Medicine, Flinders Medical
Centre, South Australia (C.G.D.P.), Adelaide, Australia
(Landmesser) Department of Cardiology, Germany (U.L.),
Charite-Universitatsmedizin Berlin
(Leng) National Heart Centre Singapore, Singapore
(van der Meer) Department of Cardiology, University Medical Center
Groningen, University of Groningen, Netherlands
(Lefkowitz, Zhou) Novartis Pharmaceutical Corporation, East Hanover,
United States
Publisher
NLM (Medline)
Abstract
BACKGROUND: In patients who survive an acute myocardial infarction (AMI),
angiotensin-converting enzyme inhibitors decrease the risk of subsequent
major cardiovascular events. Whether angiotensin-receptor blockade and
neprilysin inhibition with sacubitril/valsartan reduce major coronary
events more effectively than angiotensin-converting enzyme inhibitors in
high-risk patients with recent AMI remains unknown. We aimed to compare
the effects of sacubitril/valsartan on coronary outcomes in patients with
AMI. <br/>METHOD(S): We conducted a prespecified analysis of the
PARADISE-MI trial (Prospective ARNI vs ACE Inhibitors Trial to Determine
Superiority in Reducing Heart Failure Events After MI), which compared
sacubitril/valsartan (97/103 mg twice daily) with ramipril (5 mg twice
daily) for reducing heart failure events after myocardial infarction in
5661 patients with AMI complicated by left ventricular systolic
dysfunction, pulmonary congestion, or both. In the present analysis, the
prespecified composite coronary outcome was the first occurrence of death
from coronary heart disease, nonfatal myocardial infarction,
hospitalization for angina, or postrandomization coronary
revascularization. <br/>RESULT(S): Patients were randomly assigned at a
median of 4.4 [3.0-5.8] days after index AMI (ST-segment-elevation
myocardial infarction 76%, non-ST-segment-elevation myocardial infarction
24%), by which time 89% of patients had undergone coronary reperfusion.
Compared with ramipril, sacubitril/valsartan decreased the risk of
coronary outcomes (hazard ratio, 0.86 [95% CI, 0.74-0.99], P=0.04) over a
median follow-up of 22 months. Rates of the components of the composite
outcomes were lower in patients on sacubitril/valsartan but were not
individually significantly different. <br/>CONCLUSION(S): In survivors of
an AMI with left ventricular systolic dysfunction and pulmonary
congestion, sacubitril/valsartan-compared with ramipril-reduced the risk
of a prespecified major coronary composite outcome. Dedicated studies are
necessary to confirm this finding and elucidate its mechanism.
REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier:
NCT02924727.

<62>
Accession Number
639420668
Title
Concordance Between Patient-Reported Health Data and Electronic Health
Data in the ADAPTABLE Trial.
Source
JAMA cardiology. (no pagination), 2022. Date of Publication: 02 Nov 2022.
Author
O'Brien E.C.; Mulder H.; Jones W.S.; Hammill B.G.; Sharlow A.; Hernandez
A.F.; Curtis L.H.
Institution
(O'Brien, Hammill, Curtis) Department of Population Health Sciences, Duke
University School of Medicine, Durham, NC, United States
(O'Brien, Mulder, Jones, Hernandez, Curtis) Duke Clinical Research
Institute, Duke University School of Medicine, Durham, NC, United States
(Jones, Hernandez, Curtis) Department of Medicine, Duke University School
of Medicine, Durham, NC, United States
(Sharlow) Medidata Solutions, NY, United States
Publisher
NLM (Medline)
Abstract
Importance: Patient-reported health data can facilitate clinical event
capture in pragmatic clinical trials. However, few data are available on
the fitness for use of patient-reported data in large-scale health
research. <br/>Objective(s): To evaluate the concordance of a set of
variables reported by patients and available in the electronic health
record as part of a pragmatic clinical trial. <br/>Design, Setting, and
Participant(s): Data from ADAPTABLE (Aspirin Dosing: A Patient-Centric
Trial Assessing Benefits and Long-term Effectiveness), a pragmatic
clinical trial, were used in a concordance substudy of a comparative
effectiveness research trial. The trial randomized 15076 patients with
existing atherosclerotic cardiovascular disease in a 1:1 ratio to low- or
high-dose aspirin from April 2016 through June 30, 2019. <br/>Main
Outcomes and Measures: Concordance of data was evaluated from 4 domains
(demographic characteristics, encounters, diagnoses, and procedures)
present in 2 data sources: patient-reported data captured through an
online portal and data from electronic sources (electronic health record
data). Overall agreement, sensitivity, specificity, positive predictive
value, negative predictive value, and kappa statistics with 95% CIs were
calculated using patient report as the criterion standard for demographic
characteristics and the electronic health record as the criterion standard
for clinical outcomes. <br/>Result(s): Of 15076 patients with complete
information, the median age was 67.6 years (range, 21-99 years), and 68.7%
were male. With the use of patient-reported data as the criterion
standard, agreement (kappa) was high for Black and White race and
ethnicity but only moderate for current smoking status. Electronic health
record data were highly specific (99.6%) but less sensitive (82.5%) for
Hispanic ethnicity. Compared with electronic health record data, patient
report of clinical end points had low sensitivity for myocardial
infarction (33.0%), stroke (34.2%), and major bleeding (36.6%). Positive
predictive value was similarly low for myocardial infarction (40.7%),
stroke (38.8%), and major bleeding (21.9%). Coronary revascularization was
the most concordant event by data source, with only moderate agreement
(kappa=0.54) and positive predictive value. Agreement metrics varied by
site for all demographic characteristics and several clinical events.
<br/>Conclusions and Relevance: In a concordance substudy of a large,
pragmatic comparative effectiveness research trial, sensitivity and
chance-corrected agreement of patient-reported data captured through an
online portal for cardiovascular events were low to moderate. Findings
suggest that additional work is needed to optimize integration of
patient-reported health data into pragmatic research studies. Trial
Registration: ClinicalTrials.gov Identifier: NCT02697916.

<63>
Accession Number
2015459248
Title
Sutureless versus Hand-Sewn Coronary Anastomoses: A Systematic Review and
Meta-Analysis.
Source
Journal of Clinical Medicine. 11(3) (no pagination), 2022. Article Number:
749. Date of Publication: February-1 2022.
Author
Hoogewerf M.; Schuurkamp J.; Kelder J.C.; Jacobs S.; Doevendans P.A.
Institution
(Hoogewerf, Schuurkamp, Doevendans) Department of Cardiology, University
Medical Centre Utrecht, Utrecht 3584 CX, Netherlands
(Hoogewerf) Department of Cardiothoracic Surgery, St. Antonius Hospital,
Nieuwegein 3435 CM, Netherlands
(Kelder) Department of Cardiology, St. Antonius Hospital, Nieuwegein 3435
CM, Netherlands
(Jacobs) Department of Cardiothoracic and Vascular Surgery, German Heart
Centre Berlin, Berlin 13353, Germany
(Doevendans) Netherlands Heart Institute, Utrecht 3511 EP, Netherlands
(Doevendans) Central Military Hospital, Utrecht 3584 EZ, Netherlands
Publisher
MDPI
Abstract
Background: Sutureless coronary anastomotic devices are intended to
facilitate minimally invasive coronary artery bypass grafting (MICS-CABG)
by easing and eventually standardizing the anastomotic technique. Within
this systematic review and meta-analysis, we aim to determine patency and
to evaluate safety outcomes for the sutureless anastomoses.
<br/>Method(s): CENTRAL, MED-LINE, and EMBASE were searched from database
start till August 2021 in a predefined search strategy combining the key
concepts: 'coronary artery bypass grafting', 'sutureless coronary
anastomoses', and 'hand-sewn coronary anastomoses' by the Boolean
operation 'AND'. Study characteristics, patient demographics,
interventional details, and all available outcome data were extracted. A
meta-analysis was performed on patency at longest follow-up. Safety
outcomes were presented. <br/>Result(s): A total of eleven trials towards
six sutureless anastomotic devices were included, comprising 3724 patients
(490 sutureless and 3234 hand-sewn). There was no significant difference
in patency at a mean follow-up duration of 546.3 (range 1.5-2691) days,
with a risk ratio of 0.77 (95% CI 0.55-1.06). MACE was reported in 4.5%
sutureless and 3.9% hand-sewn patients, including all-cause mortality
(resp. 1.3 vs. 1.9%), myocardial infarction (resp. 1.6 vs. 1.7%), and
coronary revascularization (resp. 1.8 vs. 0.5%). Incomplete hemostasis
occurred in 24.8% of the sutureless anastomoses. Intra-operative device
failure forced conversion to hand-sewn or redo-anastomosis in 5.8% of the
sutureless cases. <br/>Conclusion(s): Based on the systematic review and
meta-analysis including six devices, we conclude that sutureless coronary
anastomotic devices appear safe and effective when used by well-trained
and dedicated surgical teams.<br/>Copyright &#xa9; 2022 by the authors.
Licensee MDPI, Basel, Switzerland.

<64>
Accession Number
2015447303
Title
Cerebral Oximetry-Monitored Nitroglycerin Infusion and Tissue Perfusion
during Rewarming of Cardiopulmonary Bypass in Cardiac Surgery: A
Prospective Randomized Trial.
Source
Journal of Clinical Medicine. 11(3) (no pagination), 2022. Article Number:
712. Date of Publication: February-1 2022.
Author
Chen J.-L.; Hsu Y.-C.; Huang G.-S.; Lin C.-Y.; Ke H.-Y.; Hsu P.-S.; Chung
C.-H.; Tsai C.-S.; Lin T.-C.
Institution
(Chen, Hsu, Huang, Lin) Department of Anesthesiology, Tri-Service General
Hospital, National Defense Medical Center, Taipei 11490, Taiwan (Republic
of China)
(Lin, Ke, Hsu, Tsai) Division of Cardiovascular Surgery, Department of
Surgery, Tri-Service General Hospital, National Defense Medical Center,
Taipei 11490, Taiwan (Republic of China)
(Chung) Department of Medical Research, Tri-Service General Hospital,
School of Public Health, National Defense Medical Center, Taipei 11490,
Taiwan (Republic of China)
(Tsai) Department and Graduate Institute of Pharmacology, National Defense
Medical Center, Taipei 11490, Taiwan (Republic of China)
Publisher
MDPI
Abstract
Background: Nitroglycerin facilitates microcirculation and oxygen delivery
through vasodilation. The purpose of this study was to clarify the effects
of nitroglycerin-induced vasodilation and potential hypotension on tissue
perfusion under cerebral oximetry monitoring during rewarming in
cardiopulmonary bypass. <br/>Method(s): Elective cardiac surgical patients
were randomly assigned to either a nitroglycerin group (n = 32) with an
intravenous infusion of 1-5 mcg/kg/min or a control group (n = 31) with
0-0.1 mcg/kg/min infusion, since the initiation of rewarming.
Perioperative arterial blood gas data were collected in addition to
hemodynamic variables, cerebral oximetry values, urine output, and
postoperative outcomes. <br/>Result(s): Nearly one-fifth (6/32) of
patients in the nitroglycerin group experienced transient (<= 5 min)
profound hypotension (mean arterial blood pressure <= 40 mmHg) after the
initiation of infusion. There were no significant differences between
groups in terms of perioperative levels of cerebral oximetry, cardiac
index, plasma glucose, lactate, bicarbonate, base excess, or post-bypass
activated coagulation time. In the nitroglycerin group, urine output was
nonsignificantly higher during cardiopulmonary bypass (p = 0.099) and
within 8 h after surgery (p = 0.157). Perioperative transfused blood
products, postoperative inotropic doses, extubation time, and intensive
care unit stay were comparable for the two groups. <br/>Conclusion(s):
Initiation of intravenous nitroglycerin infusion (at 1- 5 mcg/kg/min)
during rewarming in hypothermic cardiopulmonary bypass resulted in
transient profound hypotension in one-fifth of patients and did not
improve perioperative cerebral oxygenation, tissue perfusion, and
coagulation in cardiac surgery.<br/>Copyright &#xa9; 2022 by the authors.
Licensee MDPI, Basel, Switzerland.

<65>
Accession Number
2019835019
Title
Propofol versus insulin cardioplegia in valvular heart surgeries assessed
by myocardial histopathology and troponin I.
Source
Egyptian Journal of Anaesthesia. 38(1) (pp 587-596), 2022. Date of
Publication: 2022.
Author
Mohamed O.S.; Al-Elwany S.E.; Raouf M.M.; Tawfik H.M.; Youssef I.A.
Institution
(Mohamed, Raouf, Youssef) Department of Anesthesia and Intensive Care
Unit, Minia University Hospital, Faculty of Medicine, Minia University,
Minya, Egypt
(Al-Elwany) Department of Cardiothoracic Surgery. Faculty of Medicine,
Minia University, Minya, Egypt
(Tawfik) Department of Histopathology, Faculty of Medicine, Minia
University, Minya, Egypt
Publisher
Taylor and Francis Ltd.
Abstract
Background and Aims: Despite of the effectiveness of on pump cardiac
surgeries in valvular diseases, cardioplegic arrest and myocardial
reperfusion injury are still an obstacle. Many cardioprotective additives
are tried but the obtained laboratory results are mixed. Our objective was
to compare the effects of supplementing the cardioplegia solution with
propofol or insulin evaluated not only by laboratory biomarkers but also
with papillary muscle biopsy in patients undergoing on pump valvular
surgeries. <br/>Method(s): Sixty adult patients were randomly assigned
into three equal groups to receive: cold blood cadioplegia (control (C)
group), supplemented with either 9 mg/L propofol 10% (P group), or 10 IU/L
regular insulin (I group) Results: Propofol induced significant higher
myocardial protection presented by better histopathological grading of the
obtained muscle biopsies when compared to either group C (P = 0.0460) or
group I (P = 0.014), lower postoperative dysrhythmia (P = 0.004), lower
troponin I release (40.57 +/- 8.5 vs 47.7 +/- 6.22-fold increase), and
more eukalemic state with lower need for K supplementation than insulin.
<br/>Conclusion(s): Propofol was superior to insulin in providing higher
grade of myocardial protection with lower troponin I release, more steady
K level and lower postoperative complications.<br/>Copyright &#xa9; 2022
The Author(s). Published by Informa UK Limited, trading as Taylor &
Francis Group.

<66>
Accession Number
2019804991
Title
Practice-Changing Updates in Perioperative Medicine Literature 2020-2021:
A Systematic Review.
Source
American Journal of Medicine. 135(11) (pp 1306-1314.e1), 2022. Date of
Publication: November 2022.
Author
Khambaty M.; Silbert R.E.; Devalapalli A.P.; Kashiwagi D.T.; Regan D.W.;
Sundsted K.K.; Mauck K.F.
Institution
(Khambaty, Devalapalli, Kashiwagi, Regan) Division of Hospital Internal
Medicine, Department of Medicine
(Silbert, Sundsted, Mauck) Division of General Internal Medicine,
Department of Medicine, Mayo Clinic and Mayo Clinic College of Medicine,
Rochester, Minn
(Kashiwagi) Division of, Internal Medicine, Sheikh Shakhbout Medical City
in partnership with Mayo Clinic, Abu Dhabi, United Arab Emirates
Publisher
Elsevier Inc.
Abstract
Recent literature published in a variety of multidisciplinary journals has
significantly influenced perioperative patient care. Distilling and
synthesizing the clinically important literature can be challenging. This
review summarizes practice-changing articles in perioperative medicine
from the years 2020 and 2021. Embase, Ovid, and EBM reviews databases were
queried from January 2020 to December 2021. Inclusion criteria were
original research, systematic review, meta-analysis, and important
guidelines. Exclusion criteria were conference abstracts, case reports,
letters, protocols, pediatric and obstetric articles, and cardiac surgery
literature. Two authors reviewed each reference using the Distiller SR
systematic review software (Evidence Partners Inc., Ottawa, Ont., Canada).
A modified Delphi technique was used to identify 9 practice-changing
articles. We identified another 13 articles for tabular summaries, as they
were relevant to an internist's perioperative evaluation of a patient.
Articles were selected to highlight the clinical implications of new
evidence in each field. We have also pointed out limitations of each study
and clinical populations where they are not applicable.<br/>Copyright
&#xa9; 2022 Elsevier Inc.

<67>
Accession Number
2018329133
Title
Congenital Superior Sternal Cleft Isolated in a Newborn: Report of a Rare
Case and a Literature Review.
Source
American Journal of Case Reports. 23 (no pagination), 2022. Article
Number: e937443. Date of Publication: 2022.
Author
Sha Y.; Deng Y.; Ou M.
Institution
(Sha, Ou) Central Laboratory, Guangxi Health Commission Key Laboratory of
Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of
Guilin Medical University, Guangxi, Guilin, China
(Deng) Department of Neonatology, The Second Affiliated Hospital of Guilin
Medical University, Guangxi, Guilin, China
Publisher
International Scientific Information, Inc.
Abstract
Objective: Rare disease Background: Sternal cleft is a greatly rare
congenital thoracic deformity, arising from a failure of the sternal bars
fusion pro-cess that should be completed in the fetal period, the
incidence of which is less than 0.15%. Case Report: Herein, we present a
case report of a newborn girl having a superior congenital sternal cleft.
After the baby was born, scar-like tissue was found in the middle of the
chest and extended to the root of the umbilical cord. Based on the imaging
data, this newborn was diagnosed with sternal cleft belonging to the
superior sternal cleft and not associated with other congenital
deformities. <br/>Conclusion(s): As a rare congenital thoracic deformity,
postpartum diagnosis of the sternal cleft mainly is currently based on
medical imaging, including thoracic computed tomography (CT),
three-dimensional (3D) reconstruction CT, and magnetic resonance imaging
(MRI). Sternum cleft not only affects the aesthetic appearance but also
leads to the destruction of the bone structure of the thorax, resulting in
opposing thoracic movements. Therefore, early diagnosis and early
treatment play significant roles in the treatment of this congenital
sternal deformi-ty. Regardless of whether there are clinical symptoms of
sternal cleft, primary repair surgery must be done as soon as possible and
during the neonatal period is best, in which simple surgical techniques
achieve remark-able effects.<br/>Copyright &#xa9; Am J Case Rep, 2022.

<68>
Accession Number
2018145169
Title
Efficacy of N-acetylcysteine in Preventing Acute Kidney Injury and Major
Adverse Cardiac Events After Cardiac Surgery: A Meta-Analysis and Trial
Sequential Analysis.
Source
Frontiers in Medicine. 9 (no pagination), 2022. Article Number: 795839.
Date of Publication: 22 Jun 2022.
Author
Zhao J.; Li M.; Tan C.
Institution
(Zhao, Tan) Hebei Yanda Hospital, Langfang, China
(Li) No. 988th Hospital of Joint Logistic Support Force of PLA, Zhengzhou,
China
Publisher
Frontiers Media S.A.
Abstract
Background: The effect of N-acetylcysteine (NAC), an antioxidant, on
preventing acute kidney injury (AKI) and major adverse cardiac events
(MACE) remains controversial. Therefore, we conducted this meta-analysis
and trial sequential analysis to evaluate its efficacy on cardiac
surgery-related adverse events. <br/>Method(s): PubMed, Embase, and
Cochrane Library were searched for relevant studies from inception to June
2021. We selected randomized controlled trials comparing NAC with controls
in patients undergoing cardiac surgery. <br/>Result(s): Twenty-five
studies including 2,444 patients met the inclusion criteria. The pooled
results showed that there was no significant difference in the incidence
of AKI between the NAC and control groups [relative risk (RR) = 0.91, 95%
confidence interval (CI) = 0.77, 1.08, P = 0.28], but the trial sequential
analysis (TSA) could not confirm this result. No difference was observed
in the need for renal replacement therapy (RRT), all-cause mortality,
MACE, length of stay in the intensive care unit (ICU), and length of stay
in the hospital. Results of subgroup analysis results showed that
intravenous infusion instead of oral NAC could significantly reduce the
incidence of AKI and arrhythmia (RR = 0.84, 95% CI = 0.71, 0.99, P = 0.03,
I² = 3% and RR = 0.74, 95% CI = 0.61, 0.91, P = 0.004,
I² = 48%, respectively). <br/>Conclusion(s): Intravenous
administration of NAC can reduce the incidence of AKI and arrhythmia in
patients after cardiac surgery, but cannot reduce all-cause mortality,
AMI, cardiac insufficiency, and the number of patients using RRT. Oral NAC
has no significant effect on the outcomes of patients after cardiac
surgery.<br/>Copyright &#xa9; 2022 Zhao, Li and Tan.

<69>
Accession Number
639404979
Title
Association between periprocedural myocardial injury and long-term
all-cause mortality in patients undergoing transcatheter aortic valve
replacement: a systematic review and meta-analysis.
Source
Scandinavian cardiovascular journal : SCJ. 56(1) (pp 387-393), 2022. Date
of Publication: 01 Dec 2022.
Author
Han Y.; Wang C.; Chen W.
Institution
(Chen, Han, Wang, Chen) Key Laboratory of Cardiovascular Remodeling and
Function Research, Chinese Ministry of Education, Chinese National Health
Commission and Chinese Academy of Medical Sciences, State and Shandong
Province Joint Key Laboratory of Translational Cardiovascular Medicine,
Department of Cardiology, Qilu Hospital of Shandong University, Jinan,
China
Publisher
NLM (Medline)
Abstract
Objective. The purpose of this meta-analysis was to investigate the effect
of periprocedural myocardial injury (PPMI) on long-term all-cause
mortality in patients undergoing transcatheter aortic valve replacement
(TAVR) and to explore potential factors associated with mortality risk.
Design. The PubMed, Embase, and Cochrane Library databases were searched
up to April 2022. Studies reporting the effect of PPMI on the risk of
long-term all-cause mortality were included. The summary odds ratio (OR)
was calculated using a random effects model. Additionally, meta-regression
and subgroup analyses were conducted according to specific research
characteristics to explore sources of heterogeneity. Results. Fourteen
studies involving 6,415 patients who underwent TAVR showed that the
occurrence of PPMI was associated with a higher risk of long-term
mortality. Subgroup analysis showed that in the group of aged >=82years,
men accounted for less than 50%, coronary artery disease patients
accounted for more than 50%, and the proportion of patients with chronic
kidney disease accounted for more than 60%, the proportion of patients
with atria fibrillation accounted for less than 30%, and the Society of
Thoracic Surgeons predicted risk of mortality score was >8 points,
patients with PPMI had higher long-term all-cause mortality than those
without PPMI. Conclusions. Among the patients who underwent TAVR, those
who developed PPMI had higher long-term all-cause mortality.

<70>
Accession Number
639045842
Title
Does sex impact outcomes after mitral valve surgery? A systematic review
and meta-analysis.
Source
Scandinavian journal of surgery : SJS : official organ for the Finnish
Surgical Society and the Scandinavian Surgical Society. 111(4) (pp
99-109), 2022. Date of Publication: 01 Dec 2022.
Author
El-Andari R.; Bozso S.J.; Fialka N.M.; Kang J.J.H.; Nagendran J.
Institution
(El-Andari, Bozso, Kang) Division of Cardiac Surgery, Department of
Surgery, University of Alberta, Edmonton, AB, Canada
(Fialka) Faculty of Medicine and Dentistry, University of Alberta,
Edmonton, AB, Canada
(Nagendran) Cardiac Surgeon Minimally Invasive and Transcatheter Valve
SurgeryAssociate Professor of Surgery Division of Cardiac Surgery
Department of Surgery Mazankowski Alberta Heart Institute University of
Alberta 4-108A Li Ka Shing Health Research Centre 8602 - 112 Street
Edmonton AB T6G 2E1 Canada
Publisher
NLM (Medline)
Abstract
BACKGROUND AND OBJECTIVE: The published literature investigating the
impact of sex on outcomes after mitral valve (MV) surgery has demonstrated
inferior outcomes for females over males. However, the true relationship
between sex and outcomes after MV surgery continues to be poorly
understood. MATERIALS: PubMed, Medline, and Embase were systematically
searched for articles published from 1 January 2005 to 1 August 2021. This
systematic review included retrospective and prospective studies
investigating the relationship between sex and outcomes after MV surgery.
In all, 2068 articles were initially screened and 12 studies were included
in this review. <br/>RESULT(S): Few studies were adequately powered or
structured to investigate this topic. Few studies propensity matched
patients or isolated for surgical approach. In individual studies, females
experienced increased rates of short-term and long-term mortality and
increased 1-year mortality in the pooled data. Males experienced increased
rates of required pacemaker insertion. The remaining rates of morbidity
and mortality did not differ significantly between males and females.
<br/>CONCLUSION(S): This review identified increased rates of 1-year
mortality in the pooled data for females, while males had increased rates
of pacemaker insertion. Despite this, the absence of propensity matching
and isolating for surgical approach has introduced confounding variables
that impair the ability of the included studies to interpret the results
found in the current literature. Studies isolating for surgical approach,
propensity matching patients, and examining outcomes with long-term
follow-up are required to elucidate the true nature of this relationship.

<71>
Accession Number
638717413
Title
Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve
Replacement in Low-risk Patients: A Meta-Analysis Based on a 2-Year
Follow-Up.
Source
Anatolian journal of cardiology. 26(11) (pp 802-809), 2022. Date of
Publication: 01 Nov 2022.
Author
Chen C.-G.; Xi B.-B.; Deng Q.-F.; Zhang X.-Y.; Lin W.-C.; Chen L.-W.; Qiu
Z.-H.
Institution
(Chen, Xi, Deng, Zhang, Lin, Chen, Qiu) Department of Cardiovascular
Surgery, Union Hospital, Fujian Medical University, Fujian, China; Key
Laboratory of Cardio-Thoracic Surgery Fujian Medical University, Fujian
Province University, Fujian, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Previous studies have shown that transcatheter aortic valve
implantation is the best alternative therapy to surgical aortic valve
replacement in high-risk surgical patients with aortic stenosis. However,
it is not clear whether transcatheter aortic valve implantation can be
utilized in low-risk surgical patients with aortic stenosis. This
studyaimed to evaluate the safety and efficacy of transcatheter aortic
valve implantation in low-risk patients. <br/>METHOD(S): From the outset
of our initiative until April 2022, PubMed, EMBASE, and the Cochrane
database were thoroughly searched, yielding the selection of 3 randomized
controlled trials including 2644 patients with aortic stenosis, to assess
outcome measures at distinct follow-up time. <br/>RESULT(S): The mean
Society of Thoracic Surgeons Predicted Risk of Mortality score of patients
was 2.2. At the 30-day and 1-year follow-up, transcatheter aortic valve
implan- tation was associated with a lower incidence of all-cause
mortality, cardiovascular mor- tality, acute kidney injury (stage 2 or 3),
life-threatening or significant bleeding, and new atrial fibrillation but
an increased risk of permanent pacemaker implantation. At the 2-year
follow-up, transcatheter aortic valve implantation only had an advantage
in new atrial fibrillation (relative risk, 0.27; 95% CI, 0.14-0.51; P <
.0001), with no significant differ- ence in all-cause mortality or
cardiovascular mortality. <br/>CONCLUSION(S): For low-risk surgical
patients with aortic stenosis, compared to surgical aortic valve
replacement, transcatheter aortic valve implantation was associated with
lower all-cause mortality at 30-day follow-up and lower cardiovascular
mortality at 1-year follow-up. Except for the advantages in new atrial
fibrillation, transcatheter aor- tic valve implantation had no significant
impact on mortality at 2-year follow-up.

<72>
Accession Number
2019875753
Title
Mitral valve surgery assisted by virtual and augmented reality: Cardiac
surgery at the front of innovation.
Source
Perfusion (United Kingdom). (no pagination), 2022. Date of Publication:
2022.
Author
Nanchahal S.; Arjomandi Rad A.; Naruka V.; Chacko J.; Liu G.; Afoke J.;
Miller G.; Malawana J.; Punjabi P.
Institution
(Nanchahal, Arjomandi Rad) Department of Medicine, Faculty of Medicine,
Imperial College London, London, United Kingdom
(Naruka, Chacko, Liu, Afoke, Punjabi) Department of Cardiothoracic
Surgery, Imperial College Healthcare NHS Trust, Hammersmith Hospital,
London, United Kingdom
(Miller, Malawana) Research Unit, The Healthcare Leadership Academy,
London, United Kingdom
(Punjabi) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
Publisher
SAGE Publications Ltd
Abstract
Background: Given the variety in mitral valve (MV) pathology and
associated surgical techniques, extended reality (XR) holds great
potential to assist MV surgeons. This review aims to systematically
evaluate the currently available evidence investigating the use of XR and
associated technologies in MV surgery. <br/>Method(s): A systematic
database search was conducted of original articles and case reports that
explored the use of XR and MV surgery in EMBASE, MEDLINE, Cochrane
database and Google Scholar, from inception to February 2022.
<br/>Result(s): Our search yielded 171 articles, of which 15 studies were
included in this review, featuring 328 patients. Two main areas of
application were identified: (i) pre-operative planning and (ii)
predicting post-operative outcomes. The articles reporting outcomes
relating to pre-operative planning were further categorised as exploring
themes relevant to (i) mitral annular assessment; (ii) training; (iii)
evaluation of surgical technique; (iv) surgical approach or plan and (v)
selecting ring size or type. Preoperatively, XR has been shown to evaluate
mitral annular pathology more accurately than echocardiography, informing
the surgeon about the optimal surgical technique, approach and plan for a
particular patient's MV pathology. Furthermore, XR could simulate and aid
ring size/type selection for MV annuloplasty, creating a personalized
surgical plan. Additionally, XR could estimate the postoperative MV
biomechanical and physiological characteristics, predicting and
pre-empting post-operative complications. <br/>Conclusion(s): XR
demonstrated promising applications for assisting MV surgery, enhancing
outcomes and patient-centred care, nevertheless, there remain the need for
randomized studies to ascertain its feasibility, safety, and validity in
clinical practice.<br/>Copyright &#xa9; The Author(s) 2022.

<73>
Accession Number
2020496663
Title
Cytokines associated with immune response in atherosclerosis.
Source
American Journal of Translational Research. 14(9) (pp 6424-6444), 2022.
Date of Publication: 2022.
Author
Ma J.; Luo J.; Sun Y.; Zhao Z.
Institution
(Ma, Zhao) Department of Vascular Surgery, Changhai Hospital, Naval
Medical University, Shanghai 200433, China
(Luo) National Key Laboratory of Medical Immunology, Institute of
Immunology, Naval Medical University, Shanghai 200433, China
(Sun) Department of General Surgery, Jinling Hospital, Medical School of
Nanjing University, Nanjing 210002, China
Publisher
E-Century Publishing Corporation
Abstract
Inflammation is an essential mechanism of immune response that involves a
large number of different immune cells. Atherosclerosis is essentially an
inflammatory disease caused by inappropriate activities of immune cells.
During this process, various cytokines activate immune cells, regulate and
transmit immune cell signals, and stimulate a local inflammatory
environment. In this study, we reviewed the cytokines associated with
immune activity in atherosclerosis, including their roles in immune cell
activation and mediating immune cell chemotaxis. The findings give
important insights into inflammatory immune microenvironment, including
basic mechanisms and interactions, providing new ideas and options for
clinical detection and treatment of this disease.<br/>Copyright &#xa9;
2022 E-Century Publishing Corporation. All rights reserved.

<74>
[Use Link to view the full text]
Accession Number
2020240861
Title
Catheter ablation for treatment of bradycardia-tachycardia syndrome: Is it
time to consider it the therapy of choice? A systematic review and
meta-analysis.
Source
Journal of Cardiovascular Medicine. 23(10) (pp 646-654), 2022. Date of
Publication: 01 Oct 2022.
Author
Magnano M.; Bissolino A.; Budano C.; Abdirashid M.; Devecchi C.; Oriente
D.; Matta M.; Occhetta E.; Gaita F.; Rametta F.
Institution
(Magnano, Abdirashid, Devecchi, Oriente, Matta, Occhetta, Rametta)
Cardiology Department, St. Andrea Hospital, Vercelli, Italy
(Bissolino, Budano, Gaita) Maria Pia Hospital, GVM Care & Research,
Torino, Italy
Publisher
Lippincott Williams and Wilkins
Abstract
BackgroundAtrial fibrillation catheter ablation (AFCA) should be
considered as a strategy to avoid pacemaker (PM) implantation for patients
with bradycardia-tachycardia syndrome (BTS), but lack of evidence is
remarkable.MethodsOur aim was to conduct a random-effects model
meta-analysis on safety and efficacy data from controlled trials and
observational studies. We compared atrial fibrillation (AF) recurrence, AF
progression, procedural complication, additional procedure, cardiovascular
death, cardiovascular hospitalization, heart failure and stroke in
patients undergoing AFCA vs. PM implantation.ResultsPubMed/MEDLINE,
Cochrane Database and Google Scholar were screened, and four retrospective
studies were selected. A total of 776 patients (371 in the AFCA group, 405
in the PM group) were included. After a median follow-up of 67.5 months,
lower AF recurrence [odds ratio (OR) 0.06, confidence interval (CI)
0.02-0.18, I²= 82.42%, P < 0.001], AF progression (OR 0.12, CI
0.06-0.26, I²= 0%, P < 0.001), heart failure (OR 0.12, CI
0.04-0.34, I²= 0%, P < 0.001), and stroke (OR 0.30, CI
0.15-0.61, I²= 0%, P = 0.001) were observed in the AFCA group.
No differences were observed in cardiovascular death and hospitalization
(OR 0.48, CI 0.10-2.28, I²= 0%, P = 0.358 and OR 0.43, CI
0.14-1.29, I²= 87.52%, P = 0.134, respectively). Higher need
for additional procedures in the AFCA group was highlighted (OR 3.65, CI
1.51-8.84, I²= 53.75%, P < 0.001). PM implantation was avoided
in 91% of BTS patients undergoing AFCA.ConclusionsAFCA in BTS patients
seems to be more effective than PM implantation in reducing AF recurrence
and PM implantation may be waived in most BTS patients treated by AFCA.
Need for additional procedures in AFCA patients is balanced by long-term
benefit in clinical end points.<br/>Copyright &#xa9; 2022 Lippincott
Williams and Wilkins. All rights reserved.

<75>
Accession Number
2019764647
Title
Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial.
Source
Journal of Cardiovascular Development and Disease. 9(10) (no pagination),
2022. Article Number: 363. Date of Publication: October 2022.
Author
Shvartz V.; Le T.; Enginoev S.; Sokolskaya M.; Ispiryan A.; Shvartz E.;
Nudel D.; Araslanova N.; Petrosyan A.; Donakanyan S.; Chernov I.; Bockeria
L.; Golukhova E.
Institution
(Shvartz, Le, Sokolskaya, Ispiryan, Petrosyan, Donakanyan, Bockeria,
Golukhova) Bakulev Scientific Center for Cardiovascular Surgery, Moscow
121552, Russian Federation
(Enginoev, Nudel, Araslanova, Chernov) Federal Center for Cardiovascular
Surgery of the Russian Federation Ministry of Healthcare (Astrakhan),
Astrakhan 414011, Russian Federation
(Enginoev) Astrakhan State Medical University of the Russian Federation
Ministry of Healthcare, Astrakhan 414000, Russian Federation
(Shvartz) National Medical Research Center for Therapy and Preventive
Medicine, Moscow 101990, Russian Federation
Publisher
MDPI
Abstract
Background. In patients who underwent cardiac surgery, first-time
postoperative atrial fibrillation (POAF) is associated with increased
incidence of hospital-acquired complications and mortality. Systemic
inflammation is one of confirmed triggers of its development. The
anti-inflammatory properties of colchicine can be effective for the POAF
prevention. However, the results of several studies were questionable and
required further investigation. Hence, we aimed to evaluate the
effectiveness of low-dose short-term colchicine administration for POAF
prevention in patients after the open-heart surgery. This double-blind
randomized placebo-controlled trial included 267 patients, but 27 of them
dropped out in the course of the study. Study subjects received the test
drug on the day before the surgery and on postoperative days 2, 3, 4 and
5. The rhythm control was conducted immediately after the operation and
until the discharge from the hospital. The final analysis included 240
study subjects: 113 in the colchicine group and 127 in the placebo group.
POAF was observed in 21 (18.6%) patients of the colchicine group vs. 39
(30.7%) control patients (OR 0.515; 95% Cl 0.281-0.943; p = 0.029). We
observed no statistically significant differences between the patient
groups in the secondary endpoints of the study (hospital mortality,
respiratory failure, stroke, bleeding, etc.). For other parameters
characterizing the severity of inflammation (pericardial effusion, pleural
effusion, WBC count, neutrophil count), there were statistically
significant differences between the groups in the early postoperative
period (days 3 and 5). Also, statistically significant differences between
the groups in the frequency of adverse events were revealed: the incidence
of diarrhea in the colchicine group was 25.7% vs. 11.8% in the placebo
group (OR 2.578; 95% Cl 1.300-5.111; p = 0.005); for abdominal pain,
incidence values were 7% vs. 1.6%, correspondingly (OR 4.762; 95% Cl
1.010-22.91; p = 0.028). Thus, there were statistically significant
differences between groups in the primary endpoint, thereby confirming the
effectiveness of short-term colchicine use for the POAF prevention after
coronary artery bypass grafting and/or aortic valve replacement. Also, we
detected statistically significant differences between groups in the
frequency of side effects to colchicine: diarrhea and abdominal pain were
more common in the colchicine group. This clinical trial is registered
with ClinicalTrials database under a unique identifier:
NCT04224545.<br/>Copyright &#xa9; 2022 by the authors.

<76>
Accession Number
2019702730
Title
Prediction of postoperative atrial fibrillation with postoperative
epicardial electrograms.
Source
Scandinavian Cardiovascular Journal. 56(1) (pp 378-386), 2022. Date of
Publication: 2022.
Author
Feilberg Rasmussen L.; Andreasen J.J.; Riahi S.; Lip G.Y.H.;
Lundbye-Christensen S.; Melgaard J.; Graff C.
Institution
(Feilberg Rasmussen, Andreasen) Department of Cardiothoracic Surgery,
Aalborg University Hospital, Aalborg, Denmark
(Feilberg Rasmussen, Andreasen, Riahi, Lip) Department of Clinical
Medicine, Aalborg University, Aalborg, Denmark
(Andreasen, Riahi, Lip, Lundbye-Christensen) Atrial Fibrillation Study
Group, Aalborg University Hospital, Aalborg, Denmark
(Riahi) Department of Cardiology, Aalborg University Hospital, Aalborg,
Denmark
(Lundbye-Christensen) Unit of Clinical Biostatistics, Aalborg University
Hospital, Aalborg, Denmark
(Melgaard, Graff) Department of Health Science and Technology, Aalborg
University, Aalborg, Denmark
Publisher
Taylor and Francis Ltd.
Abstract
Objectives. New-onset postoperative atrial fibrillation (POAF) is a common
complication after cardiac surgery. The arrhythmia often entails a longer
hospital stay, greater risk of other complications, and higher mortality
both short- and long-term. An investigation of the use of early atrial
electrograms in predicting POAF in cardiac surgery was performed. Design.
In this prospective observational study, a total of 99 consecutive adult
patients undergoing coronary artery bypass grafting, valve surgery or both
were included. On the first postoperative morning, standard 12-lead
electrograms (ECG), unipolar atrial electrograms (aEG), and vital values
were recorded. The outcome was new-onset POAF within one month
postoperatively. Results. Three multivariable prediction models for POAF
were formed using measurements derived from the ECG, aEG, and patient
characteristics. Age, body mass index, and two unipolar electrogram
measurements quantifying local activation time and fractionation were
strongly associated with the outcome POAF. The performance of the POAF
prediction models was assessed through receiver operating curve
characteristics with cross-validation, and discrimination using the
leave-one-out-method to internally validate the models. The
cross-validated area under the receiver operating characteristic curve
(AUC) was improved in a prediction model using atrial-derived electrogram
variables (AUC 0.796, 95% CI 0.698-0.894), compared with previous ECG and
clinical models (AUC 0.716, 95% CI 0.606-0.826 and AUC 0.718, 95% CI
0.613-0.822, respectively). Conclusions. This study found that easily
obtainable measurements from atrial electrograms may be helpful in
identifying patients at risk of POAF in cardiac surgery.<br/>Copyright
&#xa9; 2022 The Author(s). Published by Informa UK Limited, trading as
Taylor & Francis Group.

<77>
Accession Number
2018228944
Title
Doxycycline can reduce glycocalyx shedding by inhibiting matrix
metalloproteinases in patients undergoing cardiopulmonary bypass: A
randomized controlled trial.
Source
Microvascular Research. 142 (no pagination), 2022. Article Number: 104381.
Date of Publication: July 2022.
Author
Gao W.; Fang F.; Xia T.J.; Zhang Y.; Sun J.; Wu Q.; Wang W.
Institution
(Gao, Sun, Wu, Wang) Department of Anaesthesiology, The First Affiliated
Hospital of Wenzhou Medical University, Zhejiang Province, Wenzhou, China
(Fang) Department of Anaesthesiology, Zhejiang University School of
Medicine First Affiliated Hospital, Zhejiang Province, Hangzhou, China
(Xia) Department of Anaesthesiology, The Ohio State University College of
Medicine, Columbus, OH, United States
(Zhang) Department of the Operating Room, The First Affiliated Hospital of
Wenzhou Medical University, Zhejiang Province, Wenzhou, China
Publisher
Academic Press Inc.
Abstract
Background: Cardiopulmonary bypass (CPB) leads to shedding of the
glycocalyx of endothelial cells, resulting in a series of complications
such as tissue edema and coagulatory and microcirculatory dysfunctions.
Matrix metalloproteinases (MMPs) can cause glycocalyx shedding in a
variety of pathological processes, but their role in the process of CPB is
still unclear. We hypothesized that the MMPs inhibitor doxycycline would
reduce glycocalyx shedding by inhibiting MMPs during CPB. <br/>Method(s):
Thirty-six patients were randomized to receive either 100 mg oral
doxycycline (an MMPs inhibitor) or a matching placebo pill twice a day for
three days before CPB. The primary outcome was the concentration of plasma
syndecan-1. Secondary outcomes included heparan sulphate, MMP-2, MMP-9,
ratio of urinary albumin to creatinine, and short-term clinical outcomes.
In order to further prove that MMPs in plasma caused the glycocalyx
shedding, human umbilical vein endothelial cells were cultured with plasma
obtained from cardiac surgery patients before or after CPB (with or
without MMPs inhibitor GM6001). The change in glycocalyx content was
detected by immunofluorescence. <br/>Result(s): CPB resulted in an
increase of MMPs and shedding of the glycocalyx. Plasma syndecan-1 was
higher in the control group than in the doxycycline group (median
difference:15.04 mug/L; 95% CI: 9.14-20.94 mug/L; P < 0.001). Similar to
syndecan-1, plasma heparan sulphate, MMP-2, and MMP-9 concentrations in
the doxycycline group were significantly lower than those in the control
group during CPB. Doxycycline was also correlated with a reduction in the
ratio of urinary albumin to creatinine and improved the short-term
clinical outcomes of patients. Endothelial cells cultured with plasma from
patients after CPB showed significant shedding of syndecan-1 and heparan
sulphate (post-CPB group vs pre-CPB group, P < 0.001). GM6001 was shown to
reduce shedding of syndecan-1 and heparan sulphate by inhibiting MMPs
(post-CPB + GM6001 group vs post-CPB group, P < 0.001).
<br/>Conclusion(s): Doxycycline can reduce glycocalyx shedding by
inhibiting MMPs during CPB.<br/>Copyright &#xa9; 2022 Elsevier Inc.

<78>
Accession Number
2018119249
Title
Gene-based whole genome sequencing meta-analysis of 250 circulating
proteins in three isolated European populations.
Source
Molecular Metabolism. 61 (no pagination), 2022. Article Number: 101509.
Date of Publication: July 2022.
Author
Gilly A.; Klaric L.; Park Y.-C.; Png G.; Barysenka A.; Marsh J.A.;
Tsafantakis E.; Karaleftheri M.; Dedoussis G.; Wilson J.F.; Zeggini E.
Institution
(Gilly, Park, Png, Barysenka, Zeggini) Institute of Translational
Genomics, Helmholtz Zentrum Munchen - German Research Center for
Environmental Health, Ingolstaedter Landstr. 1, Neuherberg 85764, Germany
(Klaric, Marsh, Wilson) MRC Human Genetics Unit, Institute of Genetics and
Cancer, University of Edinburgh, Western General Hospital, Edinburgh EH4
2XU, United Kingdom
(Png, Zeggini) TUM School of Medicine, Technical University of Munich and
Klinikum Rechts der Isar, Ismaninger Strase 22, Munich 8167, Germany
(Tsafantakis) Anogia Medical Centre, Anogia 74051, Greece
(Karaleftheri) Echinos Medical Centre, Echinos 67300, Greece
(Dedoussis) Department of Nutrition and Dietetics, School of Health
Science and Education, Harokopio University of Athens, 70, El. Venizelou
ave., Kallithea 17671, Greece
(Wilson) Centre for Global Health Research, Usher Institute, University of
Edinburgh, Teviot Place, Edinburgh EH8 9AG, United Kingdom
Publisher
Elsevier GmbH
Abstract
Objective: Deep sequencing offers unparalleled access to rare variants in
human populations. Understanding their role in disease is a priority, yet
prohibitive sequencing costs mean that many cohorts lack the sample size
to discover these effects on their own. Meta-analysis of individual
variant scores allows the combination of rare variants across cohorts and
study of their aggregated effect at the gene level, boosting discovery
power. However, the methods involved have largely not been field-tested.
In this study, we aim to perform the first meta-analysis of gene-based
rare variant aggregation optimal tests, applied to the human
cardiometabolic proteome. <br/>Method(s): Here, we carry out this analysis
across MANOLIS, Pomak and ORCADES, three isolated European cohorts with
whole-genome sequencing (total N = 4,422). We examine the genetic
architecture of 250 proteomic traits of cardiometabolic relevance. We use
a containerised pipeline to harmonise variant lists across cohorts and
define four sets of qualifying variants. For every gene, we interrogate
protein-damaging variants, exonic variants, exonic and regulatory
variants, and regulatory only variants, using the CADD and Eigen scores to
weigh variants according to their predicted functional consequence. We
perform single-cohort rare variant analysis and meta-analyse variant
scores using the SMMAT package. <br/>Result(s): We describe 5 rare variant
pQTLs (RV-pQTL) which pass our stringent significance threshold (7.45 x
10^-11) and quality control procedure. These were split between
four cis signals for MARCO, TEK, MMP2 and MPO, and one trans association
for GDF2 in the SERPINA11 gene. We show that the cis-MPO association,
which was not detectable using the single-point data alone, is driven by 5
missense and frameshift variants. These include rs140636390 and
rs119468010, which are specific to MANOLIS and ORCADES, respectively. We
show how this kind of signal could improve the predictive accuracy of
genetic factors in common complex disease such as stroke and
cardiovascular disease. <br/>Conclusion(s): Our proof-of-concept study
demonstrates the power of gene-based meta-analyses for discovering
disease-relevant associations complementing common-variant signals by
incorporating population-specific rare variation.<br/>Copyright &#xa9;
2022 The Author(s)

<79>
Accession Number
2016454838
Title
Triglyceride-glucose index as a marker in cardiovascular diseases:
landscape and limitations.
Source
Cardiovascular Diabetology. 21(1) (no pagination), 2022. Article Number:
68. Date of Publication: December 2022.
Author
Tao L.-C.; Xu J.-N.; Wang T.-T.; Hua F.; Li J.-J.
Institution
(Tao, Xu, Wang, Hua) The Third Affiliated Hospital of Soochow University,
Juqian Road, Changzhou 213000, China
(Li) State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital,
National Center for Cardiovascular Diseases, Chinese Academy of Medical
Sciences and Peking Union Medical College, No 167 BeiLiShi Road, XiCheng
District, Beijing 100037, China
Publisher
BioMed Central Ltd
Abstract
The triglyceride-glucose (TyG) index has been identified as a reliable
alternative biomarker of insulin resistance (IR). Recently, a considerable
number of studies have provided robust statistical evidence suggesting
that the TyG index is associated with the development and prognosis of
cardiovascular disease (CVD). Nevertheless, the application of the TyG
index as a marker of CVD has not systemically been evaluated, and even
less information exists regarding the underlying mechanisms associated
with CVD. To this end, in this review, we summarize the history of the use
of the TyG index as a surrogate marker for IR. We aimed to highlight the
application value of the TyG index for a variety of CVD types and to
explore the potential limitations of using this index as a predictor for
cardiovascular events to improve its application value for CVD and provide
more extensive and precise supporting evidence.<br/>Copyright &#xa9; 2022,
The Author(s).

<80>
Accession Number
2008581210
Title
Cardiovascular impact of COVID-19 with a focus on children: A systematic
review.
Source
World Journal of Clinical Cases. 8(21) (pp 5250-5283), 2020. Date of
Publication: November 2020.
Author
Rodriguez-Gonzalez M.; Castellano-Martinez A.; Cascales-Poyatos H.M.;
Perez-Reviriego A.A.
Institution
(Rodriguez-Gonzalez) Pediatric Cardiology Division, Puerta del Mar
University Hospital, Cadiz 11009, Spain
(Rodriguez-Gonzalez, Castellano-Martinez) Biomedical Research and
Innovation Institute of Cadiz, Puerta del Mar University Hospital, Cadiz
11009, Spain
(Castellano-Martinez) Pediatric Nephrology Division, Puerta del Mar
University Hospital, Cadiz 11009, Spain
(Cascales-Poyatos) Pediatrics Division, Motril-San Antonio Primary Care
Center, Motril 18600, Spain
(Perez-Reviriego) Pediatrics Division, UGC Pediatria AG Sur Granada, Santa
Ana Hospital, Motril 18600, Spain
Publisher
Baishideng Publishing Group Inc
Abstract
Background Since the beginning of the pandemic, coronavirus disease-2019
(COVID-19) in children has shown milder cases and a better prognosis than
adults. Although the respiratory tract is the primary target for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cardiovascular
involvement is emerging as one of the most significant and
life-threatening complications of SARS-CoV-2 infection in adults. Aim To
summarize the current knowledge about the potential cardiovascular
involvement in pediatric COVID-19 in order to give a perspective on how to
take care of them during the current pandemic emergency. Methods Multiple
searches in MEDLINE, PubMed were performed using the search terms
"COVID-19" or "SARS-CoV-2" were used in combination with "myocardial
injury" or "arrhythmia" or "cardiovascular involvement" or "heart disease"
or "congenital heart disease" or "pulmonary hypertension" or "long QT" or
"cardiomyopathies" or "channelopathies" or "Multisystem inflammatory
system" or "PMIS" or "MIS-C" or "Pediatric multisystem inflammatory
syndrome" or "myocarditis" or "thromboembolism to identify articles
published in English language from January 1st, 2020 until July 31st,
2020. The websites of World Health Organization, Centers for Disease
control and Prevention, and the Johns Hopkins Coronavirus Resource Center
were reviewed to provide up to date numbers and infection control
recommendations. Reference lists from the articles were reviewed to
identify additional pertinent articles. Retrieved manuscripts concerning
the subject were reviewed by the authors, and the data were extracted
using a standardized collection tool. Data were subsequently analyzed with
descriptive statistics. For Pediatric multisystemic inflammatory syndrome
temporally associated with COVID-19 (PMIS), multiple meta-analyses were
conducted to summarize the pooled mean proportion of different
cardiovascular variables in this population in pseudo-cohorts of observed
patients. RESULTS A total of 193 articles were included. Most publications
used in this review were single case reports, small case series, and
observational small-sized studies or literature reviews. The meta-analysis
of 16 studies with size > 10 patients and with complete data about
cardiovascular involvement in children with PMIS showed that PMIS affects
mostly previously healthy school-aged children and adolescents presenting
with Kawasaki disease-like features and multiple organ failure with a
focus on the heart, accounting for most cases of pediatric COVID-19
mortality. They frequently presented cardiogenic shock (53%), ECG
alterations (27%), myocardial dysfunction (52%), and coronary artery
dilation (15%). Most cases required PICU admission (75%) and inotropic
support (57%), with the rare need for extracorporeal membrane oxygenation
(4%). Almost all of these children wholly recovered in a few days,
although rare deaths have been reported (2%). Out of PMIS cases we
identified 10 articles reporting sporadic cases of myocarditis, pulmonary
hypertension and cardiac arrythmias in previously healthy children. We
also found another 10 studies reporting patients with preexisting heart
diseases. Most cases consisted in children with severe COVID-19 infection
with full recovery after intensive care support, but cases of death were
also identified. The management of different cardiac conditions are
provided based on current guidelines and expert panel recommendations.
Conclusion There is still scarce data about the role of cardiovascular
involvement in COVID-19 in children. Based on our review, children
(previously healthy or with preexisting heart disease) with acute COVID-19
requiring hospital admission should undergo a cardiac workup and close
cardiovascular monitoring to identify and treat timely life-threatening
cardiac complications.<br/>Copyright &#xa9; The Author(s) 2020. Published
by Baishideng Publishing Group Inc. All Rights Reserved.

<81>
Accession Number
639395973
Title
Big Data in cardiac surgery: real world and perspectives.
Source
Journal of cardiothoracic surgery. 17(1) (pp 277), 2022. Date of
Publication: 29 Oct 2022.
Author
Montisci A.; Palmieri V.; Vietri M.T.; Sala S.; Maiello C.; Donatelli F.;
Napoli C.
Institution
(Montisci) Division of Cardiothoracic Intensive Care, Cardiothoracic
Department, ASST Spedali Civili, Brescia 25123, Italy
(Palmieri, Maiello) Department of Cardiac Surgery and Transplantation,
Naples, Italy
(Vietri) Department of Precision Medicine, University of Campania Luigi
Vanvitelli, Naples, Italy
(Sala) Division of Anesthesiology, Intensive Care and Emergency Medicine,
University of Brescia, Brescia, Italy
(Donatelli) Department of Cardiac Surgery, Istituto Clinico Sant'Ambrogio,
Milan, Italy
(Donatelli) Chair of Cardiac Surgery, University of Milan, Milan, Italy
(Napoli) Clinical Department of Internal Medicine and Specialistics,
University Department of Advanced Clinical and Surgical Sciences,
University of Campania Luigi Vanvitelli, Naples, Italy
Publisher
NLM (Medline)
Abstract
Big Data, and the derived analysis techniques, such as artificial
intelligence and machine learning, have been considered a revolution in
the modern practice of medicine. Big Data comes from multiple sources,
encompassing electronic health records, clinical studies, imaging data,
registries, administrative databases, patient-reported outcomes and OMICS
profiles. The main objective of such analyses is to unveil hidden
associations and patterns. In cardiac surgery, the main targets for the
use of Big Data are the construction of predictive models to recognize
patterns or associations better representing the individual risk or
prognosis compared to classical surgical risk scores. The results of these
studies contributed to kindle the interest for personalized medicine and
contributed to recognize the limitations of randomized controlled trials
in representing the real world. However, the main sources of evidence for
guidelines and recommendations remain RCTs and meta-analysis. The extent
of the revolution of Big Data and new analytical models in cardiac surgery
is yet to be determined.<br/>Copyright &#xa9; 2022. The Author(s).

<82>
Accession Number
639388721
Title
Long-term Outcomes of Transcatheter Aortic Valve Replacement With the
Lotus Valve vs CoreValve/EvolutR: A Secondary Analysis of the REPRISE III
Randomized Clinical Trial.
Source
JAMA network open. 5(10) (pp e2238792), 2022. Date of Publication: 03 Oct
2022.
Author
Rizik D.G.; Rajagopal V.; Makkar R.R.; Bajwa T.; Kleiman N.S.; Linke A.;
Kereiakes D.J.; Waksman R.; Thourani V.H.; Stoler R.C.; Mishkel G.J.; Iyer
V.S.; Buchbinder M.; Gotberg M.; Bjursten H.; Allocco D.J.; Reardon M.J.
Institution
(Rizik) Department of Cardiology, HonorHealth and the Scottsdale-Lincoln
Health Network, Scottsdale, AZ, United States
(Rajagopal) Cardiology Department, Piedmont Hospital, Atlanta, Georgia
(Makkar) Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Bajwa) Department of Medicine, Aurora St Luke's Medical Center,
Milwaukee, WI, United States
(Kleiman) Department of Cardiology, Houston Methodist DeBakey Heart and
Vascular Center, Houston, TX, United States
(Linke) Department of Internal Medicine and Cardiology, Technische
Universitat Dresden, Dresden, Germany
(Kereiakes) The Christ Hospital Heart and Vascular Center/The Lindner
Research Center Cincinnati, Cincinnati, OH, United States
(Waksman) Section of Interventional Cardiology, MedStar Washington
Hospital Center, WA, United States
(Thourani) Department of Cardiovascular Surgery, Marcus Valve Center,
Piedmont Heart Institute, Atlanta, Georgia
(Stoler) Baylor Heart & Vascular Hospital, Dallas, TX, United States
(Mishkel) Division of Cardiology, NorthShore University HealthSystem,
University of Chicago Pritzker School of Medicine, Chicago, IL, United
States
(Iyer) Gates Vascular Institute, Interventional Cardiology, University at
Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY, United
States
(Buchbinder) Department of Cardiology, Foundation for Cardiovascular
Medicine, Stanford University, Stanford, CA, United States
(Gotberg) Department of Cardiology, Clinical Sciences, Lund University,
Skane University Hospital, Lund, Sweden
(Bjursten) Department of Cardiothoracic Surgery, Skane University
Hospital, Lund, Sweden
(Allocco) Boston Scientific Corp, Marlborough, Massachusetts
(Reardon) Department of Cardiovascular Surgery, Houston Methodist DeBakey
Heart and Vascular Center, Houston, TX, United States
Publisher
NLM (Medline)
Abstract
Importance: Long-term follow-up after transcatheter aortic valve
replacement (TAVR) is of interest given that longitudinal data on
mortality and durability of transcatheter heart valves are limited. The
REPRISE III (Repositionable Percutaneous Replacement of Stenotic Aortic
Valve Through Implantation of Lotus Valve System-Randomized Clinical
Evaluation) randomized clinical trial compared the mechanically expanded
Lotus valve with the self-expanding CoreValve/EvolutR TAVR platforms.
<br/>Objective(s): To describe the final 5-year outcomes of the REPRISE
III trial. <br/>Design, Setting, and Participant(s): This prespecified
secondary analysis assessed the final 5-year clinical, functional, and
echocardiographic outcomes of 912 patients from the REPRISE III trial,
which was conducted at 55 centers in North America, Europe, and Australia
between September 22, 2014, and December 24, 2015. Patients had high risk
for aortic stenosis or severe or symptomatic aortic stenosis. Data were
analyzed from September 22, 2014, to May 21, 2021. <br/>Intervention(s):
Lotus valve or CoreValve/EvolutR TAVR platforms. <br/>Main Outcomes and
Measures: Valve Academic Research Consortium-2 end points, hemodynamic
measures, functional status, and health status were examined through the
5-year follow-up. <br/>Result(s): A total of 912 patients (mean [SD] age,
82.8 [7.3] years; 463 women [50.8%]) were randomized to either the Lotus
valve group (n=607) or CoreValve/EvolutR group (n=305), with a baseline
Society of Thoracic Surgeons risk score of 6.8%. Clinical follow-up data
from the REPRISE III trial were available for 581 patients (95.7%) in the
Lotus valve group and 285 patients (93.4%) in the CoreValve/EvolutR group.
At 5 years, the cumulative event rate for all-cause mortality was 50.9% in
the Lotus valve group vs 52.8% in the CoreValve/EvolutR group (P=.59).
Disabling stroke was less frequent with the Lotus valve vs
CoreValve/EvolutR (cumulative event rates, 8.3% vs 12.2%; P=.04), whereas
the cumulative event rates for overall stroke were similar in both groups
(14.1% vs 15.3%; P=.38). Insertion of a new permanent pacemaker (38.9% vs
27.3%; P<.001) and detection of prosthetic aortic valve thrombosis (5.8%
vs 1.8%; P=.007) were more common in the Lotus valve group than in the
CoreValve/EvolutR group. A smaller proportion of patients who received the
Lotus valve experienced valve malpositioning (0% vs 2.6%; P<.001) and
required the use of a second valve (1.0% vs 3.8%; P<.001) during the
procedure compared with those who received the CoreValve/EvolutR. Compared
with the Lotus valve group, the CoreValve/EvolutR group had a
significantly lower mean (SD) aortic gradient (7.8 [4.2] mm Hg vs 12.6
[6.7] mm Hg; P<.001) and larger valve areas (1.57 [0.56] cm2 vs 1.42
[0.42] cm2; P=.10). After 5 years, the proportion of patients with
moderate or greater paravalvular leak was not significantly higher with
the CoreValve/EvolutR than with the Lotus valve (1.9% vs 0%; P=.31);
however, the proportion of patients with mild paravalvular leak was higher
in the CoreValve/EvolutR group compared with the Lotus valve group (23.1%
vs 7.8%; P=.006). Long-term, similar improvements in New York Heart
Association class and Kansas City Cardiomyopathy Questionnaire score were
observed in both groups. <br/>Conclusions and Relevance: The REPRISE III
trial found that, at 5 years, the clinical outcomes of the Lotus valve
were comparable to those of the CoreValve/EvolutR and that the Lotus valve
was safe and effective. Trial Registration: ClinicalTrials.gov Identifier:
NCT02202434.

<83>
Accession Number
638019248
Title
Custodiol-N versus Custodiol: a prospective randomized double-blind
multicentre phase III trial in patients undergoing elective coronary
bypass surgery.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 62(5) (no pagination),
2022. Date of Publication: 04 Oct 2022.
Author
Szabo G.; Brlecic P.; Loganathan S.; Wagner F.; Rastan A.; Doenst T.;
Karck M.; Veres G.
Institution
(Szabo, Brlecic, Loganathan, Karck, Veres) Department of Cardiac Surgery,
University of Heidelberg, Heidelberg, Germany
(Szabo, Loganathan, Veres) Department of Cardiac Surgery, University of
Halle, Halle (Saale), Germany
(Wagner) Department of Cardiac Surgery, University of Hamburg, Hamburg,
Germany
(Rastan) Department of Cardiac and Vascular Surgery, Heart Center
Rotenburg, Germany
(Doenst) Department of Cardiac Surgery, University of Jena, Jena, Germany
Publisher
NLM (Medline)
Abstract
OBJECTIVES: HTK-Solution (Custodiol) is a well-established cardioplegic
and organ preservation solution. We currently developed a novel HTK-based
solution, Custodiol-N, which includes iron chelators to reduce oxidative
injury, as well as l-arginine, to improve endothelial function. In this
first-in-human study, Custodiol-N was compared to Custodiol in patients
undergoing elective coronary artery bypass surgery. The aim of this
comparison was to evaluate the safety and ability of Custodiol-N to
protect cardiac tissue. <br/>METHOD(S): The study was designed as a
prospective randomized double-blind non-inferiority trial. Primary end
point was area under the curve (AUC) of creatine kinase muscle-brain
(CK-MB) within the first 24h after surgery. Secondary end points included
peak CK-MB and troponin-T and AUC of troponin-T release, cardiac index,
cumulative catecholamine dose, intensive care unit stay and mortality. All
values in the abstract are given as mean +/- SD, P<0.05 was considered
statistically significant. <br/>RESULT(S): Early termination of the trial
was performed per protocol as the primary non-inferiority end-point was
reached after inclusion of 101 patients. CK-MB AUC (878+/-549 vs
779+/-439h U/l, non-inferiority P<0.001, Custodiol vs Custodiol-N) and
troponin-T AUC (12990+/-8347 vs 13498+/-6513h pg/ml, noninferiority
P<0.001, Custodiol vs Custodiol-N) were similar in both groups. Although
the trial was designed for non-inferiority, peak CK-MB (52+/-40 vs 42+/-28
U/l, superiority P<0.03, Custodiol vs Custodiol-N) was significantly lower
in the Custodiol-N group. <br/>CONCLUSION(S): This study shows that
Custodiol-N is safe and provides similar cardiac protection as the
established HTK-Custodiol solution. Significantly reduced peak CK-MB
levels in the Custodiol-N group in the full analysis set may implicate a
beneficial effect on ischaemia/reperfusion injury in the setting of
coronary bypass surgery.<br/>Copyright &#xa9; The Author(s) 2022.
Published by Oxford University Press on behalf of the European Association
for Cardio-Thoracic Surgery. All rights reserved.

<84>
Accession Number
637840912
Title
Preoperative oral magnesium loading to prevent postoperative atrial
fibrillation following coronary surgery: a prospective randomized
controlled trial.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 62(5) (no pagination),
2022. Date of Publication: 04 Oct 2022.
Author
Tohme J.; Sleilaty G.; Jabbour K.; Gergess A.; Hayek G.; Jebara V.;
Madi-Jebara S.
Institution
(Tohme, Jabbour, Gergess, Hayek, Madi-Jebara) Department of Anesthesia and
Critical Care, Hotel-Dieu de France hospital, Universite Saint-Joseph,
Beirut, Lebanon
(Sleilaty, Jebara) Department of Cardiovascular and Thoracic Surgery,
Hotel-Dieu de France hospital, Universite Saint-Joseph, Beirut, Lebanon
(Sleilaty) Clinical Research Center, Faculty of Medicine, Universite
Saint-Joseph, Beirut, Lebanon
Publisher
NLM (Medline)
Abstract
OBJECTIVES: Postoperative atrial fibrillation (POAF) is common following
coronary artery bypass grafting (CABG) surgery. Hypomagnesemia is frequent
after CABG surgery. No previous trials have assessed the effect of
preoperative magnesium (Mg) loading on POAF incidence. <br/>METHOD(S):
This was a single-centre, double-blind, placebo-controlled, parallel-group
trial, with balanced randomization [1:1]. The participants were recruited
from November 2018 until May 2019. Patients received either 3.2g of Mg
daily (4 tablets of 0.4g each twice daily) for 72h preoperatively and 1.6g
of Mg (4 tablets) on the day of surgery or placebo tablets.
<br/>RESULT(S): The primary outcome was the incidence of POAF. Secondary
outcomes included time to extubation, transfusion rate, critical care unit
and hospital length of stay. Of the 210 randomized participants, 200 (100
in each group) completed the study. A total of 10 (10%) and 22 (22%)
subjects developed POAF in the Mg and placebo groups, respectively
(RR=0.45, 95% confidence interval: 0.23-0.91). Hospital and critical care
unit length of stay were comparable between the 2 groups. No side effects
related to Mg administration were documented. <br/>CONCLUSION(S): In this
randomized controlled trial, preoperative loading with oral administration
of Mg for 3days in patients admitted for CABG surgery decreases the
incidence of POAF compared to placebo. CLINICAL TRIAL REGISTRATION NUMBER:
NCT03703349.<br/>Copyright &#xa9; The Author(s) 2022. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<85>
Accession Number
637760264
Title
Effects of postoperative cognitive training on neurocognitive decline
after heart surgery: a randomized clinical trial.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 62(5) (no pagination),
2022. Date of Publication: 04 Oct 2022.
Author
Butz M.; Gerriets T.; Sammer G.; El-Shazly J.; Tschernatsch M.; Huttner
H.B.; Braun T.; Boening A.; Mengden T.; Choi Y.-H.; Schoenburg M.;
Juenemann M.
Institution
(Butz, Gerriets, Sammer, Tschernatsch, Braun, Schoenburg, Juenemann) Heart
and Brain Research Group, Kerckhoff Heart and Thorax Center, Bad Nauheim,
Germany
(Butz, Gerriets, Tschernatsch, Huttner, Braun, Juenemann) Department of
Neurology, University Hospital Giessen and Marburg, Giessen, Germany
(Sammer) Cognitive Neuroscience at the Center of Psychiatry, University
Giessen, Giessen, Germany
(Sammer) Department of Psychology, Justus-Liebig University, Giessen,
Germany
(El-Shazly) Department of Psychocardiology, Kerckhoff Heart and Thorax
Center, Bad Nauheim, Germany
(Boening) Department of Cardiovascular Surgery, University Hospital
Giessen and Marburg, Giessen, Germany
(Mengden) Department of Rehabilitation, Kerckhoff Heart and Thorax Center,
Bad Nauheim, Germany
(Choi, Schoenburg) Department of Cardiac Surgery, Kerckhoff Heart and
Thorax Center, Bad Nauheim, Germany
Publisher
NLM (Medline)
Abstract
OBJECTIVES: Following cardiac surgery, postoperative cognitive decline
(POCD) is a common complication that can impair the quality of life and
increase mortality. The aim of this study was to investigate whether early
postoperative cognitive training can decrease POCD after cardiac surgery.
<br/>METHOD(S): The study was a multi-centred, two-arm, randomized (1:1
ratio), controlled trial involving older patients undergoing elective
heart valve surgery with extracorporeal circulation. Recruitment took
place at the Department of Cardiac Surgery of the Kerckhoff-Clinic in Bad
Nauheim (Germany) and the University-Hospital in Giessen (Germany). The
patients were randomized to either a paper-and-pencil-based cognitive
training group or a standard rehabilitation care control group. The
cognitive training started 1week after surgery and lasted about 3weeks
until discharge from rehabilitation. To detect POCD, neuropsychological
functions were assessed prior to surgery, upon discharge from
rehabilitation (primary outcome), and 3months after discharge (secondary
outcome). Data were primarily analysed in a per-protocol fashion.
<br/>RESULT(S): The frequency of POCD at discharge from rehabilitation
(training group, n=37; control group, n=44) was 50% in the control group
and 19% in the training group (chi2[1] = 8.45, P=0.004; odds ratio=4.29,
95% confidence interval [1.56-11.80]). Three months after the cognitive
training (training group, n=33; control group, n=34), POCD frequency was
29% in the control group and 6% in the training group (chi2[1] = 6.21,
P=0.013; odds ratio=6.46, 95% confidence interval [1.29-32.28]).
<br/>CONCLUSION(S): Since our cognitive training showed beneficial
effects, it could be a promising method to prevent POCD.<br/>Copyright
&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf
of the European Association for Cardio-Thoracic Surgery. All rights
reserved.

<86>
Accession Number
639392510
Title
Stroke prevention of thoracoscopic left atrial appendage clipping in
patients with non-valvular atrial fibrillation at high risk of stroke and
bleeding: study protocol for a non-randomised controlled clinical trial.
Source
BMJ open. 12(10) (pp e063931), 2022. Date of Publication: 28 Oct 2022.
Author
Ye C.; Han X.; Chen Y.; Liu F.; Ma H.; Yang Y.; Liu Y.; Hu Q.; Yao Q.; Xie
W.; Xu D.
Institution
(Ye) Department of Cardiac Surgery, Capital Medical University, Beijing,
China
(Ye, Han, Chen, Liu, Ma, Yang, Liu, Hu, Yao, Xie, Xu) Department of
Cardiac Surgery, Beijing Tiantan Hospital, Beijing, China
Publisher
NLM (Medline)
Abstract
INTRODUCTION: Non-valvular atrial fibrillation (NVAF) is a high-risk
factor for ischaemic stroke. The 2016 European Society of Cardiology
Atrial Fibrillation Management guidelines recommend oral anticoagulants
(OACs) to prevent stroke in men with CHA2DS2-VASc scores >=2and women >=3.
However, in patients with a high risk of stroke and a high risk of
bleeding (HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Labile international normalized ratio,
Elderly (> 65 years), Drugs/alcohol concomitantly) score>=3), OAC had a
higher risk of bleeding. Left atrial appendage closure (LAAC) is
non-inferior to OAC as a means of preventing stroke in several studies. As
a minimally invasive intervention to prevent stroke, transthoracic LAAC
(TS-LAAC) has a high successful closure rate, but there is a lack of
literature reports directly comparing it with OAC. Our research compares
TS-LAAC with novel oral anticoagulants (NOACs) and provides an appropriate
programme for stroke prevention in a specific population. METHODS AND
ANALYSIS: This is a non-randomised controlled trial study protocol, and we
will conduct this study from April 2022 to April 2025. The study included
186 patients with confirmed NVAF, 93 of whom completed thoracoscopic LAAC,
and the control group treated with NOACs. The primary outcome was the
incidence of stroke and systemic embolism, as well as the composite
endpoint events (stroke, systemic embolism, myocardial infarction,
bleeding, cardiovascular death, etc). Secondary outcomes were ischaemic
stroke, haemorrhagic stroke, any bleeding events, death from
cardiovascular causes, death from all causes, residual root rate in the
surgery group, device-related thrombosis in the surgery group, changes in
blood pressure, cardiac chamber size changes, etc. Each subject completed
at least 1year of follow-up. ETHICS AND DISSEMINATION: The study has been
approved by the Medical Ethics Committee of Beijing Tiantan Hospital,
Capital Medical University, China (approval number: KY2022-013-02). The
results from this study will be disseminated through manuscript
publications and national/international conferences. TRIAL REGISTRATION
NUMBER: ChiCTR2200058109.<br/>Copyright &#xa9; Author(s) (or their
employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use.
See rights and permissions. Published by BMJ.

<87>
Accession Number
2020976082
Title
The effect of massage therapy on pain after surgery: A comprehensive
meta-analysis.
Source
Complementary Therapies in Medicine. 71 (no pagination), 2022. Article
Number: 102892. Date of Publication: December 2022.
Author
Liu C.; Chen X.; Wu S.
Institution
(Liu, Wu) Department of Cancer Rehabilitation, Lishui Hospital of
Traditional Chinese Medicine, Affiliated to Zhejiang University of
Traditional Chinese Medicine, Zhejiang, Lishui, China
(Chen) The Second Affiliated Hospital of Wenzhou Medical University,
Zhejiang, Wenzhou, China
Publisher
Churchill Livingstone
Abstract
Background: Findings on the usefulness of massage therapy (MT) in
postoperative pain management are often inconsistent among studies.
<br/>Objective(s): This study's aim is to conduct a meta-analysis of
randomized controlled trials (RCT) to clarify the effects of massage
therapy in the treatment of postoperative pain. <br/>Method(s): Three
databases (PubMed, Embase, and Cochrane Central Register of Controlled
Trials) were searched for RCTs published from database inception through
January 26, 2021. The primary outcome was pain relief. The quality of RCTs
was appraised with the Cochrane Collaboration risk of bias tool. The
random-effect model was used to calculate the effect sizes and
standardized mean difference (SMD) with 95 % confidential intervals (CIs)
as a summary effect. The heterogeneity test was conducted through
I². Subgroup and sensitivity analyses were used to explore the
source of heterogeneity. Possible publication bias was assessed using
visual inspection of funnel plot asymmetry. <br/>Result(s): The analysis
included 33 RCTs and showed that MT is effective in reducing postoperative
pain (SMD, -1.32; 95 % CI, -2.01 to -0.63; p = 0.0002; I² =
98.67 %). A similar significant effect was found for both short (immediate
assessment) and long terms (assessment performed 4-6 weeks after the MT).
Remarkably, we found neither the duration per session nor the dose had an
impact on the effect of MT and there seemed to be no difference in the
effects of different MT types. In addition, MT seemed to be more effective
for adults. Furthermore, MT had better analgesic effects on cesarean
section and heart surgery than orthopedic surgery. <br/>Limitation(s):
Publication bias is possible due to the inclusion of studies in English
only. Additionally, the included studies were extremely heterogeneous.
Double-blind research on MT is difficult to implement, and none of the
included studies is double-blind. There was some heterogeneity and
publication bias in the included studies. In addition, there is no uniform
evaluation standard for the operation level of massage practitioners,
which may lead to research implementation bias. <br/>Conclusion(s): MT is
effective in reducing postoperative pain in both short and long
terms.<br/>Copyright &#xa9; 2022 The Authors

<88>
Accession Number
2020983839
Title
Hospitalizations and Mortality in Patients With Secondary Mitral
Regurgitation and Heart Failure: The COAPT Trial.
Source
Journal of the American College of Cardiology. 80(20) (pp 1857-1868),
2022. Date of Publication: 15 Nov 2022.
Author
Giustino G.; Camaj A.; Kapadia S.R.; Kar S.; Abraham W.T.; Lindenfeld J.;
Lim D.S.; Grayburn P.A.; Cohen D.J.; Redfors B.; Zhou Z.; Pocock S.J.;
Asch F.M.; Mack M.J.; Stone G.W.
Institution
(Giustino, Camaj, Stone) The Zena and Michael A. Wiener Cardiovascular
Institute Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Kapadia) Cleveland Clinic, Cleveland, OH, United States
(Kar) Los Robles Regional Medical Center, Thousand Oaks, CA, United States
(Kar) Bakersfield Heart Hospital, Bakersfield, CA, United States
(Abraham) Division of Cardiovascular Medicine, The Ohio State University
Medical Center, Columbus, OH, United States
(Lindenfeld) Advanced Heart Failure and Cardiac Transplantation Section,
Vanderbilt Heart and Vascular Institute, Nashville, TN, United States
(Lim) Division of Cardiology, University of Virginia, Charlottesville, VA,
United States
(Grayburn) Baylor University Medical Center, Baylor Heart and Vascular
Institute, Dallas, TX, United States
(Cohen) St Francis Hospital, Roslyn, NY, United States
(Cohen, Redfors, Zhou) Clinical Trials Center Cardiovascular Research
Foundation, New York, NY, United States
(Pocock) London School of Hygiene and Tropical Medicine, London, United
Kingdom
(Asch) MedStar Health Research Institute, Washington, DC, United States
(Asch) Georgetown University, Washington, DC, United States
(Mack) Baylor Scott and White Health, Plano, TX, United States
Publisher
Elsevier Inc.
Abstract
Background: The impact of transcatheter edge-to-edge repair (TEER) on the
rate and prognostic impact of hospitalizations in patients with heart
failure (HF) and severe secondary mitral regurgitation is unknown.
<br/>Objective(s): This study sought to evaluate the effect of the
MitraClip percutaneous edge-to edge repair system on fatal and nonfatal
hospitalizations and their relationship with mortality in the COAPT
(Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
for Heart Failure Patients With Functional Mitral Regurgitation) trial.
<br/>Method(s): Patients with HF (n = 614) with severe secondary mitral
regurgitation were randomized to TEER plus guideline-directed medical
therapy (GDMT) versus GDMT alone. Hospitalizations were classified as
fatal if death occurred during that hospitalization or nonfatal if the
patient was discharged alive. <br/>Result(s): At 2 years, TEER treatment,
compared with GDMT alone, resulted in lower time-to-first-event rates of
any heart failure hospitalization (HFH) (34.8% vs 56.4%; HR: 0.51; 95% CI:
0.39-0.66) and fatal HFH (6.5% vs 12.6%; HR: 0.47; 95% CI: 0.26-0.85).
TEER also resulted in lower rates of all-cause nonfatal and fatal
hospitalizations. During the 2-year follow-up period, patients who
underwent TEER spent an average of 2 more months alive and out of the
hospital than did patients treated with GDMT alone (581 +/- 27 days vs 519
+/- 26 days; P = 0.002). All HFHs (adjusted HR: 6.37; 95% CI: 4.63-8.78)
and nonfatal HFHs (adjusted HR: 1.78; 95% CI: 1.27-2.49) were consistently
independently associated with increased 2-year mortality in both the TEER
and GDMT groups (P<inf>interaction</inf> = 0.34 and 0.39, respectively).
<br/>Conclusion(s): In the COAPT trial, compared with GDMT alone, patients
with HF and severe secondary mitral regurgitation undergoing TEER with the
percutaneous edge-to edge repair system had lower 2-year rates of fatal
and nonfatal all-cause hospitalizations and HFH and spent more time alive
and out of the hospital. HFHs were strongly associated with mortality,
irrespective of treatment. (Cardiovascular Outcomes Assessment of the
MitraClip Percutaneous Therapy for Heart Failure Patients With Functional
Mitral Regurgitation [The COAPT Trial] and COAPT CAS [COAPT];
NCT01626079)<br/>Copyright &#xa9; 2022 American College of Cardiology
Foundation

<89>
Accession Number
2019875135
Title
Massive pleural effusion following high-power and short-duration
radiofrequency ablation for treatment of atrial fibrillation: A case
report and review of the literature.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 996481. Date of Publication: 14 Oct 2022.
Author
He M.; Qiu J.; Bai Y.; Wang Y.; Chen G.
Institution
(He, Qiu, Bai, Wang, Chen) Division of Cardiology, Department of Internal
Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China
Publisher
Frontiers Media S.A.
Abstract
Postpericardial injury syndrome (PPIS) is defined as pericarditis or
pericardial effusion that results from recent myocardial infarction or
intracardiac interventions. These symptoms typically include fever,
leukocytosis, a high erythrocyte sedimentation rate, and elevated
C-reactive protein levels. Additionally, pericardial effusion and pleural
effusion may be present. It is considered to be a common complication in
cardio-surgery with an occurrence of 3-30%. In the past 20 years, a high
number of patients with atrial fibrillation have suffered from PPIS
following radiofrequency catheter ablation. However, previous reports
focused on identifying cardiac tamponade and pericardial effusion as their
main clinical manifestations. Solitary pulmonary involvement following
PPIS with the radiofrequency catheter ablation may occur. We report a case
of PPIS that presented pleural effusion as the dominant feature soon after
the operation and systematic review to illustrate the clinical
characteristics of PPIS.<br/>Copyright &#xa9; 2022 He, Qiu, Bai, Wang and
Chen.

<90>
Accession Number
2020982989
Title
Prediction of Survival After Implantation of a Fully Magnetically
Levitated Left Ventricular Assist Device.
Source
JACC: Heart Failure. (no pagination), 2022. Date of Publication: 2022.
Author
Mehra M.R.; Nayak A.; Morris A.A.; Lanfear D.E.; Nemeh H.; Desai S.;
Bansal A.; Guerrero-Miranda C.; Hall S.; Cleveland J.C.; Goldstein D.J.;
Uriel N.; Chen L.; Bailey S.; Anyanwu A.; Heatley G.; Chuang J.; Estep
J.D.
Institution
(Mehra) Brigham and Women's Hospital, Boston, MA, United States
(Nayak, Morris) Emory University, Atlanta, GA, United States
(Lanfear, Nemeh) Henry Ford Hospital, Detroit, MI, United States
(Desai, Bansal) Ochsner Medical Center, New Orleans, LA, United States
(Guerrero-Miranda, Hall) Baylor University Medical Center, Dallas, TX,
United States
(Cleveland) University of Colorado School of Medicine, Aurora, CO, United
States
(Goldstein) Montefiore Einstein Center for Heart and Vascular Care, New
York, NY, United States
(Uriel) NewYork-Presbyterian Hospital, Columbia University College of
Physicians and Surgeons, New York, NY, United States
(Chen) University of Rochester Medical Center, Rochester, NY, United
States
(Bailey) Allegheny Health Network, Pittsburgh, PA, United States
(Anyanwu) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Heatley, Chuang) Abbott, Abbott Park, IL, United States
(Estep) Cleveland Clinic Florida, Weston, FL, United States
Publisher
Elsevier Inc.
Abstract
Background: Clinical trials inform on average efficacy, but individualized
risk assessments for outcome prediction are important in guiding treatment
implementation. <br/>Objective(s): The authors developed and validated a
patient-specific risk score to predict survival at 1 and 2 years after
HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation.
<br/>Method(s): The MOMENTUM 3 (Multicenter Study of MagLev Technology in
Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate
3) trial includes 2,200 HM3 LVAD patients in the pivotal trial and
Continued Access Protocol study (2014-2018). The authors randomly assigned
all patients to a derivation cohort (n = 1,540) or validation cohort (n =
660). Univariate mortality predictors were screened for potential model
inclusion, stepwise selection was used to build the multivariable Cox
proportional hazards regression model, and performance (discrimination and
calibration) was evaluated. <br/>Result(s): Age, prior cardiac surgery
(coronary artery bypass grafting [CABG] or valve procedure), lower serum
sodium, higher blood urea nitrogen (BUN), small left ventricular size, and
right atrial pressure-to-pulmonary capillary wedge pressure (RAP/PCWP)
ratio >0.6 were significant risk factors for mortality. Receiver-operating
characteristic (ROC) analysis in the validation cohort demonstrated an
area under the curve (AUC) of 0.76 (95% CI: 0.70-0.81) at 1 year and 0.71
(95% CI: 0.66-0.77) at 2 years. Calibration between predicted and observed
survival of the risk quintiles was high, with Pearson correlation
coefficients of 0.986 and 0.994 at 1 and 2 years, respectively. Patients
were successfully stratified into tertiles with higher-than-average,
average, and lower-than-average survival, and observed mortality risk
increased by 2-fold from one tertile to the next. <br/>Conclusion(s): A
practical, easy-to-use HM3 Survival Risk Score with 6 components was
developed to accurately predict 1- and 2-year survival after HM3 LVAD
implantation. The survival risk score can be used to provide individual
survival estimates to facilitate shared decision making when considering
HM3 LVAD therapy. (MOMENTUM 3 Trial Portfolio (NCT02224755,
NCT02892955).<br/>Copyright &#xa9; 2022 The Authors

<91>
Accession Number
639403936
Title
Review of bioprosthetic structural valve deterioration: Patient or valve?.
Source
Journal of cardiac surgery. (no pagination), 2022. Date of Publication:
01 Nov 2022.
Author
Tnay T.D.; Shell D.; Lui A.
Institution
(Tnay, Shell, Lui) Department of Cardiothoracic Surgery, St Vincent's
Hospital - Melbourne St Vincent's Health Australia, Melbourne, Australia
Publisher
NLM (Medline)
Abstract
BACKGROUND: With guidelines progressively recommending bioprosthetic
aortic valves in younger patients, a greater emphasis is placed on
structural valve deterioration (SVD) as an important clinical endpoint for
both transcatheter and surgically implanted valves. However, SVD of
bioprosthetic valves is a complex entity with varying definitions in the
literature and a multifaceted pathogenesis. AIM: This review first aims to
establish the most updated definitions of SVD as per the literature. We
then explore the patient- and valve-related factors that play the greatest
roles in facilitating early SVD. <br/>METHOD(S): A PubMed literature
review was conducted to identify the relevant research in this field
within the past two decades. <br/>CONCLUSION(S): Increasing rates of
obesity and metabolic syndrome pose a significant risk to the longevity of
bioprosthetic valves. Additionally, externally mounted valves have proven
to sacrifice durability for superior haemodynamics. Bioprosthetic SVD
continues to be a multifactorial issue that will require various patient-
and valve-related factors to be addressed.<br/>Copyright &#xa9; 2022 Wiley
Periodicals LLC.